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Skeletal and cardiac muscle disorders are associated with substantial morbidity and 
mortality. Collectively, these diseases affect millions of people worldwide and 
enormous amount of time, effort and money have been spent to identify and improve 
recuperative strategies for prevention and treatment of such disorders. Although 
many striated muscle diseases manifest themselves only in the heart or skeletal 
musculature, others affect both tissues although the moment of onset, progression, 
severity of disease and specific disease symptoms may differ between skeletal and 
cardiac muscle tissue.1 The existence of a large number of disorders with both 
skeletal and cardiac muscle involvement is a direct consequence of the large overlap 
in gene expression profile between skeletal and cardiac myocytes, which relates to 
commonalities in their contractile systems. In many striated muscle diseases loss of 
functional myocytes eventually exceeds the tissue’s regenerative capacity. This 
causes gradual replacement of these parenchymal cells by adipocytes and/or 
(myo)fibroblasts leading to progressive wasting and pathological remodelling of 
skeletal and cardiac muscle tissue, respectively.  
 
Skeletal muscle wasting 
A common feature of many skeletal muscle disorders is gradual muscle 
degeneration leading to impairment or loss of mobility. In healthy individuals, skeletal 
muscle damage triggers the activation of a population of muscle-resident stem cells 
called satellite cells. Following their activation, satellite cells start to proliferate giving 
rise to myoblasts, which are responsible for skeletal muscle repair and regeneration 
by fusion with injured myofibers or formation of new myofibers. Hence, fusion plays a 
key role in the regeneration process.2-4 In muscular dystrophies, because of the 
repetitive cycles of degeneration and regeneration the myoregenerative potential of 
skeletal muscle tissue becomes progressively exhausted. As a consequence, 
damaged myofibers are gradually replaced by fibroblasts and adipocytes. One of the 
therapeutic options to overcome this problem is cell transplantation. The success 
rate of transplantation is highly dependent on the ability of the donor cells to fuse 
with each other and/or with the recipient’s skeletal myocytes in order to produce new 
myofibers and repair existing ones, respectively.5 Mechanistic studies on (myogenic) 




cell fusion may thus be of great help to further optimize cell-based therapies for 
degenerative skeletal muscle diseases. 
 
 
Pathological cardiac remodelling 
Cardiac diseases are usually associated with distinct alterations of the expression 
and function of ion channels, Ca2+-handling proteins, metabolic enzymes and 
structural proteins including sarcomeric components, and intercellular adhesion 
molecules. These changes are often accompanied by pathological cardiac 
hypertrophy (PCH) and fibrosis leading to electrophysiological and structural 
remodelling, which have been identified to increase pro-arrhythmic risk.6-8  
An increase in cardiac demand due to physiological or pathological changes in 
hemodynamics makes the heart respond in several ways, including by the 
enlargement of cardiomyocytes. Such cardiac hypertrophy is essentially a beneficial 
compensatory process as it decreases wall stress, while increasing cardiac output.9 
This adaption by growth occurs under physiological conditions like exercise and 
pregnancy, but also in response to myocardial infarction and other cardiac 
pathologies (e.g. hypertension, aortic stenosis, aortic coarctation, valvular 
regurgitation, septal defects and arteriovenous fistulae).10 Physiological hypertrophy 
typically is a reversible process to fulfill a temporary need for additional cardiac 
output. Pathological hypertrophy, on the other hand, is essentially an irreversible 
process involving permanent changes in cardiac structure and function that initially 
secure but subsequently reduce cardiac output. Besides an increase in 
cardiomyocyte size, diseased hearts usually also display a decrease in 
cardiomyocyte number together with a (compensatory) fibrotic response. The 
changes in cardiac geometry, myocardial tissue composition and cardiomyocyte 
biology increase the risk of cardiac arrhythmias and thus both directly and indirectly 
contribute to a reduction in the pumping capacity of the heart, which may ultimately 
lead to heart failure.11,12 The exact pro-arrhythmic mechanisms of PCH are not well 
understood, partly because of the concurrent presence of fibrosis which is a pro-
arrhythmic feature by itself. 
Adult heart displays limited regenerative capacity.13 In case of cardiac injury, 
fibroblasts get activated, proliferate and form myofibroblasts, which secrete large 
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amounts of extracellular matrix.14 This process, which is called fibrosis, helps to 
maintain the heart’s integrity; but negatively affects heart function due to the 
replacement of contractile by non-contractile tissue, an increase in myocardial 
stiffness and disturbed impulse generation and propagation. The disturbances in the 
heart’s electrical activity are caused by the (electrical) isolation of cardiomyocytes by 
newly deposited extracellular matrix resulting in slowing or even block of conduction. 
Coupling of cardiomyocytes with (myo)fibroblasts may also add to disturbed impulse 
generation and propagation in fibrotic hearts. Taken together, structural and 




Proper electrical cardiac function relies on coordinated and well-timed generation of 
electrical impulses (i.e. action potentials) by cardiomyocytes and propagation of 
these impulses from cell to cell through gap junctions. Disturbances in electrical 
impulse generation and propagation could contribute to cardiac arrhythmias.17 Such 
heart rhythm disturbances concern any type of condition in which the atrial and/or 
ventricular rhythm is irregular, slower than normal (bradycardia) or faster than normal 
(tachycardia). In general, tachyarrhythmias are maintained by reentrant electrical 
activity or high-frequency electrical signals originating from focal sources. The most 
dangerous types of cardiac arrhythmias are those which are maintained by fibrillatory 
conduction (i.e. by chaotic activation patterns) especially when this happens in 
ventricular myocardium. Although our understanding of heart rhythm disturbances 
has surely improved over time, more insight, especially related to the underlying 
molecular and cellular mechanisms, is needed in order to improve the diagnosis and 
treatment of these disorders.  
 
Focal tachyarrhythmias  
Disturbances in repolarization can lead to prolongation of action potential duration 
(APD) and, when occurring at the earlier phases of repolarization (between -40 and 
0 mV), may favor formation of aberrant electrical signals, referred to as early 
afterdepolarizations (EADs). These EADs, in combination with other pro-arrhythmic 




conditions could give rise to focal or reentrant tachyarrhythmias. EADs are mainly 
Ca2+-dependent and can be induced by anachronistic reactivation of the L-type Ca2+ 
channel, sarcoplasmic Ca2+ release and inward Na+/Ca2+ exchanger activity.18-20 
EADs can occur during phase 2 (i.e. the plateau phase) or phase 3 of the cardiac 
action potential. The mechanisms involved in the generation of phase-2 and phase-3 
EADs are not the same as reflected by their different responsiveness to 
pharmacological inhibitors of ion channels. Since at the depolarized membrane 
voltages of phase 2, most Na+ channels are inactivated, the L-type Ca2+ current (ICaL) 
and the Na+/Ca2+ exchanger current (INCX) are the main currents responsible for 
phase-2 EADs. During the plateau phase of the action potential, L-type Ca2+ 
channels can undergo transitions between closed and open states. An increase in 
ICaL in this phase can provide enough depolarizing force for EAD formation. At the 
same time, the cardiac Na+/Ca2+ exchanger generates a net inward current by 
coupling the export of a single Ca2+ ion to the import of three Na+ ions, thereby 
resisting repolarization. The increase in the ICaL further increases the inward current 
of the Na+/Ca2+ exchanger, and thereby may increase the probability of an EAD-
triggered action potential.21 Forward mode of Na+/Ca2+ exchanger activity and 
possibly INa can promote phase-3 EAD generation. Finally, recent evidences suggest 
that electrotonic current flow in response to large voltage gradients resulting from 
heterogeneous repolarization are an important cause of phase-3 EADs.21,22  
 
Reentrant arrhythmias 
Reentrant arrhythmias are those electrical impulses which are propagated in self-
sustaining circuits that do not follow the normal cardiac conduction pattern, in which 
action potentials generated in the sinoatrial node move through the atrial 
myocardium and to the atrioventricular node and, after some delay, via the bundle of 
His and Purkinje fibers through the ventricular myocardium. Under normal 
conditions, impulses disappear automatically after the entire heart has been 
activated because the duration of the refractory period exceeds that of the excitation 
wave. However, if the heart contains an area of inexcitable tissue causing local 
conduction block and at the same time the tissue around this area shows large 
heterogeneity in repolarization or conduction, unidirectional block may develop 
forcing the wavefront of excitation to move in one direction which based on the 
timing may reenter the original site of excitation, establishing a reentrant circuit. 
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Reentry can occur in the presence (anatomical reentry),23 or absence (functional 
reentry)24 of an anatomical obstruction (e.g. myocardial scar tissue) or can be the 
result of both structural and functional disturbances in electrical impulse 
propagation.25,26 While anatomical reentry in many cases leads to reentrant circuits 
of constant wavelength and position, rotors caused by functional reentry often 
meander throughout the tissue.27,28  
 
Challenges in skeletal and cardiac muscle research 
Research in the field of skeletal and cardiac muscle diseases mainly focuses on 
unravelling the underlying pathogenic mechanisms and on developing (better) 
therapeutic interventions. Despite many improvements in the medical and surgical 
management of skeletal and cardiac muscle disorders, development of effective and 
durable treatments has proven to be challenging. In cardiac muscle disorders, device 
therapies and interventional procedures such as catheter ablation have multiple 
limitations and are associated with a risk of complications.29,30 Pharmacological 
therapies for skeletal and cardiac muscle diseases are largely directed toward 
palliation of the symptoms of the disease rather than targeting the underlying 
causes.31-33 Improvement in therapeutic modalities requires better understanding of 
molecular pathways involved in the initiation and progression of these diseases. 
Much of the available information about the underlying mechanisms of skeletal and 
cardiac muscles disorders is obtained from in vivo studies. These studies are, 
however, complicated by the complexity of three-dimensional (3D) tissues, the 
occurrence of disease symptoms secondary to the primary condition, primary causes 
directly affecting other organs besides the heart and skeletal muscles and the 
interplay between different organ systems. For example, Duchenne muscular 
dystrophy (DMD), the most common inherited myopathy affects different skeletal 
muscles to a different extent but may also impair cardiac and brain function to 
various degrees depending on the specific mutation involved.34-37 Also, the 
coincident presence of e.g. inflammation, hypoxia and fibrosis in PCH makes it very 
hard to determine its specific/mechanistic contribution to the occurrence of 
arrhythmias.38,39  
The development and use of dedicated cellular experimental models to study the 
mechanisms underlying skeletal and cardiac muscle diseases in combination with 




genetic interventions to investigate the role of specific factors, may resolve these 
limitations and lay the basis for the development of novel treatment options. 
 
Cellular models 
Cultures of skeletal myoblasts or cardiomyocytes offer the possibility to analyse 
cellular functions and molecular pathways in a highly specific and controllable 
manner, which is difficult to accomplish in vivo. Given the ease with which in vitro 
models can be established and manipulated to mimic physiological or pathological 
conditions, they are ideally suited for proof-of-concept studies and testing new 
therapeutic interventions targeting specific aspects of disease. Indeed, cellular 
models have greatly contributed to our current understanding of skeletal and cardiac 
muscle diseases.40,41 Although their relative simplicity facilitates data interpretation, 
cells in culture are not subjected to the complex regulatory systems controlling organ 
function in vivo. Accordingly, results obtained in in vitro experiments will always need 
to be validated in clinical studies. In spite of their shortcomings, in vitro models keep 
on being highly useful for mechanistic and therapy-directed skeletal and cardiac 
muscle research. This is particularly true when cell culture models are combined with 
genetic interventions to investigate the involvement of specific genes in physiological 
and pathophysiological processes. 
 
Genetic interventions 
Recently, there has been considerable interest in the application of gene therapy in 
the field of skeletal and cardiac muscle diseases. Many of these genetic 
interventions have focussed on counteracting the pathological processes in failing 
myocytes either directly by correction of the underlying genetic defect if applicable or 
indirectly by inhibition of pathogenic mechanisms or stimulation of physiological 
processes. Gene therapy has, for example, been used to complement gene 
mutations causing various types of muscular dystrophy including DMD as well as 
defects in several sarcomeric protein genes linked to PCH.42,43  Genetic intervention 
can be also employed for overexpression of a protein like sarcoplasmic reticulum 
Ca2+-ATPase pump (Serca2a) to improve cardiac function44 or downregulation of a 
protein like the acetylcholine-acticated K+ channel Kir3.4 to terminate atrial fibrillation 
(AF).45 Clinical and preclinical studies have shown beneficial effects of myocardial 
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gene transfer in neovascularization of ischemic myocardium, increasing myocardial 
contractility, induction of cardiac repair and reduction of AF and ventricular 
tachycardia vulnerability. 46-51 Gene therapy has also demonstrated improvements in 
skeletal muscle disorders.52-54 The safe and successful delivery of a gene is very 
important in order to gain high therapeutic efficacy. A large number of gene delivery 
methods have been developed using both viral and non-viral vectors, each of which 
have their own pros and cons. Non-viral methods include using naked DNA alone or 
in combination with cationic liposomes or polymers.55,56 Non-viral vectors are 
typically easy to synthesize and can be used for the transfer of genetic material of all 
kind of different sizes. Additional advantages of non-viral vectors are their safety and 
the ease with which they can be modified e.g. to alter their cell tropism. By applying 
non-viral gene delivery one can avoid disadvantages intrinsic to the use of viral 
vectors such as limited genetic payloads and expensive/laborious production 
methods. Also, nonviral vectors are generally less immunogenic and have a lower 
risk of insertional oncogenesis than viral vectors.57 Major limitations of non-viral 
vectors are their very low in vivo gene transfer activity and their difficulty to efficiently 
transduce differentiated cells both in vitro and in vivo. Viral vectors are much better 
suited for this purpose especially when high transduction rates and transgene 




Viral vectors are commonly used for the genetic modification of skeletal and cardiac 
muscle cells and tissues because they transfer genes much more efficiently than any 
of the non-viral vectors. The most commonly used viral vectors are derived from 
retroviruses (including lentiviruses), adenoviruses and adeno-associated virus, which 
belongs to the parvoviruses. These potentially harmful viruses are converted into 
innocuous viral vectors by the replacement of one or more essential viral genes by 
heterologous gene expression units, which renders the viral vectors replication-
deficient but still allows introduction and expression of their genetic cargo into target 
cells. The production of these vectors requires the missing viral genes to be provided 
in trans through packaging plasmids, complementing cell lines or helper viruses.  
 





The first retroviral vectors were derived in the 1980s from gammaretroviruses. Since 
these vectors require cell division for efficient transduction, they are not suitable for 
the genetic modification of differentiated cell types like skeletal and cardiac 
myocytes. Unlike gammaretroviral vectors, lentivirus vectors (LVs) do not depend on 
cell division for efficient transduction of target cells. Following target cell entry, the LV 
genome, which consists of a positive-sense, single-stranded linear RNA molecule, is 
reverse transcripted into cDNA and subsequently integrated into the host cell 
genome. LV vectors can accommodate a fair amount of foreign DNA due to the 
absence of a strict upper packaging limit. There is, however, an inverse relationship 
between LV yields and genome lengths59 which practically restricts insert sizes to ± 5 
kb. LVs are generally produced in human embryonic kidney (HEK) 293T cells by a 
simple transfection procedure involved a LV shuttle plasmid and two or three so-
called helper or packaging plasmids. These features and the ease with which LVs 
can be generated may explain why LVs have become such popular gene delivery 
vehicles for the permanent ex vivo genetic modification of both differentiated and 
proliferating cell populations.60,61 LVs are much less suitable for in vivo gene 
therapies due to their large diameter, which hampers their spreading through tissues, 
and the preferential integration of LV genomes into transcriptionally active 
chromosome loci imposing a certain risk of insertional oncogenesis.62,63 Currently, 
much effort is put in the improvement of lentiviral vector design to reduce as much as 
possible the risk of insertional oncogenesis.64,65  
 
Adenoviral vectors 
Adenoviral vectors (AdVs) have the capacity to carry large DNA molecules (± 37 kb 
for human adenovirus type 5), can be produced in very large quantities and very 
efficiently transduce all kinds of cells, irrespective of their cell cycle status. AdV 
genomes are linear double-stranded DNA molecules covalently linked at their 5’ 
ends to the so-called terminal protein.66 These genomes normally do not integrated 
to the host chromosomal DNA but reside in the nucleus of the target cells as 
nonreplicating episomes, which causes transient expression especially in dividing 
cell populations but simultaneously limits concerns related to oncogene activation. 
The main disadvantages of AdVs are their large size limiting their dissemination 
through tissue and their relatively high immunogenicity, which may result in the in 
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vivo elimination of transduced cells by cell-mediated immune responses. This latter 
problem especially applies to first- and second-generation AdVs, which in contrast to 
their third-generation counterparts still contain adenoviral genes that are express at 
low levels in target cells. As a consequence, severe inflammation leading to toxicity 
and even, in very rare cases, organ failure has been reported following in vivo 
administration of early-generation AdVs.67 In recent year, AdV vector development 
has mainly focussed on lowering the immunogenicity of the adenovirus particle, 
reducing unintended interactions with host proteins and increasing target cell 
specificity by chemical or genetic modification of the adenoviral capsid/coat 
proteins.68,69  
 
Adeno-associated virus vectors 
Adeno-associated virus vectors (AAVs) carry a single-stranded DNA genome with a 
T-shaped hairpin at both termini. Following their delivery in the target cell nucleus 
most AAV DNA is converted into highly stable double-strand circular monomers and 
concatemers. Moreover, AAVs are significantly less immunogenic than AdVs, which 
is partially explained by the absence in the vector genome of parvoviral genes. 
Because of these property AAVs can mediate long-term albeit not permanent gene 
expression.70 Another advantage of AAVs is their small diameter, which allows them 
to easily penetrate tissues. The downside of their small size is their limited packaging 
capacity, which does not allow incorporation of transgene > 4.7 kb. Other 
disadvantages of AAVs include the time-consuming and expensive procedures 
needed for their production and purification and their relatively low gene transfer 
activity requiring high amount of AAV particles to achieve efficient transduction.71 In 
addition, due to the slow onset of transgene expression AAVs cannot be used for 
studies with a short time course. Still, at present AAVs are the only viral vectors that 
can tranduce entire organs, including the heart.72 Therefore, currently, much effort is 
put in improving AAV production methods and in modifying the vector genome and 
capsid to increase the specific gene transfer activity of AAVs and to overcome their 









Aim an outline of the thesis 
The limited suitability of existing experimental models for acquiring a thorough 
understanding of the mechanisms underlying skeletal and cardiac muscle diseases 
and the lack of efficiency and specificity of many of the currently available 
therapeutic interventions have made efficient treatment of these diseases 
challenging. Therefore, the aim of this thesis is to establish dedicated cellular models 
and use viral vector systems to study the biology of skeletal and cardiac muscles in 
healthy and diseased states and thereby identify potential targets for future 
therapeutic interventions. 
Chapter I of this thesis explains the common pathological features of skeletal and 
cardiac muscle diseases, the limitations of current therapies and advantages of 
cellular models and genetic interventions in improved treatment of these diseases. 
The successful deployment of cell transplantation in skeletal muscle disorders 
depends on the potential of the donor cells to engage in myotube formation 
(myogenesis), which is amongst others determined by the ability of the transplanted 
cells to fuse with cells present in the host tissue.5,74 Cell fusion also plays an 
important role in fertilization, syncytiotrophoblast production, bone remodelling, eye 
lens development and certain forms of tissue repair.75 Different methods can be used 
for monitoring cell fusion activity. These methods and a newly developed non-
destructive quantitative cell fusion assay are described in chapter II.  
Efficient engraftment of transplanted cells is another factor which determines the 
success rate of transplantation. Scaffolds provide a framework for cells to attach, 
proliferate, and form extracellular matrix in vivo. The scaffolds may also serve as 
carriers for cells, growth factors, and/or other biomolecular signals. Ideally, scaffolds 
should be degraded in vivo at an appropriate rate to allow its gradual replacement by 
regenerated host tissue. Therefore, the in vivo biodegradability of 
Gelatin/Siloxane/Hydroxyapatite scaffolds and their ability to support adhesion and 
proliferation of rat bone marrow mesenchymal stem cells have been studied in 
chapter III.  
Employment of 2D cell culture models makes it possible to study the contribution of 
PCH per se to arrhythmogenicity, which cannot be easily done in vivo due to the 
simultaneous presence of other pro-arrhythmic features. Induction of hypertrophy-
related pathological changes in cardiomyocyte cultures can be achieved by exposing 
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the cells to a variety of different peptide and non-peptide hormones and growth 
factors. It has been shown that phorbol 12-myristate 13-acetate (PMA), which 
activates protein kinases C and D, induces a gene expression program in cardiac 
muscle cells resembling that of cardiomyocytes in pathologically hypertrophied 
hearts.76-78 In chapter IV, the use of the PMA to establish an in vitro model of PCH 
based on ventricular neonatal rat cardiomyocytes is described and its pro-arrhythmic 
features are studied. 
Early- and no-reperfusion after myocardial infarction (MI) leads to formation of 
patchy and compact scars, respectively. These post MI scars facilitate circular 
conduction of the impulses in the heart. How scar composition affects 
arrhythmogenicity and arrhythmic phenotype has been investigated in an in vitro 
model in chapter V. 
Atrium-selective drugs and interventions with higher efficacy in AF rhythm control but 
fewer side effects such as ventricular pro-arrhythmia are paramount needs in AF 
treatment. In chapter VI, the role of acetylcholine-activated K+ channels, whose 
expression in mammalian hearts is largely restricted to the atria, has been studied in 
AF initiation, dynamics and termination in a cell culture and whole-heart model of AF.  
Finally, chapter VII summarizes the findings of this thesis and provides future 
perspectives based on the conclusions drawn from each study.  
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Cell-to-cell fusion can be quantified by endowing acceptor and donor cells with latent 
reporter genes/proteins and activators of these genes/proteins, respectively. One 
way to accomplish this goal is by using a bipartite lentivirus vector (LV)-based cell 
fusion assay system in which the cellular fusion partners are transduced with a 
flippase-activatable Photinus pyralis luciferase (PpLuc) expression unit (acceptor 
cells) or with a recombinant gene encoding FLPeNLS+, a nuclear-targeted and 
molecularly evolved version of flippase (donor cells). Fusion of both cell populations 
will lead to the FLPe-dependent generation of a functional PpLuc gene. PpLuc 
activity is typically measured in cell lysates, precluding consecutive analysis of one 
cell culture. Therefore, in this study the PpLuc-coding sequence was replaced by 
that of Gaussia princeps luciferase (GpLuc), a secretory protein allowing repeated 
analysis of the same cell culture. In myotubes the spread of FLPeNLS+ may be limited 
due to its nuclear localization signal (NLS) causing low signal outputs. To test this 
hypothesis, myoblasts were transduced with LVs encoding either FLPeNLS+ or an 
NLS-less version of FLPe (FLPeNLS-) and subsequently co-cultured in different ratios 
with myoblasts containing the FLPe-activatable GpLuc expression cassette. At 
different times after induction of cell-to-cell fusion the GpLuc activity in the culture 
medium was determined. FLPeNLS+ and FLPeNLS- both activated the latent GpLuc 
gene but when the percentage of FLPe-expressing myoblasts was limiting, FLPeNLS+ 
generally yielded slightly higher signals than FLPeNLS- while at low acceptor-to-donor 
cell ratios FLPeNLS- was usually superior. The ability of FLPeNLS+ to spread through 
myofibers and to induce reporter gene expression is thus not limited by its NLS. 
However, at high FLPe concentrations the presence of the NLS negatively affected 
reporter gene expression. In summary, a rapid and simple chemiluminescence assay 
for quantifying cell-to-cell fusion progression based on GpLuc has been developed. 






During cell-to-cell fusion, plasma membranes of individual cells merge to form a 
multinucleated structure called a syncytium. Plasma membrane fusion is a crucial 
event during, for example, fertilization, syncytiotrophoblast production, skeletal 
muscle formation, bone remodeling, eye lens development and certain forms of 
tissue repair.1 In general, cell fusion is a tightly regulated and highly selective 
process involving specific cell types. Inappropriate cell fusion has been implicated in 
tumor development and progression.2 
Cell fusion can be easily observed using microscopic techniques and in many 
studies the extent of cell fusion is expressed as fusion index, which either stands for 
the percentage of cells with two or more nuclei or the percentage of nuclei present in 
syncytia.3 However, without continuous monitoring, it is impossible to decide by 
microscopy alone whether multinucleation is caused by cell fusion or the result of 
karyokinesis without cytokinesis. In addition, cells growing on top of each other can 
be mistaken for syncytia. Furthermore, as fusion index determinations are generally 
carried out manually, they are laborious, error-prone and often inaccurate. This has 
led to the development of methods for quantifying cell fusion independent of 
microscopic inspection. Nearly all these methods are based on systems of two 
components that interact to create a novel detectable signal only after cell fusion.3 
Mohler and Blau, for example, developed a quantitative cell fusion assay based on 
functional complementation between two biologically inactive β-galactosidase 
deletion mutants.4 Another possibility to produce fusion-dependent signals is by 
applying site-specific recombination systems such as Cre-loxP and FLP-FRT. In 
these systems, a latent reporter gene is activated by the action of the site-specific 
DNA recombinase Cre from bacteriophage P1 or flippase/FLP from Saccharomyces 
cerevisiae, which catalyze the excision and inversion of DNA flanked by 34-base pair 
(bp) recognition sequences (loxP for Cre and FRT for FLP) in a direct or inverted 
repeat configuration, respectively.5,6 
Gonçalves et al. previously developed a bipartite lentivirus vector (LV)-based cell 
fusion assay system in which the cellular fusion partners are endowed with a FLP-
activatable Photinus pyralis luciferase (PpLuc) expression unit/”gene switch” 
(acceptor cells) or with a recombinant gene encoding a molecularly evolved version 
of FLP (FLPe) with a nuclear localization signal (NLS) derived from the simian virus 
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40 large T antigen (donor cells).7 Fusion between acceptor and donor cells led to the 
FLPe-dependent generation of a functional episomal PpLuc expression module. This 
cell fusion monitoring system was successfully used to study the role of the p38 
MAPK signaling pathway in myoblast fusion/myotube formation. However, since 
PpLuc is a cytoplasmic protein and its substrate D-luciferin is poorly membrane-
permeable, this assay requires lysis of the cells prior to luminometry and does not 
allow repeated analysis of the same cell culture. This prompted us to develop a 
nondestructive method to quantify cell fusion using the bipartite LV-based cell fusion 
assay system described by Gonçalves and colleagues as starting point. 
The key difference between the new and “old” version of the LV-based cell fusion 
assay system is the replacement of the PpLuc open reading frame (ORF) in the 
“original” gene switch construct by the humanized coding sequence of Gaussia 
princeps luciferase (GpLuc), which is a secretory protein converting the substrate 
coelenterazine into coelenteramide plus light. GpLuc also displays a much higher 
specific luciferase activity than PpLuc and is exceptionally resistant to exposure to 
heat and strongly acidic and basic conditions.8 In addition, we hypothesized that in 
myotubes the spread of nuclear-targeted FLPe (FLPeNLS+) beyond the direct 
surroundings of donor nuclei may be limited due to the presence of the NLS. This 
would result in the activation of only a fraction of the reporter genes especially in 
hybrid myotubes containing a relatively low percentage of FLPe gene-positive donor 
nuclei compared to GpLuc-encoding acceptor nuclei. To test this hypothesis, we 
generated an LV encoding an NLS-less version of FLPe (FLPeNLS-) and compared, in 
myogenic fusion assays, its ability to activate latent GpLuc genes with that of 
FLPeNLS+. 
 
Materials and Methods 
 
Plasmids 
DNA constructions were carried out with enzymes from Fermentas (Fisher Scientific, 
Landsmeer, the Netherlands) or from New England Biolabs (Bioké, Leiden, the 
Netherlands) by using established procedures9 or following the instructions provided 
with specific reagents. 
To generate a bicistronic self-inactivating (SIN) human immunodeficiency virus 
type 1 (HIV1) vector shuttle plasmid coding for Streptomyces alboniger puromycin N-




acetyl transferase (PurR) and FLPeNLS-, pLV.FLPe.PurR (7; GenBank accession 
number: GU253314; hereinafter referred to as pLV.hCMV-
IE.FLPeNLS+.IRES.PurR.hHBVPRE; Figure 1A) was digested with BshT1 and Eco81I 
and the 9.6-kb DNA fragment containing the vector backbone was purified from 
agarose gel. The hybridization product of oligodeoxyribonucleotides 5’ 
CCGGTACCATGAGTCAATTTGATATATTATGTAAAAC-ACCACC 3’ and 5’ 
TTAGGTGGTGTTTTACATAATATATCAAATTGACTCATGGTA 3’ (both from 
Eurofins MWG Operon, Ebersberg, Germany) was combined with the 9.6-kb 
BshT1×Eco81I fragment of pLV.hCMV-IE.FLPeNLS+.IRES.PurR.hHBVPRE by ligation 
with bacteriophage T4 DNA ligase producing pLV.hCMV-IE.FLPeNLS-





Figure 1. Structure of the LV DNA in the LV shuttle plasmids. (A): pLV.hCMV-
IE.FLPeNLS+.IRES.PurR.hHBVPRE (B): pLV.hCMV-IE.FLPeNLS-.IRES.PurR.hHBVPRE (C): 
pLV.hCMV-IE.IRES.PurR.hHBVPRE and (D): pLV.GS.GpLuc.v1. The start codons of the 
FLPeNLS+ and FLPeNLS- ORFs are shown in boldface. 5’ LTR, chimeric 5’ long terminal repeat 
containing the Rous sarcoma virus U3 region and the HIV1 R and U5 regions; Ψ, HIV1 
packaging signal; RRE, HIV1 Rev-responsive element; cPPT, HIV1 central polypurine tract 
and termination site; hCMV-IE, human cytomegalovirus immediate early gene promoter; 
FLPeNLS+, molecularly evolved flippase with simian virus 40 (SV40) nuclear localization 
signal (NLS; black bar); FLPeNLS-, molecularly evolved flippase without NLS; EMCV IRES, 
encephalomyocarditis virus internal ribosomal entry site; PurR; Streptomyces alboniger 
puromycin N-acetyl transferase-coding sequence; hHBVPRE, human hepatitis B virus 
posttranscriptional regulatory element; black triangle/FRT, flippase recognition target 
sequence; hGAPDH, human glyceraldehyde 3-phosphate dehydrogenase gene promoter; 
rHBB2 pA, rabbit β-hemoglobin gene polyadenylation signal; GpLuc, Gaussia princeps 
luciferase-coding sequence; mMT1 pA, mouse metallothionein 1 gene polyadenylation 
signal; 3’ LTR, 3’ HIV1 long terminal repeat containing a deletion in the U3 region to render 
the LV self-inactivating. 
 




To generate a SIN-LV shuttle plasmid carrying a silent GpLuc gene that can be 
activated by FLP, cloning vector pR6K.MCS was digested with XmaJI and NotI, the 
2.2-kb DNA fragment containing the vector backbone was purified from agarose gel 
and combined with the 0.6-kb GpLuc-encoding XmaJI×NotI fragment of 
phGluc.dBamHI yielding construct pR6K.GpLuc. The cloning vector pR6K.MCS was 
derived from construct pA1.GFP.A2 (10; GenBank accession number: GQ380658) by 
combining its 2.0-kb SalI×Aflll fragment with the 0.3-kb SalI×Aflll fragment of 
pMOLUC (11; Addgene, Cambridge, MA; plasmid number: 12514). Plasmid 
phGluc.dBamHI was made from the mammalian expression vector phGluc (12; 
Addgene; plasmid number: 22522) by self-ligation of its 2.9-kb BamHI fragment. The 
GpLuc ORF was excised from pR6K.GpLuc by digestion with XmaJI and MluI and 
combined with the 7.2-kb BcuI×MluI fragment of pLV.GS.DsRed.dKpnI to generate 
pLV.GS.GpLuc.v1 (Figure 1D). The LV shuttle plasmid pLV.GS.DsRed.dKpnI was 
derived from pLV.pA+.GS.DsRed (7; GenBank accession number: GU253312) by 
self-ligation of its 7.9-kb KpnI fragment. The SIN-LV shuttle plasmid 
pLV.GS.GpLuc.v6 is a derivative of construct pLV.pA+.GS.Luc (7, hereinafter 
referred to as pLV.GS.PpLuc), in which the sequences interspersed between the 
rabbit β-hemoglobin gene polyadenylation signal (rHBB pA) and the mouse 
metallothionein 1 gene (mMT1) pA (i.e. the PpLuc ORF and an FRT sequence) are 
replaced by a synthetic DNA fragment comprising the GpLuc ORF and an FRT 
sequence. More details about the genetic makeup of pLV.GS.GpLuc.v1, 
pLV.GS.GpLuc.v6 and pLV.GS.PpLuc and about the nucleotide sequences located 
in between the mMT1 pA and Luc ORFs of these three SIN-LV plasmids are 





Figure 2. Improved design of the GpLuc gene switch cassette. (A-C): Detailed structure of 
the areas upstream of the Luc ORFs in pLV.GS.GpLuc.v1 (A), pLV.GS.GpLuc.v6 (B) and 
pLV.GS.PpLuc (C) starting at the HIV1 3’ LTR. U5, HIV1 LTR unique 5’ region; R, HIV1 LTR 
repeat region; ΔU3, enhancer- and promoterless HIV1 LTR unique 3’ region; blue arrow, 
mouse metallothionein 1 gene polyadenylation signal (mMT1 pA); small black triangle, 
AATAAA motif in mMT1 pA; red diamonds, stop codons in frame with Luc ORFs; large black 
triangle, minimal FRT sequence; light yellow arrow, GpLuc ORF; green box, 5’ in-frame 
extension of the GpLuc ORF; white arrows, out-of-frame ORFs preceding Luc ORFs; red 
arrows, in-frame ORFs preceding Luc ORFs; dark yellow arrow, PpLuc ORF. 
 





Figure 3. Alignment of the nucleotide sequences immediately upstream of the Luc ORFs in 
pLV.GS.GpLuc.v1, pLV.GS.PpLuc and pLV.GS.GpLuc.v6. Blue box, 3’ end of the mMT1 pA; 
underlined sequences, out-of-frame ORFs preceding Luc ORFs; boxed TAA sequences, in-
frame stop codons preceding Luc ORFs; red letters, in-frame ORFs preceding Luc ORFs; 
green letters, 5’ in-frame extension of the GpLuc ORF in pLV.GS.GpLuc.v1; black box, 
minimal FRT sequence; boxed ATG sequences, Luc initiation codons; light yellow box, 5’ 
end GpLuc ORF; dark yellow box, 5’ end PpLuc ORF. 
 
The ligation mixtures were introduced in chemocompetent cells of Escherichia coli 
strain GeneHogs (Life Technologies Europe, Bleiswijk, the Netherlands) or GT115 
(InvivoGen, San Diego, CA). Large-scale plasmid purifications were performed using 




The culture and differentiation conditions of the murine Bmi1- and human TERT-
immortalized human myoblasts (iDMD myoblasts) have been described previously.13 
 
Viral vectors 
The vesicular stomatitis virus G protein-pseudotyped SIN-LVs LV.FLPeNLS+.PurR, 
LV.FLPeNLS-.PurR, LV.PurR (negative control vector), LV.GS.GpLuc.v1, 
LV.GS.PpLuc and LV.GS.GpLuc.v6 were generated in 293T cells with the aid of the 
LV shuttle plasmids pLV.hCMV-IE.FLPeNLS+.IRES.PurR.hHBVPRE, pLV.hCMV-
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IE.FLPeNLS-.IRES.PurR.hHBVPRE, pLV.CMV.IRES.PURO (14, hereinafter referred to 
as pLV.hCMV-IE.IRES.PurR.hHBVPRE; Figure 1C), pLV.GS.GpLuc.v1, 
pLV.GS.PpLuc and pLV.GS.GpLuc.v6, respectively. The 293T cells were transfected 
with one of the LV shuttle constructs and the packaging plasmids psPAX2 (Addgene; 
plasmid number: 12260) and pLP/VSVG (Life Technologies Europe) at a molar ratio 
of 2:1:1. To concentrate and purify the LV particles, producer cell supernatants were 
layered onto 5-ml cushions of 20% (wt/vol) sucrose in phosphate-buffered saline 
(PBS) and centrifuged at 15,000 rotations per minute for 2 h at 4°C in an SW32 rotor 
(Beckman Coulter Nederland, Woerden, the Netherlands). Prior to ultracentifugation, 
producer cell supernatants were clarified by low speed centrifugation and filtration 
through 0.45-µm pore-sized cellulose acetate filters (Pall Netherlands, Mijdrecht, the 
Netherlands). For more details about the SIN-LV production method, see 15. The 
titers of the resulting LV stocks were determined using the RETROTEK HIV-1 p24 
Antigen ELISA kit (ZeptoMetrix, Franklin, MA) following the instructions provided by 
the manufacturer. To derive functional titers from these measurements a conversion 
factor of 2.5 transducing units (TUs) per pg of HIV-1 p24 protein was used. 
 
Cell transductions 
Cryopreserved LV.FLPeNLS+.PurR-transduced iDMD myoblasts (7; hereinafter 
referred to as myoblasts-FLPeNLS+) were thawed and cultured in the presence of 
puromycin (Life Technologies Europe) at a final concentration of 0.4 µg/ml to prevent 
transgene silencing. FLPeNLS--expressing iDMD myoblasts were generated by 
overnight (± 20 h) exposure of 105 cells in a well of a 24-well cell culture plate 
(Greiner Bio-One, Alphen aan den Rijn, the Netherlands) to 30 TUs of LV.FLPeNLS-
.PurR per cell in 500 µl of growth medium in a humidified atmosphere of 5% 
CO2/95% air at 37°C. The next day, the cell monolayer was rinsed three times with 1 
ml of PBS after which fresh culture medium was added. At 3 days post transduction, 
the culture of LV.FLPeNLS-.PurR-treated cells (hereinafter referred to as myoblasts-
FLPeNLS-) as well as a control culture of untransduced iDMD myoblasts were given 
medium containing 0.8 µg/ml of puromycin. Within a week, all cells in the culture of 
untransduced iDMD myoblasts had died while the cells in the LV.FLPeNLS-.PurR-
treated culture were nicely expanding. The myoblasts-FLPeNLS- were passaged once 
a week (split ratio 1:3) in growth medium containing 0.4 µg/ml of puromycin. 
MyoblastsGS.GLuc, myoblastsGS.PLuc and myoblastsGS.GLuc+ were generated likewise by 




exposure of iDMD myoblasts to LV.GS.GpLuc.v1, LV.GS.PpLuc and 
LV.GS.GpLuc.v6, respectively. Before being used for co-culture experiments, the 
cells were passaged at least three times to rule out secondary transduction of the 
FLPe-expressing myoblasts in the co-cultures with luciferase-encoding SIN-LVs.16 
 
Co-culture establishment and maintenance 
Co-cultures containing a total number of 2×105 cells were established in wells of 24-
well culture plates by mixing myoblasts-FLPeNLS+ or myoblasts-FLPeNLS- with 
myoblastsGS.GLuc at the indicated ratios. Following an incubation period of about 72 h 
when the cell monolayers had reached 90-100% confluency, the growth medium was 
substituted by 400 µl of either differentiation medium or fresh growth medium. At 
specified time points thereafter, the culture medium (400 µl) was collected and 
stored at -80°C for luciferase assay. The co-cultures were then either terminated or 
further incubated at 37°C in a water-saturated atmosphere of 5% CO2/95% air. 
To compare the performance of the newly developed LV.GS.GpLuc.v1-based cell 
fusion assay system with that of the previously described LV.GS.PpLuc-based cell 
fusion quantification method7, myoblastsGS.GLuc or myoblastsGS.PLuc were co-cultured 
with myoblasts-FLPeNLS+ in different ratios in 24-well culture plates containing 2×105 
cells per well. Samples (culture fluid for cultures containing myoblastsGS.GLuc and cell 
lysates for cultures containing myoblastsGS.PLuc) were harvested 96 h and 120 h after 
induction of myogenic differentiation. Exactly the same approach was used to 
compare the LV.GS.GpLuc.v1- and LV.GS.GpLuc.v6-based cell fusion assays. 
 
Immunocytology 
At different time points after the initiation of differentiation, 1:1 co-cultures of 
myoblasts-FLPeNLS- and myoblastsGS.GLuc were fixed by incubation for 30 minutes at 
room temperature (RT) in PBS containing 4% formaldehyde. To permeabilize the 
cells, they were exposed for 10 minutes at RT to 0.1% Triton X-100 in PBS. Next, 
cells were incubated overnight at 4°C with mouse anti-skeletal muscle troponin I 
(skTnI) primary antibody (HyTest, Turku, Finland; clone 12F10) diluted 1:100 in PBS 
+ 0.1% donkey serum (Santa Cruz Biotechnology, Santa Cruz, CA) followed by a 2-h 
incubation at RT with Alexa Fluor 568-conjugated donkey anti-mouse IgG (H+L) 
secondary antibody (Life Technologies Europe) diluted 1:400 in PBS + 0.1% donkey 
serum. Counterstaining of nuclei was performed with 10 µg/ml Hoechst 33342 (Life 
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Technologies Europe) in PBS. Cells were washed three times with PBS after 
fixation, permeabilization and incubation with primary antibody, secondary antibody 
and DNA-binding fluorochrome. To minimize photobleaching, coverslips were 
mounted in Vectashield mounting medium (Vector Laboratories, Burlingame, CA). 
Pictures were taken with a fluorescence microscope equipped with a digital color 
camera (Nikon Eclipse 80i; Nikon Instruments Europe, Amstelveen, the Netherlands) 
using NIS Elements software (Nikon Instruments Europe). 
 
Subcellular fractionation and western blotting 
Myoblasts-FLPeNLS+ and myoblasts-FLPeNLS- were cultured separately in 24-well cell 
culture plates at a density of 2×105 cells per well. Following an incubation period of 
72 h when the cell monolayers had reached 90-100% confluency, the growth 
medium was substituted by 400 µl of either differentiation medium or fresh growth 
medium. Ninety-six h later, cell fractionation was carried out as described by Suzuki 
et al.17 with the following modifications. Cell pellets were suspended in 97.5 μl of ice-
cold 0.1% NP40 in PBS. One-third of the lysate was removed as “whole cell lysate” 
and mixed with 5 μl of 10× NuPAGE Sample Reducing Agent and 12.5 μl of 4× 
NuPAGE LDS Sample Buffer (both from Life Technologies Europe). The rest of the 
lysate was briefly centrifuged at 4°C after which 32.5 μl of the supernatant was 
removed as “cytosolic fraction” and supplemented with 5 μl of 10× NuPAGE Sample 
Reducing Agent and 12.5 μl of 4× NuPAGE LDS Sample Buffer. The remaining 
supernatant was removed and the pellet was washed with and suspended in 30 μl 
PBS, after which 5 μl of 10× NuPAGE Sample Reducing Agent and 12.5 μl of 4× 
NuPAGE LDS Sample Buffer were added to produce the “nuclear fraction”. Nuclear 
fractions and whole cell lysates were sonicated for 2 times 10 seconds at 200 Hz 
using a Soniprep 150 ultrasonic disintegrator (Measuring and Scientific Equipment, 
London, United Kingdom). After incubating the samples for 1 minute at 100°C, 10 μl 
of whole cell lysate, 10 μl of cytosolic fraction and 5 μl of nuclear fraction were 
applied to a NuPAGE Novex 12% Bis-Tris gel (Life Technologies Europe). Following 
electrophoretic separation, the proteins were transferred to a polyvinylidene 
difluoride membrane (Amersham Hybond P; GE Healthcare Europe, Diegem, 
Belgium) by wet electroblotting. Next, the membrane was incubated with 2% ECL 
AdvanceTM blocking agent (GE Healthcare Europe) in PBS-0.1% Tween 20 (PBST) 
for 1 h at RT and probed with rabbit anti-FLP (1:200; Diagenode, Seraing, Belgium; 




CS-169-100), mouse anti-glyceraldehyde 3-phosphate dehydrogenase (GAPDH; 
1:10,000; Merck Millipore, Billerica, MA; clone 6C5) or rabbit anti-lamin A/C 
(1:10,000; Santa Cruz Biotechnology; sc-20681) primary antibodies overnight at 4°C, 
followed by a 1-h incubation with appropriate horseradish peroxidase-conjugated 
secondary antibodies (Santa Cruz Biotechnology). GAPDH served as cytoplasmic 
marker protein and lamin A/C antibody was used as nuclear marker protein. Target 
protein signals were visualized using the SuperSignal West Femto Maximum 
Sensitivity Substrate Kit (Thermo Scientific, Rockford, IL) and chemiluminescence 
was measured with the ChemiDoc XRS imaging system (Bio-Rad Laboratories, 
Veenendaal, the Netherlands). 
 
FLPe functionality test 
To test the functionality of the FLPe molecules encoded by LV.FLPeNLS+.PurR and 
LV.FLPeNLS-.PurR, myoblastsGS.GLuc were transduced with LV.FLPeNLS+.PurR, 
LV.FLPeNLS-.PurR or LV.PurR. MyoblastsGS.GLuc were seeded in a 24-well cell culture 
plate at a density of 105 cells per well and exposed for 20 h to 75 μl per well of 
concentrated vector stock diluted in growth medium to a final volume of 500 µl. Next, 
the cell monolayers were rinsed three times with 1 ml of PBS after which 400 µl fresh 
growth medium was added. At 24 h after the removal of the inoculum, the culture 
medium was collected and transiently stored at -80°C for subsequent analysis of 
luciferase activity. The cells were overlaid with 400 µl of fresh growth medium, which 
was harvested 24 h later for storage at -80°C until luciferase activity measurement. 
 
Luciferase assay 
After thawing the GpLuc-containing samples on ice, 50 µl of each sample was 
transferred to a well of a white opaque 96-well flat-bottom microtiter plate (OptiPlate-
96; PerkinElmer, Groningen, the Netherlands) for chemiluminescence 
measurements. The native coelenterazine (Promega Benelux, Leiden, the 
Netherlands) stock solution (5 mg/ml in acidified methanol) was diluted 1,000 times 
in phenol red-free Dulbecco’s modified Eagle’s medium (Life Technologies Europe) 
and equilibrated for 1 h in the dark at RT before starting the measurements. The 
luciferase activity was measured at RT with the aid of a Wallace 1420 VICTOR 3 
multilabel plate reader with automatic injection system (PerkinElmer). Immediately 
after automated addition of 20 µl of substrate to a well, substrate and sample were 
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mixed by shaking for 1 second (double orbital, 0.1 mm, normal speed). PpLuc 
activity was measured in cell lysates as previously described.7 For each condition, 
three independent samples were measured in three series of measurements. 
 
Statistical analysis 
Different experimental groups were compared using the independent samples t-test. 
Differences among means were considered significant at P≤0.05. Graphs were 




Microscopic analysis of cell fusion kinetics 
Cultured myoblasts can be prompted to fuse with each other by withdrawing 
mitogens from the culture medium. This causes a time-dependent accumulation of 
nuclei in syncytial structures called myotubes or myosacs depending on whether 
these structures are elongated or rounded. To get a first impression of the cell-to-cell 
fusion kinetics of the genetically modified iDMD myoblasts, 1:1 co-cultures of 
myoblasts-FLPeNLS- and myoblastsGS.GLuc were exposed to myogenic differentiation 
conditions. As shown in the upper panel of Figure  4, the myoblasts started to fuse 
48 h after serum withdrawal resulting in the formation of myotubes/sacs. Both the 
percentage of nuclei present in myotubes/sacs as well as the size of the syncytia 
increased with time until 120 h following serum removal, after which the cells started 
to detach from the surface of the culture plates. The fusion process was 
accompanied by the accumulation of sarcomeric proteins as evinced by the results 
of the skTnI-specific immunostaining depicted in the lower panel of Figure 4. 
  





Figure 4. Microscopic analysis of cell fusion kinetics in 1:1 co-cultures of myoblasts-FLPeNLS- 
and myoblastsGS.GLuc after maintenance for 72 h in growth medium and subsequent exposure 
to differentiation medium. At 24, 48, 72, 96 or 120 h after initiation of differentiation the cells 
were fixed and immunostained for skTnI (red fluorescence). The blue fluorescence 
corresponds to nuclei labeled with the karyophilic dye Hoechst 33342. The upper and lower 
row of pictures show phase-contrast images and fluoromicrographs, respectively. The first 
syncytia appeared at ± 48 h after serum removal. The cell cultures displayed a time-
dependent increase in frequency and size of myotubes/sacs until the cells started to detach 
from the surface of the culture plates. In parallel cultures of myoblasts kept in normal growth 
medium the cells remained firmly attached to their support and only few small syncytia were 
observed at late times after culture initiation (data no shown). 
 
Immunodetection of FLPe in LV.FLPeNLS+/-.PurR-transduced iDMD myoblasts 
To compare FLPe protein level and intracellular distribution between myoblasts-
FLPeNLS+ and myoblasts-FLPeNLS-, western blot analysis was performed on whole 
cell lysates as well as on nuclear and cytosolic cell fractions (Figure 5A). As 
expected from the presence at its amino terminus of the SV40 NLS, FLPeNLS+ 
(predicted molecular weight: 49.7 kilodaltons) had a slightly lower gel mobility than 
FLPeNLS- (predicted molecular weight: 48.6 kilodaltons). Both under growth and 
differentiation conditions, the steady-state level of FLPeNLS+ was considerably higher 
than that of FLPeNLS- even though the nucleotide sequences upstream of the FLPe 
start codon are very similar and both proteins contain a “destabilizing” amino acid 
residue (serine in FLPeNLS- versus alanine in FLPeNLS+;18) immediately downstream 
of the initiator methionine. Figure 5A also reveals that a larger fraction of FLPeNLS+ 
molecules than of FLPeNLS- molecules resides in the nucleus (nuclear-to-cytosolic 
ratios under differentiation conditions of 8.4 and 3.1, respectively) consistent with the 






Figure 5. Analysis of FLPeNLS+/- level, intracellular localization and enzymatic activity. (A): 
Western blotting analysis of whole protein lysates, nuclear cell fractions and cytosolic cell 
fractions of myoblasts-FLPeNLS+ (+) and of myoblasts-FLPeNLS- (-) maintained in growth 
medium (no differentiation) or exposed to differentiation conditions for 96 h (differentiation). 
(B): Luciferase activity measurements in culture media of myoblastsGS.GLuc transduced with 
LV.FLPeNLS+.PurR, LV.FLPeNLS-.PurR or LV.PurR (negative control vector) representing 
different intervals (i.e. 0-24 h and 24-48 h) post transduction. Bars show mean ± standard 
error of the mean (n=3). (C): Fold change in luciferase activity calculated on the basis of the 
data presented in (B). The average light production by samples of LV.PurR-transduced 
myoblastsGS.GLuc was the denominator and the mean of the RLUs produced by 
LV.FLPeNLS+.PurR-transduced myoblastsGS.GLuc (NLS+) or by LV.FLPeNLS-.PurR-transduced 
myoblastsGS.GLuc (NLS-) was the numerator. NLS, nuclear localization signal; FLPe, 
molecularly evolved flippase; GAPDH, glyceraldehyde 3-phosphate dehydrogenase; RLUs, 
relative light units. 





Assessment of FLPeNLS+/- functionality 
To investigate the functionality of the FLPe molecules encoded by LV.FLPeNLS+.PurR 
and LV.FLPeNLS-.PurR, myoblastsGS.GLuc were transduced with either of these FLPe-
encoding SIN-LVs or with LV.PurR (negative control vector). Production of functional 
recombinases by the FLPe-encoding SIN-LVs should result in activation of the 
GpLuc gene switch cassettes incorporated into the genomes of the myoblastsGS.GLuc 
and the secretion of active GpLuc molecules in their culture medium (Figure 6). 
Analysis of the culture media harvested at 24 h after vector removal showed strong 
luciferase activity in the samples derived from the LV.FLPeNLS+.PurR- and 
LV.FLPeNLS-.PurR-transduced myoblastsGS.GLuc, while hardly any luciferase activity 
was detected in the culture medium of LV.PurR-transduced myoblastsGS.GLuc (Figure 
5B). During the next 24-h interval the luciferase activity in the culture media of 
LV.FLPeNLS+.PurR- and LV.FLPeNLS-.PurR-transduced myoblastsGS.GLuc further 
increased whereas the luciferase activity in the negative control samples remained 
very low. As a result, luciferase activity was 94/154- and 156/162-fold higher in 0-24 
h and 24-48 h culture medium of LV.FLPeNLS+.PurR- and LV.FLPeNLS-.PurR-
transduced myoblastsGS.GLuc, respectively, than in the corresponding culture media of 
LV.PurR-infected cells (Figure 5C). These findings confirm the presence of FLP 
recombinase-activatable GpLuc expression units in myoblastsGS.GLuc and 







Figure 6. Schematic overview of the activation of the GpLuc gene switch cassette. 
Recognition of the FRT sites in chromosomally integrated copies of the LV.GS.GpLuc 
genome by FLPe leads to the activation of the latent GpLuc gene through the formation of 
circular episomes positioning the hGAPDH gene promoter upstream of the GpLuc ORF. 
Black triangle/FRT, flippase recognition target sequence; hGAPDH, human glyceraldehyde 
3-phosphate dehydrogenase gene promoter; rHBB2 pA, rabbit β-hemoglobin gene 
polyadenylation signal; GpLuc, Gaussia princeps luciferase-coding sequence; FLPe, 
molecularly evolved flippase. 
 
  




Validation of the LV.FLPeNLS+/-.PurR/LV.GS.GpLuc-based cell fusion assay system 
To compare the ability of FLPeNLS+ and FLPeNLS- to activate the GpLuc gene switch 
upon cell fusion, myoblastsGS.GLuc were co-cultured with myoblasts-FLPeNLS+ or 
myoblasts-FLPeNLS- at different ratios (i.e. 95:5, 90:10, 75:25, 50:50, 25:75, 10:90 
and 5:95). Monocultures of myoblasts-FLPeNLS+, myoblasts-FLPeNLS- or 
myoblastsGS.GLuc exposed to growth or differentiation medium and co-cultures of 
FLPe-expressing myoblasts and myoblastsGS.GLuc maintained in growth medium 
served as negative controls. Based on the results of the microscopic analysis of cell 
fusion activity (Figure 4), the culture medium was harvested 96 h after induction of 
myogenic differentiation. It should be noted, however, that the kinetics of cell fusion 
progression slightly differed between individual experiments probably reflecting small 
differences in the myoblast populations used for different experiments. Luciferase 
activity in the medium of the fusogenic cell cultures depended on the ratio of 
myoblastsGS.GLuc and myoblasts-FLPe, showed a similar trend for myoblasts-
FLPeNLS+- and myoblasts-FLPeNLS--containing co-cultures and was highest when co-
cultures contained 50-95% myoblastsGS.GLuc (Figure 7A). The peak of GpLuc activity 
was reached at myoblastGS.GLuc:myoblast-FLPe ratios of 90:10 and 75:25 for 
myoblasts-FLPeNLS+ and myoblasts-FLPeNLS-, respectively (Figure 7A). Interestingly, 
at low myoblastGS.GLuc:myoblast-FLPe ratios (i.e. 10:90 and 5:95) the luciferase 
activity was significantly higher for myoblasts-FLPeNLS- than for myoblasts-FLPeNLS+ 
(Figure 7A). Myoblast cultures kept under growth conditions and myoblast-FLPe 
monocultures maintained in differentiation medium yielded luminescence signals 
close to or at background levels. The monocultures of myoblastsGS.GLuc did, however, 
secrete detectable amounts of GpLuc under differentiation conditions although the 
signal intensity was much lower than that produced by serum-deprived co-cultures 
containing 50-90% myoblastsGS.GLuc. For the co-cultures containing 50-90% 
myoblastsGS.GLuc shifting from growth to differentiation medium resulted in a >100-





Figure 7. Validation of the LV.FLPeNLS+/-.PurR/LV.GS.GpLuc.v1-based cell fusion assay 
system. (A): Luminometric analysis of culture medium of myoblastsGS.GLuc co-cultured with 
myoblasts-FLPeNLS+ (+) or with myoblasts-FLPeNLS- (-) at the indicated ratios. At 72 h after 
cell seeding, the culture fluid in each well was replaced by fresh culture medium with (growth 
conditions, no differentiation) or without (differentiation conditions) serum. Nighty-six h later 
the culture media were collected and subjected to luciferase activity measurements. Bars 
represent mean ± standard error of the mean (n=3). (B): Fold change in luciferase activity 
calculated on the basis of the data presented in (A). For each culture composition the 
average light production under growth conditions was the denominator and the mean of the 
RLUs produced under differentiation conditions was the numerator. RLUs, relative light units; 
MBsGS.GLuc, myoblastsGS.GLuc; MBs-FLPe, myoblasts-FLPe; NLS, nuclear localization signal. 
 
 




Use of the LV.FLPeNLS+/-.PurR/LV.GS.GpLuc-based cell fusion assay system to 
analyse cell fusion progression 
To investigate the utility of the LV.FLPeNLS+/-.PurR/LV.GS.GpLuc-based cell fusion 
assay system to follow cell fusion progression, myoblastsGS.GLuc were mixed with 
myoblasts-FLPeNLS+ or with myoblasts-FLPeNLS- at a ratio of 50:50. After the cell 
cultures had become nearly confluent, they were either given fresh growth medium 
or exposed to differentiation medium. This was followed by the periodic collection of 
culture fluid for luciferase measurements using two different approaches. In one 
experiment, the culture medium was left on the cells for different time periods (i.e. 
from 0-24, 0-36, 0-48, 0-60, 0-72, 0-84, 0-96, 0-108 and 0-120 h) before being 
harvested for luminometry (“cumulative assay”; Figure 8). In the other experiment, 
the culture fluid was refreshed every 24 h and the amount of biologically active 
luciferase that had been secreted between 0-24, 24-48, 48-72, 72-96 and 96-120 h 
after the start of the differentiation process was determined (“kinetics assay”; Figure 
9). As shown in Figure 8A, following an initial slow increase, the luciferase activity in 
the culture medium of the serum-deprived co-cultures rose sharply at late times (>72 
h) after initiation of differentiation. Co-cultures of myoblastsGS.GLuc and myoblasts-
FLPeNLS- produced better results than the combination of myoblastsGS.GLuc and 
myoblasts-FLPeNLS+ (Figure 8A,B) in spite of the much higher FLPe concentration in 
myoblasts-FLPeNLS+ than in myoblasts-FLPeNLS- (Figure 5A). These findings were 





Figure 8. Analysis of GpLuc accumulation in proliferating and differentiating 1:1 co-cultures 
of myoblastsGS.GLuc and either myoblasts-FLPeNLS+ or myoblasts-FLPeNLS-. (A): Luminometric 
analysis of culture medium of co-cultures of 50% myoblastsGS.GLuc and 50% myoblasts-
FLPeNLS+ (+) or 50% myoblasts-FLPeNLS- (-). At 72 h after cell seeding, the culture fluid was 
replaced by fresh culture medium with (growth conditions, no differentiation) or without 
(differentiation conditions) serum, which was left on the cells for the indicated periods of 
time. Bars represent mean ± standard error of the mean (n=3). (B): Fold change in 
luciferase activity calculated on the basis of the data presented in (A). For each sampling 
time the average light production under growth conditions was the denominator and the 
mean of the RLUs produced under differentiation conditions was the numerator. RLUs, 
relative light units; NLS, nuclear localization signal. 





Figure 9. Analysis of GpLuc secretion in proliferating and differentiating 1:1 co-cultures of 
myoblastsGS.GLuc and either myoblasts-FLPeNLS+ or myoblasts-FLPeNLS-. (A): Luminometric 
analysis of culture medium of co-cultures of 50% myoblastsGS.GLuc and 50% myoblasts-
FLPeNLS+ (+) or 50% myoblasts-FLPeNLS- (-). At 72 h after cell seeding, the culture fluid was 
replaced by fresh culture medium with (growth conditions, no differentiation) or without 
(differentiation conditions) serum, which was left on the cells for the indicated 24-h time 
intervals. Bars represent mean ± standard error of the mean (n=3). (B): Fold change in 
luciferase activity calculated on the basis of the data presented in (A). For each sampling 
time the average light production under growth conditions was the denominator and the 
mean of the RLUs produced under differentiation conditions was the numerator. RLUs, 
relative light units; NLS, nuclear localization signal. 
50 
 
On the basis of the previous results, another experiment was carried out in which 
we directly compared the performance of FLPeNLS+ and FLPeNLS- at different 
myoblastGS.GLuc:myoblast-FLPe ratios (i.e. 95:5, 75:25, 25:75 and 5:95) and different 
time points (i.e. 72, 96 and 120 h after serum withdrawal). The culture medium was 
refreshed just before the start of the first sampling interval (i.e. at 48 h after serum 
removal) and after each round of sample collection. This experiment confirmed that 
at high myoblastGS.GLuc:myoblast-FLPe ratios FLPeNLS- was nearly as efficient as 
FLPeNLS+ at inducing reporter gene expression while at low myoblastGS.GLuc:myoblast-
FLPe ratios FLPeNLS- gave rise to more RLUs (Figure 10A) and to higher signal-to-
noise ratios (Figure 10B). In accordance with the experiment presented in Figure 7, 
the co-cultures consisting of 75% myoblastsGS.GLuc and 25% myoblasts-FLPe yielded 
the highest signals both in absolute (Figure 10A) and relative (Figure 10B) terms. 
Also in line with the previous experiments was the finding that most GpLuc 
accumulation takes place between 96 and 120 h after serum removal. 
  





Figure 10. Performance of FLPeNLS+ and FLPeNLS- at different acceptor-to-donor cell ratios 
and time points. (A): GpLuc release by proliferating or differentiating co-cultures of 
myoblastsGS.GLuc and myoblasts-FLPeNLS+ (+) or myoblasts-FLPeNLS- (-) at different time 
intervals after culture initiation. MyoblastsGS.GLuc and myoblasts-FLPe were seeded in 
different ratios (i.e. 95:5%, 75:25%, 25:75% and 5:95%). At 72 h after cell seeding, the 
culture fluid was replaced by fresh culture medium with (growth conditions, no differentiation) 
or without (differentiation conditions) serum. Fourthy-eight h later the culture medium was 
refreshed once again. Twenty-four h later the culture fluid was harvested for luciferase 
activity measurement and replaced by the same volume of fresh culture medium. This 
procedure was repeated every 24 h until 120 h after the first medium change. Bars represent 
mean ± standard error of the mean (n=3). (B): Fold change in luciferase activity calculated 
on the basis of the data presented in (A). For each experimental condition the average light 
production under growth conditions was the denominator and the mean of the RLUs 
produced under differentiation conditions was the numerator. RLUs, relative light units; 




Comparison of LV.GS.GpLuc.v1- and LV.GS.PpLuc-based cell fusion assay systems 
In the next experiment, a direct comparison was made between the previously 
described LV.GS.PpLuc-based quantitative cell fusion assay system7 and the new 
LV.GS.GpLuc-based method to quantify cell-to-cell fusion. Consistent with the much 
higher light output of GpLuc than of PpLuc8, LV.GS.GpLuc yielded up to 23-fold 
higher signals than LV.GS.PpLuc (Figure 11A). However, the LV.GS.PpLuc-based 
cell fusion assay system appeared to be approximately twice as sensitive as its 
LV.GS.GpLuc-based counterpart at detecting myoblast-to-myoblast fusion at 120 h 
after initiation of differentiation (Figure 11B). The difference in sensitivity between the 
GS.GpLuc.v1- and LV.GS.PpLuc-based cell fusion assay systems was even bigger 
for the samples collected at 96 h after serum removal especially at the lowest two 
myoblastGS.Luc:myoblast-FLPeNLS+ ratios (i.e. when FLPe levels are highest). 
  





Figure 11. Comparison of LV.GS.GpLuc.v1- and LV.GS.PpLuc-based cell fusion assay 
systems. (A): GpLuc and PpLuc production by proliferating or differentiating co-cultures of 
myoblastsGS.GLuc or myoblastsGS.PLuc with myoblasts-FLPeNLS+ at different times after culture 
initiation. Cells were seeded in different ratios (i.e. 100:0%, 90:10%, 75:25% and 50:50%). 
At 72 h after cell seeding the culture fluid was replaced by fresh culture medium with (growth 
conditions, no differentiation) or without (differentiation conditions) serum. Ninety-six h and 
120 h later samples (culture fluid for cultures containing myoblastsGS.GLuc and cell lysates for 
cultures containing myoblastsGS.PLuc) were harvested for luciferase activity measurements. 
Bars represent mean ± standard error of the mean (n=3). (B): Fold change in luciferase 
activity calculated on the basis of the data presented in (A). For each experimental condition 
the average light production under growth conditions was the denominator and the mean of 
the RLUs produced under differentiation conditions was the numerator. RLUs, relative light 
units; G, LV.GS.GpLuc.v1-based cell fusion assay; P, LV.GS.PpLuc-based cell fusion assay; 




Improvement of the GS.GpLuc-based cell fusion assay system 
The results presented in Figures 7 and 11 identify the FLP-independent increase in 
GpLuc production when shifting from growth to differentiation medium as the main 
contributor to the reduced signal-to-noise ratio of the LV.GS.GpLuc-based cell fusion 
assay system as compared to its LV.GS.PpLuc-based counterpart. In search for a 
possible explanation for the high background signal produced by LV.GS.GpLuc.v1 in 
comparison to LV.GS.PpLuc, we compared their genetic organization upstream of 
the Luc start codon. As shown in Figures 2 A,B and 3 the PpLuc ORF in 
LV.GS.PpLuc is preceded by an out-of-frame ORF (uORF) starting with 2 ATG 
codons in a favourable context for translational initiation19 and ending with a highly 
efficient stop codon20 separated by only 7 nucleotides from the PpLuc initiation 
codon. This specific genetic makeup will be effective in supressing any PpLuc 
expression directed by mRNAs with 5’ ends located upstream of the second ATG 
codon in the uORF. Oppositely, in LV.GS.GpLuc.v1 the previously mentioned 
tandem of ATG codons are in-frame with the GpLuc initiation codon allowing the 
synthesis of an N-terminally extended GpLuc fusion protein. Located further 
upstream of the GpLuc ORF in LV.GS.GpLuc.v1 is an out-of-frame ORF with 
suboptimal start and stop codons. LV.GS.GpLuc.v1 thus offers much more 
possibilities for “leaky” Luc expression than LV.GS.PpLuc. To solve this problem, we 
designed LV.GS.GpLuc.v6. In this construct, the distance between the mMT1 pA 
and GpLuc ORF is kept very short to minimize the chance of creating transcriptional 
start sites in the intervening region. As an additional measure to limit leaky GpLuc 
expression, LV.GS.GpLuc.v6 contains a 21-bp uORF starting immediately upstream 
of the FRT sequence and ending with an efficient stop codon provided by the FRT 
sequence. Between the stop codon of the uORF and the PpLuc initiation codon only 
20 nucleotides are present comprising the remainder of the FRT sequence and an 
optimal start site for GpLuc translation. 
LV.GS.GpLuc.v6 was used to generate myoblastsGS.GLuc+ carrying the optimized 
GpLuc gene switch cassette. Next, the performance of the LV.GS.GpLuc.v1- and 
LV.GS.GpLuc.v6-based cell fusion assay systems was compared in an experiment 
with the same setup as used for the comparison of LV.GS.GpLuc.v1 with 
LV.GS.PpLuc except for the omission of the 1:1 myoblastGS.GLuc(+):myoblast-
FLPeNLS+ ratio. Luciferase activity in 0-96 h and 0-120 h culture medium of serum-




deprived myoblastGS.GLuc+ monocultures was ± 3-fold lower than in culture medium of 
differentiating myoblastGS.GLuc monocultures (Figure 12), demonstrating the 
effectiveness of the new gene switch design to inhibit leaky GpLuc expression. 
However, since the improved gene switch design also reduced FLPe-dependent 
signal output the fold increase in GpLuc activity during myogenic differentiation of 
myoblastGS.GLuc(+):myoblast-FLPeNLS+ co-cultures was quite similar for 
LV.GS.GpLuc.v1 and LV.GS.GpLuc.v6 (Figure 12B). Still, in comparison to 
LV.GS.GpLuc.v1 for LV.GS.GpLuc.v6 a much larger part of the increase in GpLuc 
activity observed in differentiating myoblastGS.GLuc(+):myoblast-FLPeNLS+ co-cultures is 






Figure 12. Comparison of LV.GS.GpLuc.v1- and LV.GS.GpLuc.v6-based cell fusion assay 
systems. (A): GpLuc production by proliferating or differentiating co-cultures of 
myoblastsGS.GLuc or myoblastsGS.GLuc+ with myoblasts-FLPeNLS+ at different times after culture 
initiation. Cells were seeded in different ratios (i.e. 100:0%, 90:10% and 75:25%). At 72 h 
after cell seeding the culture fluid was replaced by fresh culture medium with (growth 
conditions, no differentiation) or without (differentiation conditions) serum. Ninety-six h and 
120 h later culture medium collected for luciferase activity measurement. Bars represent 
mean ± standard error of the mean (n=3). (B): Fold change in luciferase activity calculated 
on the basis of the data presented in (A). For each experimental condition the average light 
production under growth conditions was the denominator and the mean of the RLUs 
produced under differentiation conditions was the numerator. RLUs, relative light units; G1, 
LV.GS.GpLuc.v1-based cell fusion assay; G6, LV.GS.GpLuc.v6-based cell fusion assay; 
MBsGS.GLuc(+), myoblastsGS.GLuc or myoblastsGS.GLuc+; MBs-FLPeNLS+, myoblasts-FLPeNLS+. 







Apart from being involved in the formation and maintenance of skeletal muscles, 
bones and the placenta, cell-to-cell fusion plays an important role in numerous other 
biological processes like fertilization. It has also been implicated in the initiation and 
progression of cancer2 and as a driving force in evolution.21 Moreover, cell-to-cell 
fusion has been of great value to establish the chromosomal location of specific 
genes,22 can be used to induce cellular reprogramming23,24 and is indispensable for 
generating hybridomas.25 The involvement of cell-to-cell fusion in a large variety of 
biological processes and its diverse biotechnological applications have prompted 
investigations into the mechanisms of cell fusion and the contribution of specific 
factors to this process. Instrumental to this research is the availability of robust 
assays to determine cell fusion kinetics and extent. However, most of the existing 
quantitative cell fusion assays do not allow consecutive analysis of the same 
cells/tissue. Accordingly, in this paper a new quantitative assay is presented to 
monitor cell-to-cell fusion. This assay is based on the activation of a latent GpLuc 
gene after fusion of cells containing this latent reporter gene with cells encoding a 
recombinase that activates the dormant GpLuc gene. The extent of cell-to-cell fusion 
is subsequently quantified by simply measuring the enzymatic activity of the 
luciferase molecules secreted by the cellular fusion products. To the best of our 
knowledge this is the first assay that allows quantification of cell fusion activity by 
medium sampling. 
To validate the new cell fusion assay it was used to monitor the formation of 
myotubes/sacs in cultures of serum-deprived human myoblasts. In these 
experiments, several parameters were varied including the acceptor-to-donor cell 
ratio and the sample regimen(s) of the cell culture medium. In general, transgene 
expression increased with increasing fractions of myoblastsGS.GLuc up to the point at 
which the number of active/nuclear FLPe molecules became limiting (i.e. at 
myoblastGS.GLuc:myoblast-FLPe ratios of 90:10 for FLPeNLS- and of 95:5 for FLPeNLS+; 
Figure 7). 
At high myoblastGS.GLuc:myoblast-FLPe ratios LV.FLPeNLS+ was slightly more 
effective than LV.FLPeNLS- in activating the latent GpLuc gene most likely due to fact 
that under differentiation conditions myoblasts-FLPeNLS+ contain ± 5-fold more 
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nuclear FLPe molecules than myoblasts-FLPeNLS- (Figure 5A). In contrast, at low 
myoblastGS.GLuc:myoblast-FLPe ratios (i.e. when FLPe is no longer limiting) 
LV.FLPeNLS- consistently outperformed LV.FLPeNLS+ (Figures 7 and 10). Collectively, 
these findings suggest that its NLS does not noticeably hamper the spreading of 
FLPeNLS+ through myofibers/sacs but that high nuclear FLPe levels may somehow 
limit reporter gene expression. A possible explanation for the higher GpLuc 
expression in differentiating co-cultures containing large percentages of myoblasts-
FLPeNLS- in comparison to those with large fractions of myoblasts-FLPeNLS+ may be 
the more frequent occurrence of secondary recombination events in the latter co-
cultures leading to the deactivation of functional GpLuc expression modules. 
While monocultures of myoblastsGS.GLuc maintained in growth medium displayed 
very little if any leaky GpLuc expression, considerable amounts of GpLuc were 
produced by myoblastGS.GLuc monocultures exposed to differentiation medium. There 
are several possible explanations for this finding. Firstly, growth and differentiation 
medium may differently affect light output e.g. by (i) causing different levels of 
coelenterazine “auto-oxidation”, (ii) containing different concentrations of 
chemiluminescence inhibitors or (iii) absorbing blue light to a different extent. 
Possibilities (i) and (iii) can be ruled out since mixing of coelenterazine substrate 
solution with fresh or myoblasts-FLPeNLS+-conditioned growth or differentiation 
medium produced very similar signals (data not shown). This leaves us with the 
possibility that transcription termination by the mMT1 pA incorporated into the gene 
switch constructs is not very efficient or that differentiation conditions somehow 
stimulate transcription initiation in the region located in between the mMT1 pA and 
the Luc ORFs. For LV.GS.PpLuc and LV.GS.GpLuc.v6 the resulting transcripts may 
not lead to substantial luciferase production due to the presence of “decoy” ORFs 
immediately upstream of the Luc initiation codons (Figures 2 and 3). A similar 
favorable situation does not exist for LV.GS.GpLuc.v1, which may explain the high 
background signals produced by this construct under differentiation conditions. Even 
though the luciferase activity in culture medium of differentiating myoblastGS.GLuc+ 
monocultures is ± 3-fold lower than in culture medium of differentiating 
myoblastGS.GLuc monocultures LV.GS.GpLuc.v6 still gives rise to a higher background 
signal under differentiation conditions than LV.GS.PpLuc (compare Figure 11 with 
12). Considering that the sequences in between the mMT1 pA and the Luc start 
codon in LV.GS.PpLuc and LV.GS.GpLuc.v1 are nearly identical this may suggest 




that the GpLuc-coding sequence itself is the source of the relatively high luciferase 
activity detected in medium of differentiating LV.GS.GpLuc monocultures. If so, the 
problem could be overcome by switching to another secretory luciferase (e.g. 
Vargula hilgendorfii luciferase26, Lucia luciferase (InvivoGen Europe, Toulouse, 
France) or secretory NanoLuc27). Also the fact that GpLuc is a secretory protein with 
a long half-life (± 6 days in culture medium)28 while Ppluc has a relatively short half-
life (± 2 hours in cells)29 may contribute to the higher background signals associated 
with LV.GS.GpLuc.v1 and LV.GS.GpLuc.v6 than with LV.GS.PpLuc.   
Taken together, in this paper a new assay to quantify (the progression of) cell-to-
cell fusion activity is described. Due to its nondestructive nature allowing repeated 
sampling of the same specimen, this assay will be an attractive alternative to existing 
quantitative cell fusion assays based on (i) light microscopic assessment of 
multinucleation, (ii) fluorescence dequenching, (iii) fluorescence resonance energy 
transfer, (iv) biochemical complementation or (v) activation of reporter genes 
different from GpLuc including LacZ and PpLuc.3 Other advantages of the 
LV.FLPeNLS+/-.PurR/LV.GS.GpLuc-based cell fusion assay include the simplicity and 
speed of the analytical procedures and the ability to combine it with 
(immuno)cytology, real-time microscopy, cell function assays and other methods to 
study cell behavior. 
The sensitivity of the current assay could be improved by changing the human 
glyceraldehyde 3-phosphate dehydrogenase (hGAPDH) gene promoter driving 
GpLuc expression for a promoter with higher activity in the cell type(s) under 
investigation. In addition, the sequences interspersed between the 3’ long terminal 
repeat (LTR) and the GpLuc initiation codon of LV.GS.GpLuc.v6 may be further 
optimized to minimize leaky GpLuc expression. 
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Recent studies have shown that the use of biomaterials and new biodegradable 
scaffolds for repair or regeneration of damaged tissues is of vital importance. 
Scaffolds used in tissue engineering should be biodegradable materials with three-
dimensional structures, which can guide the growth and differentiation of the cells. 
They also should possess physical, chemical and biological properties that allow 
efficient supply of the cells to target tissues and have proper porosity along with 
minimal toxic effects. In this study, Gelatin/Siloxane/Hydroxyapatite (GS-Hyd) 
scaffold was synthesized and its morphology, in vivo biodegradability, cytotoxic 
effects and ability for cell adhesion were investigated using mesenchymal stem cells 
(MSCs). The cells were treated with different volumes of the scaffold suspension to 
evaluate its cytotoxic effects. The MSCs were also seeded on scaffolds and cultured 
for 2 weeks for assessing the scaffold’s ability to promote cell adhesion and 
proliferation. To check the biodegradability of the GS-Hyd complex in vivo, scaffolds 
were implanted into the thigh muscle, testicle, and liver of rats and analyzed at 3, 7, 
16 and 21 days after implantation by scanning electron microscopy (SEM) and 
weighing. The viability studies showed that the GS-Hyd scaffold exerted no cytotoxic 
effects on the cells and that the MSCs readily adhered to the scaffold with the 
expansion of their elongations and the formation of colonies. The rate of scaffold 
degradation as assessed by weighing was significant within each group at some time 
points along with significant differences between different tissues at the same time 
point. SEM micrographs indicated obvious changes at the surface of the scaffold 
particles and in the diameter of their pores through different stages of implantation. 
At 21 days after implantation the loss of scaffold was highest in the muscle and 
lowest in the liver. 
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Several strategies are employed to compensate for the loss of functional tissue in 
incurable diseases including cell, tissue and organ transplantation, surgical 
reconstruction, synthetic prostheses, and medical devices. However, each of these 
treatments, suffers from some problems or limitations. For example, organ 
transplantation is limited by donor shortage and usually requires lifelong 
consumption of immunosuppressive drugs, which may cause severe complications.1 
Although the other therapies are not limited by supply, they also have limitations. For 
example, synthetic prostheses and medical devices are generally not able to replace 
all the functions of damaged, diseased or lost tissue.  
Tissue engineering has emerged as an expanding approach to address these 
problems and is now a major component of regenerative medicine.2-4 By combining 
engineering principles with material science and molecular biology, investigators 
seek to create novel constructs that will fully integrate into the host system and 
restore function of the lost tissues.5 The general principle of cell-based tissue 
engineering involves combining living cells with a natural/synthetic support or 
scaffold.6 The main roles of the porous three-dimensional (3D) scaffolds are to give 
structural support and to provide an optimal environment for the cells contained 
inside. Following their isolation from healthy tissue and in vitro expansion, the cells 
should adhere to the scaffold in all three dimensions, proliferate, differentiate and 
secrete their own extracellular matrices (ECMs), gradually replacing the scaffold.4,7 
Therefore, in addition to permitting cell adhesion, promoting cell growth, and allowing 
retention of differentiated cell functions, the scaffold should be biocompatible, 
biodegradable, highly porous with a large surface to volume ratio, able to facilitate 
the necessary crosstalk with surrounding cells, mechanically strong, and capable of 
being formed into desired shapes with considerable stability.8-11  
A variety of hydrolytically degradable polymers have been developed for scaffold 
applications in tissue engineering. The majority of these polymers are composed of 
linear aliphatic polyesters with a high molecular weight and their copolymers. These 
materials often possess mechanical properties best suited for engineering of hard 
tissues.12-17 However, for engineering of soft tissues, flexible scaffolds are 
desirable.18 The biomaterials used to construct these porous scaffolds include 
synthetic biodegradable polymers such as polyglycolic acid (PGA), polylactic acid 
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(PLA), and their copolymer poly DL-lactic-co-glycolic acid (PLGA), and also polymers 
derived from natural materials such as collagen and inorganic hydroxyapatite.17,19,20 
In this study, the GS-Hyd complex was synthesized by combining Gelatin, Siloxane 
and hydroxyapatite as will be explained below. Hydroxyapatite, mainly in a 
carbonated form, is the major inorganic constituent of natural bone.21,22 Synthetically 
made hydroxyapatite (Ca5(PO4)3(OH)) has long been used in medicine and dentistry 
due to its ability to chemically attach to bone. It has been used as a hard tissue 
replacement, usually in the form of fillers (pastes, powders), or as a bioactive agent 
in polymer composites.21 Pure, stochiometrical hydroxyapatite is the least 
degradable form of calcium phosphate.23 Often, other more soluble mineral phases 
of apatite are preferred as bone-substitute materials in order to combine calcium-ion 
release properties with chemical stability of the support.24-26 Amongst those are non-
stochiometrical hydroxyapatite (calcium-deficient hydroxyapatite (CDHA)), β-
tricalcium phosphate (β-TCP), octacalcium phosphate (OCP), or biphasic 
hydroxyapatite (BCP, various hydroxyapatite/β-TCP ratios).24-27 A number of 
synthetic routes towards the preparation of biologically active calcium phosphates, 
including different templating approaches, have been reported.28-32 The presence of 
silica in many biocompatible and bioactive materials has generally been shown to 
improve their bioactivity.33,34 Studies show that introduced or already present silanol 
groups provide good nucleation sites for hydroxyapatite.35 Silica is also one of the 
vital components in bioglass, but is also used in polymer composites and thin 
films.36-40 In addition, natural polymers like collagen, gelatin and chitosan are 
osteoconductive and biodegradable components that have been used in fabrication 
of scaffold materials for tissue engineering.41,42 Thus, combining these natural 
polymers with the inorganic species mentioned above may yield biodegradable and 
bioactive scaffolds for tissue engineering.43 Scaffolds are normally analyzed by 
scanning electron microscopy (SEM) for their pore sizes, internal connections, and 
physical appearances. In the scaffold biodegradability process, both in vitro and in 
vivo, the pore diameters and volume of the scaffolds can be determined by SEM.44  
Development of a viable construct also requires a suitable supply of cells that are 
ideally non-immunogenic, highly proliferative, easy to harvest and have the ability to 
differentiate into a variety of cell types with specialized functions.45-47 Possible 
candidates for such purpose are bone marrow-derived mesenchymal stem cells 
(BM-MSCs), which have the potential to differentiate into various types of 




mesenchymal tissues, including osteoblasts, chondroblasts, myoblasts and 
fibroblasts.48 They are present in large quantities in animal and human bodies, can 
be easily obtained, and greatly expanded in vitro.49,50 Moreover, BM-MSCs are 
hypoimmunogenic cells that do not induce immune system response51 and have 
been successfully used to promote repair of different connective tissues, such as 
bone,52 cartilage,53 tendon,54 and ligament.55 We have also shown in our previous 
studies, the capacity of MSCs to differentiate into insulin-producing and neural cells 
in animal models of diabetes and Huntington’s disease, respectively.56,57  
In this study, the GS-Hyd complex was synthesized and the three main questions 
relevant for its use as scaffold were studied, i.e. (a) whether it affects cell viability, (b) 
whether it supports the cell adhesion and proliferation, and (c) whether it is 
biodegradable in vivo. 
 
Materials and Methods 
 
Scaffold preparation 
Starting materials used in this investigation for synthesis of the scaffold, including 
analytical grade calcium nitrate tetrahydrate (Ca(NO3)2·4H2O), phosphoric pentoxide 
(P2O5) and tetraethoxyorthosilicate (TEOS) were purchased from Aldrich, Germany. 
All materials were used as received, without further purification.  
Solutions of P2O5 (0.5 mol/L (absolute ethanol)) and solution of Ca(NO3)2·4H2O 
(1.67 mol/L (absolute ethanol)) were prepared. They were mixed together in a Ca/P molar 
ratio of 1.67 to generate a calcium phosphate precursor solution. The mixture was 
then continuously stirred about 10 min at ambient temperature, followed by heating 
in a water bath at 60 °C for 1 h. A 12.5% solution of gelatin was prepared by 
dissolution in 0.1 M HCL. Addition of appropriate amount of calcium phosphate 
precursor solution to the gelatin solution resulted in the hybrid solution. After this 
ripening process, 5 ml TEOS was added to the mixture under continuous stirring, 
corresponding to 60% SiO2 in the final SiO2/calcium phosphate material. The 
obtained gel was aged at room temperature for 20 h before calcination at 550 °C for 







In all experiments, male Wistar rats with an average weight of 250 g were used. Rats 
were kept at standard conditions and subjected to 12-hour cycles of light and 
darkness. 
 
BM-MSCs extraction and culture 
Bone marrow (BM) was obtained from the femurs and tibias of rats. BM was flushed 
into Dulbecco’s Modified Eagle’s Medium (DMEM, Gibco, Scotland) supplemented 
with 15% fetal bovine serum (FBS, Gibco, Scotland), 100 units/ml penicillin, and 100 
μg/ml streptomycin (Biosera, UK) and incubated in a humidified incubator at 37 °C 
with 5% CO2. When cultures reached about 80% confluency, they were washed with 
phosphate-buffered saline (PBS) followed by a 5 min incubation with 0.05% trypsin 
solution at 37 °C. Cells were split weekly at a ratio of 1:3. 
 
Cytotoxicity assay of GS-Hyd 
5 × 103 of MSCs at passage 3 were seeded in each well of 96-well microplates and 
incubated for 48 h at 37 °C. Then, 80 mg of powdered scaffold was dissolved in 2 ml 
DMEM supplemented with 15% FBS, and cells were exposed to various volumes of 
the resulting GS-Hyd suspension (2, 4, 8, 16, 32, 64, 128 and 200 μl), with three 
repeats for each volume. Cells cultured in DMEM supplemented with 15% FBS 
without GS-Hyd were used as controls. Total volume in each well was 200 μl. The 
effect of GS-Hyd on cell viability was measured by 3-[4,5-dimethylthiazol-2-yl]-2,5-
diphenyl tetrazolium bromide (MTT, Merck, Germany) staining. MTT assay was 
performed after 48 h of treatment. Cells in each well were incubated in 20 μl MTT 
solution (5 mg/ml MTT in PBS) for 4 h at 37 °C. The intense purple-colored formazan 
derivative formed via cell metabolism was then dissolved in 200 μl/well 
dimethylsulfoxide (DMSO, Merck, Germany) and the absorbance was measured at 
570 nm by ELISA plate reader (Awareness Technology, USA). The cell viability in 
the presence of different volumes of GS-Hyd was calculated using the following 
formula: absorbance of each treated well/mean absorbance of control wells × 100. 
The average cell viability for each volume of GS-Hyd was then calculated and 
presented in a graph using Microsoft Excel. 
 
 




Seeding of MSCs on GS-Hyd scaffold 
MSCs at passage 3 were trypsinized and suspended in DMEM followed by counting 
with a hemocytometer. The cell suspension was then centrifuged at 67.2 x g for 
5 min and the pellet was resuspended in DMEM, supplemented with 15% FBS, 100 
units/ml penicillin and 100 μg/ml streptomycin at a concentration of 107 cells/ml. After 
the scaffold had been cut into small pieces (5 mm × 3 mm) and sterilized by 
autoclaving, the GS-Hyd pieces were placed on agarose-coated (1% agarose in 
sterile H2O) 6-well culture plates (3 scaffolds/well), and divided into two test and 
control groups. The scaffolds received 100 µl medium without cells served as 
controls, while each scaffold in the test group was seeded with 106 cells in 100 µl 
medium. The scaffolds were incubated for 4 h in a humidified atmosphere at 37 °C 
and 5% CO2 to allow cell attachment. Then 3 ml of the medium was added to each 
well and the scaffolds were incubated for 2 weeks. The medium was replaced every 
2–3 days. On days 1, 7 and 14 the scaffolds were collected to be evaluated for cell 
attachment by SEM. 
 
Preparation of the cell-seeded scaffolds for SEM 
Scaffolds were fixed in 3% buffered glutaraldehyde for 24 h, dehydrated with a 
graded ethanol series, and dried. The dried samples were mounted on aluminum 
stubs and sputter-coated (SC7620 sputter coater) with gold for 2 min. SEM was used 
to take micrographs of the samples. The GS-Hyd scaffold was characterized mainly 
by Fourier transform infrared spectroscopy (FTIR), differential thermal analysis 
(DTA), and transmission electron microscopy (TEM). Simultaneous DTAs were 
carried out in the range of 20–1,000 °C in a Netzsch STA 409 °C instrument under 
air and at the rate of 10 °C/ min. 
 
Preparation of scaffold for in vivo implantation 
Another series of scaffolds were cut in small segments (5 mm × 3 mm), submerged 
in 70% ethanol for 30 min, and washed with PBS. The scaffolds were then kept in 
PBS until the start of the surgery. Scaffolds were polished on the edges to ensure 
that they were not sharp. The weight of the scaffolds was recorded before the 





Preparation of animals for implantation surgery 
All tests and experimental protocols were approved by the Ethics Committee of 
Ferdowsi University of Mashhad. Animals were anesthetized by a mixture of 
ketamine hydrochloride (100 mg/kg) and xylazine (5 mg/kg). The regions for the 
surgery (thigh muscle, testicles and liver) were sterilized with 70% ethanol after 
shaving. 
For implantation of the scaffold in thigh muscle, a deep incision of 1 cm along the 
length of the muscle was made with a scalpel. Next, tampons were used to stop 
bleeding. If bleeding persisted, the site of incision was cauterized. The scaffold was 
then gently lowered in between the muscle fibers. After this step, the muscle was 
stitched layer by layer towards the surface. To implant the scaffold in a testicle, an 
incision was made in the scrotum. One of the testicles was exposed, and without 
applying too much pressure to the testicle, a hole with the exact size of the scaffold 
was made by scalpel. The scaffold was subsequently placed in the testicle and the 
testis and scrotum were stitched. For implantation of the scaffold in the liver, a deep 
incision of about 1 cm was made below the right side of the rib cage, until the 
visceral peritoneum of the liver appeared. Then, a small hole was made in the liver 
and the scaffold was placed inside and the peritoneum layers and skin were stitched 
separately. 
At the end of each surgical procedure, the stitched tissues were sterilized with 
betadine and Lidocaine gel was applied to numb them. As extra measure against 
possible infections, every rat was injected intraperitoneally with 5,000 unit/kg 
penicillin. After surgery, the animals were moved to a recovery cage to regain their 
consciousness in a warm blanket. The conditions of the rats was monitored by 
checking their breathing, taking their pulse and measuring their body temperature. 
When the rats showed normal vital signs and movements, they were returned to their 
original cage.  
 
Degradation assay of GS-Hyd 
To analyze the degradability of the scaffold by weight changes, 3 rats per scaffold 
implantation site were anaesthetized at 3, 7, 16, and 21 days after implantation, and 
the scaffolds were removed from their bodies. On these days, the anatomical 
condition and histology of the surgery site were carefully studied. When each 
scaffold was removed from the body, it was immediately washed with normal saline 




to remove blood and extra tissues. Each scaffold was placed into a separate test 
tube with specific identification number. The test tubes were then placed in oven at 
50 °C for 30 min. After the scaffolds were completely dried, they were weighed with a 
sensitive electronic scale. The weight of the scaffolds after explantation were 
compared to their weight prior to surgery and the percentile weight loss was 
recorded. To check the rate of degradation using SEM, scaffold samples from each 
part of the body (thigh muscle, testicle and liver) were prepared using the same 
procedure. The number of connections between the pores of the scaffolds and the 




Data were analyzed using one way ANOVA. All group comparisons were analyzed 
using Tukey’s post hoc test to determine which groups were significantly different 




Chemical and structural characteristics of GS-Hyd scaffold  
GS-Hyd scaffold showed sharp absorption bands in FTIR that were attributed to 
hydroxyapatite: 3th vibration of PO4
3− (υ3PO4
3−) at 1,045–1,092 cm−1 and υ2PO4
3− at 
474 cm−1, υ1PO4
3− symmetric stretch at 963 cm−1, υ4PO4
3− bending at 602 and 
572 cm−1. The broad absorption bands at 3,100–3,600 cm−1 belonged to OH 
stretching absorption bands. Extensive absorption around 630 cm−1 (structural OH 
stretching) was attributed to hydroxyapatite’s crystalline structure. The silica layer 
showed weak absorption bands around 800 cm−1 corresponding to the Si–O–Si 
bonds. Some of the silica absorption bands were hard to identify due to stronger, 
overlapping absorption bands from hydroxyapatite. That is especially true in the area 
around 1,185 and at 1,000–1,085 cm−1 where the Si–O–Si vibration bands usually 
are the strongest, but also around 960 cm−1 where the Si–OH silanol groups absorb 
(data not shown). 
Figure 1 shows the thermogram corresponding to simultaneous DTA at 70 
°C/24 h. In the DTA curve of the precursor GS-Hyd scaffold (Figure 1), after dried in 
70 °C, exothermic peaks assignable to organic combustion are visible. In order to 
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discard the presence of water occluded in the exhaustively dried sample after 150 
°C, a simultaneous DTA was carried out due to its considerably higher sensibility. 
DTA showed the combustion peak of residual gelatin at 320 °C, and a very low peak 
at 590 °C. It can thus be concluded that the microporosity observed after calcination 
is originated by the elimination of gelatin macromolecules forming microdomains in 




Figure 1. DTA thermogram of GS-Hyd. 
 
The simple one-pot synthesis method resulted in a fairly homogeneous distribution 
of the mesoporous silica throughout the apatite crystal surface as demonstrated by 
the TEM micrograph (Figure 2). The crystalline size of the GS-Hyd scaffold is about 
50 nm. This could be the reason for even distribution of hydroxyapatite over the 
surface of silica matrix. On the other hand, the material lacks a well-pronounced 
mesoporous long-range order in the silica layer. 
 





Figure 2. TEM image of GS-Hyd showing the great growth of hydroxyapatite (arrows) and 
the deposition of silica among its pores (asterisks). 
 
Homing of MSCs in GS-Hyd scaffolds 
As mentioned previously, to investigate the biocompatibility of the GS-Hyd complex, 
scaffolds were seeded with106 BM-MSCs and scaffolds without cells served as 
negative controls (Figure 3). On days 1, 7 and 14 after cell seeding, scaffolds were 
collected to be evaluated for cell attachment and proliferation by SEM. Cells were 
round shaped at the time of seeding (not shown) but adhered to the scaffold, 
expanded their elongations and obtained a fibroblast-like appearance within 24 h 
(Figure 4). Moreover, during their cultivation on scaffolds, the BM-MSCs proliferated 





Figure 3. SEM micrograph showing the morphology of the GS-Hyd scaffold without cells. 





Figure 4. SEM micrograph showing scattered distribution of MSCs on the surface of the 





Figure 5. SEM micrograph showing MSC proliferation and colony formation on the scaffold, 
7 days after cell seeding. 
 
Cytotoxicity of GS-Hyd scaffold 
The MTT assay is a colorimetric method for measuring the activity of enzymes that 
reduce the colorless MTT to purple colored formazan dyes. Its main application is 
assessment of the viability and the proliferation of cells. It can also be used to 
determine cytotoxicity of potential medicinal agents and toxic materials, since those 
agents would stimulate or inhibit cell viability and growth. 
The MTT assay showed that GS-Hyd has no detectable cytotoxic effects on the 
cells up to concentration of 25.6 mg/ml (128 µl). Cell viability decreased only at the 
highest amount of GS-Hyd (200 μl) as shown in Figure 6. 
 





Figure 6. Effects of different volumes of GS-Hyd suspension on the viability of MSCs as 
measured by MTT assay. 
 
In vivo degradability of GS-Hyd scaffold 
The degradation rate of scaffolds implanted at different sites was determined by 
weighing them following their explantation at 3, 7, 16 and 21 days after 
transplantation. The weight reduction at day 3 significantly differed from those at day 
16 and 21 for scaffolds in all three anatomical sites, but the differences between 
other days were not significant. At day 7, the differences between thigh muscle and 
liver (P < 0.0001) and between liver and testis were significant (P < 0.001), but there 
was no significant difference between thigh muscle and testicle. The differences 





Figure 7. Comparison of the rate of scaffold degradation in various anatomical positions on 
different days after implantation. There are significant differences in each group during the 
time period and between groups at the same time point. Vertical bars indicate means±SEM 
in rats of each group at each measurement (n = 3, P ≤ 0.05).  
 
Structural changes of GS-Hyd scaffolds following in vivo implantation 
Transplanted GS-Hyd particles underwent clear time-dependent morphological 
changes on their surface as evinced by SEM micrographs of scaffolds explanted at 
different times after implantation (Figure 8). These changes in surface structure were 
accompanied by an increase in diameter of the pores. Consistent with the results 
presented in Figure 7, degradation of the GS-Hyd scaffold at 21 days post 
implantation was highest in the thigh and lowest in the liver (Figure 8, B–D). 
 





Figure 8. SEM micrographs of the scaffold before (A) and after (B–D) implantation in the 




One of the main problems in cell therapy is homing of the cells and their 
maintenance in desired areas, which may be overcome by growing the cells on 
scaffolds followed by their transplantation at the target sites. The major concerns in 
applying external scaffolds in tissue engineering are severe immune responses, 
persistence to degradation, and unexpected side effects. As mentioned before (1) 
the specific material composition of the scaffold and (2) the cell source are two 
important elements, which can substantially affect the outcome of tissue 
engineering.5 Application of biodegradable materials is a vital factor in tissue 
engineering.58 Scaffolds should also be mechanically strong, capable of being 
formed into desired shapes, non-cytotoxic and highly porous for permitting cell 
adhesion and growth.8,9 Development of such an efficient scaffold also involves a 
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suitable supply of cells such as MSCs, which, due to their specific properties, are 
attractive candidates for clinical applications. For example, Liu and colleagues 
cultured anterior cruciate ligament fibroblasts (ACLFs) and BM-MSCs on combined 
silk scaffolds to determine which of these two cell types would be best suited for 
ligament tissue engineering applications. Their preliminary results demonstrated that 
BM-MSCs are superior to ACLFs, with respect to cell proliferation and in vivo 
survival.59 Moreover, the safety of MSCs for in vivo applications has been shown by 
numerous studies in animals and humans and the clinical use of MSCs is not 
associated with major ethical concerns unlike the therapeutic use of embryonic stem 
cells (ESCs). Although some studies have shown a promotion of tumor growth and 
metastasis after implantation of MSCs, tumor induction is mostly described for 
embryonic stem cells (ESCs).60,61  
Cell adhesion to substrate is known to affect cell behavior and function in both 
natural and engineered tissues and plays a key role in morphogenesis and 
organogenesis.62,63 In this study, we used MSCs as candidate stem cells and GS-
Hyd scaffold as a cell carrier for adhesion and proliferation of the cells in vitro. GS-
Hyd is a 3D scaffold which did not show any cytotoxic effects and preserved the cell 
viability in vitro. GS-Hyd also promoted cell adhesion and proliferation. Considering 
the fact that cells were round shaped at the day of seeding (not shown) but could 
expand their elongations and obtained a fibroblast-like appearance within 24 h 
(Figure 4), we conclude that MSCs very well adhere to the GS-Hyd scaffold. 
Moreover, the fact that more cells were visible on the scaffolds at day 7 than day 2 
post seeding and the observation that the MSCs had formed colonies after 7 days of 
cell seeding indicate that the GS-Hyd complex supports cell proliferation (Figures 3, 
4 and 5). The interconnected pores of the scaffold may further promote cellular 
adherence. Additionally, the pore size (1–2 μm) of the scaffolds seems to be large 
enough to allow medium flow which would provide ideal conditions for cell 
proliferation on the scaffolds. 
The composition of the scaffold and the speed of scaffold degradation in its 
biological environment, are important factors for their applicability in vivo. However, 
this is not the case for GS-Hyd scaffold, because its rate of degradation can be 
manipulated during the synthesis. In previous studies on similar scaffolds, they were 
kept in the body of rats for 30–90 days after surgery.64,65 In our study, we implanted 
and kept the scaffolds for 21 days. During this period, the speed of scaffold 




degradation was much higher shortly after implantation than at later times. This 
could be explained by the fact that gelatin, the main component of the scaffold, is 
easily degraded and could hence account for the major weight lost observed in the 
beginning. However, additional experiments are required to identify the cause(s) for 
the large loss in scaffold weight early after in vivo implantation. At 21 days after 
implantation about 30% of the initial weight of the scaffolds remained. The SEM 
analyses revealed that the loss of scaffold weight is accompanied by the 
disappearance of the interconnections between pores inside the scaffold which 
suggests a direct link between compound degradation and inter-junction loss. 
Structural degradation rates at the three examined anatomical sites proved that the 
degradative capacities are tissue-specific and according to our SEM micrographs the 
thigh muscle has the highest capacity for the scaffold degradation. During the whole 
in vivo study, the rats did not display any signs of scaffold-related toxicity, other than 
a mild inflammation. 
In conclusion, this study showed that GS-Hyd scaffolds are degraded in vivo at 
rates compatible with their application in tissue engineering. It was also shown that 
GS-Hyd did not have any cytotoxic effects and also could promote cell adhesion and 
proliferation in vitro, but to reach to a definite conclusion about the toxic effects of the 
scaffold in vivo, further experiments are needed. Therefore, we suggest that GS-Hyd 
scaffolds can be used for tissue engineering, but still more assays and in vivo 
studies are required to investigate other characteristics of this scaffold which are 
important for its clinical use. 
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Background: Different factors may trigger arrhythmias in diseased hearts including 
fibrosis, cardiomyocyte hypertrophy, hypoxia and inflammation. This makes it difficult 
to establish the relative contribution of each of them to the occurrence of 
arrhythmias. Accordingly, in this study, we used an in vitro model of pathological 
cardiac hypertrophy (PCH) to investigate its pro-arrhythmic features and the 
underlying mechanisms independent of fibrosis or other PCH-related processes. 
Methods and Results: Neonatal rat ventricular cardiomyocyte (nr-vCMC) 
monolayers were treated with phorbol 12-myristate 13-acetate (PMA) to create an in 
vitro model of PCH. Electrophysiological properties of PMA-treated and control 
monolayers were analyzed by optical mapping at day 9 of culture. PMA treatment led 
to a significant increase in cell size and total protein content. It also caused a 
reduction in sarcoplasmic/endoplasmic reticulum Ca2+ ATPase 2 level (32%) and an 
increase in natriuretic peptide A (42%) and α1-skeletal muscle actin (34%) levels 
indicating that the hypertrophic response induced by PMA was indeed pathological in 
nature. PMA-treated monolayers showed increases in action potential duration 
(APD) and APD dispersion, and a decrease in conduction velocity (CV; APD30 of 
306±39 vs 148±18 ms, APD30 dispersion of 85±19 vs 22±7 and CV of 10±4 vs 21±2 
cm/s in controls). Upon local 1-Hz stimulation, 53.6% of the PMA-treated cultures 
showed focal tachyarrhythmias based on triggered activity (n=82), while control 
group showed 4.3% tachyarrhythmias (n=70). 
Conclusion: Following PMA treatment, nr-vCMC cultures acquire features of 
pathologically hypertrophied hearts and show a high incidence of focal 
tachyarrhythmias associated with APD prolongation and an increase in APD 
dispersion. PMA-treated nr-vCMC cultures may thus represent a well-controllable in 
vitro model for testing new therapeutic interventions targeting specific aspects of 
hypertrophy-associated arrhythmias. 
Key words: phorbol 12-myristate 13-acetate, pathological cardiac hypertrophy, 
triggered activity, cell culture  
  





An increase in cardiac demand triggers the heart to respond in several ways, 
including by the enlargement of cardiomyocytes. Such cardiac hypertrophy is 
essentially a beneficial compensatory process as it decreases wall stress, while 
increasing cardiac output.1 This adaption by growth occurs under physiological 
conditions like exercise and pregnancy, but also in response to myocardial infarction 
and other cardiac pathologies. Whereas physiological cardiac hypertrophy is usually 
reversible and contributes to optimal heart function, hypertrophy due to cardiac 
disease (i.e. pathological cardiac hypertrophy [PCH]) is typically associated with 
several irreversible time-dependent detrimental changes, including maladaptive 
remodeling of cardiac structure, metabolism, electrophysiology and ion homeostasis, 
which may ultimately culminate in heart failure.2,3 Electrophysiological remodeling, 
especially if sustained, imposes an increased risk of developing cardiac arrhythmias.  
The relationship of PCH with ventricular tachyarrhythmias has been investigated in 
whole heart mapping studies.4-7 However, the complexity of three-dimensional (3D) 
myocardial tissue and the presence in pathologically hypertrophied hearts of various 
other changes in cardiac structure and function including fibrosis, inflammation and 
metabolic remodeling,7,8 complicates assessment of the specific contribution of PCH 
to the development of heart rhythm disturbances. This problem can be overcome by 
using two-dimensional (2D) cell culture models of defined composition to study PCH-
related pro-arrhythmic changes. Induction of hypertrophy-related pathological 
changes in cardiomyocyte cultures can be accomplished by exposure of the cells to 
a variety of different peptide and non-peptide hormones and growth factors including 
angiotensin II (AngII), endothelin 1 (ET-1) and certain natural and synthetic 
catecholamines.9 Many of these molecules exert their pro-hypertrophic effects 
through the activation of phospholipase C leading to the production of inositol 1,4,5-
trisphosphate (IP3) and diacylglycerol (DAG). Binding of IP3 to specific receptors 
located in the membranes of the sarcoplasmic reticulum and in the nuclear envelope 
causes Ca2+ release into the cytosol and nucleus and activation of several pro-
hypertrophic factors including calcineurin, nuclear factor of activated T cells (NFAT) 
and Ca2+/calmodulin-dependent protein kinase II (CaMKII).10 DAG, on the other 
hand, stimulates cardiac hypertrophy mainly by acting as stimulatory cofactor of 
protein kinase C (PKC) and protein kinase D (PKD).11,12 The pro-hypertrophic effects 
of DAG can be mimicked by phorbol 12-myristate 13-acetate (PMA). Indeed, 
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treatment of neonatal rat ventricular cardiomyocytes (nr-vCMCs) with PMA has been 
shown to induce a gene expression program in these cells sharing many features 
with that of pathologically hypertrophied hearts.13-15 Prominent among the PMA-
induced changes are those involving the expression level, cellular localization and 
specific activity of ion channels and transporters,16,17 connexins,18,19 and Ca2+-
handling proteins20-22 similar to what happens in pathologically hypertrophied hearts. 
Still, relatively little is known about the possible pro-arrhythmic consequences of 
these changes, which are commonly referred to as electrical remodeling. Therefore, 
the purpose of the present study was to investigate in PMA-treated nr-vCMC cultures 
the contribution of PCH to the development of cardiac arrhythmias independent of 
fibrosis, inflammation and hypoxia. 
 
Materials and Methods 
 
All animal experiments had the approval of the Animal Experiments Committee of 
the Leiden University Medical Center and complied with the Guide for the Care and 
Use of Laboratory Animals as stated by the US National Institutes of Health.  
 
Cardiomyocyte isolation 
nr-vCMCs were isolated and cultured essentially as described previously.23 In brief, 
2-day-old Wistar rats were anaesthetized with 4–5% isoflurane. After confirmation of 
anesthesia, the chest was opened, the heart was excised and the ventricles were 
separated from the remainder of the cardiac tissue. Next, the ventricular myocardium 
was cut into small pieces (~1 mm) and further dissociated by incubation at 37°C with 
a buffer solution containing 0.01 mM CaCl2, 5 mM MgCl2, 450 units/ml of 
collagenase 1 (Worthington, Lakewood, NJ, USA) and 18.75 Kunitz units/ml DNAse I 
(Sigma-Aldrich, St. Louis, MO, USA). Cells and remaining tissue fragments were 
pelleted by centrifugation at 161 × g and room temperature (RT) for 10 min and 
resuspended in growth medium (Ham’s F10 medium supplemented with 10% fetal 
bovine serum [FBS] and 10% horse serum [HS; all from Life Technologies, Bleiswijk, 
the Netherlands]). The cell suspension was then applied to Primaria culture dishes 
(Corning Life Sciences, Amsterdam, the Netherlands) and incubated for 75 min in a 
humidified incubator at 37ºC and 5% CO2 to allow preferential attachment of non-




myocytes. The unattached cells (mainly cardiomyocytes) were collected, passed 
through a cell strainer (70-μm mesh pore size; BD Biosciences, Breda, the 
Netherlands) to obtain a single cell suspension and applied at a density of 6×105 
cells/well of a 24-well cell culture plate (Corning Life Sciences) to fibronectin (Sigma-
Aldrich)-coated, round glass coverslips (15-mm diameter). One day later (i.e. at 
culture day 1), the cells were treated in growth medium with mitomycin C (10 μg/ml; 
Sigma-Aldrich) for 2 h to inhibit proliferation of remaining non-myocytes. The growth 
medium was subsequently replaced by a 1:1 mixture of Dulbecco’s modified Eagle’s 
medium [DMEM; Life Technologies] and Ham’s F10 medium supplemented with 5% 
HS, 2% bovine serum albumin (BSA) and sodium ascorbate to a final concentration 
of 0.4 mM. This so-called maintenance medium was refreshed daily. To induce 
pathological hypertrophy cultures were exposed to 1 µM PMA (BioVision, Milpitas, 
CA, USA) for 24 h at day 3 and 8 of culture.  
 
Optical mapping  
Optical mapping was done at day 9 of culture. Prior to optical mapping, the cells 
were incubated for 10 min in maintenance medium containing 8 µM of the voltage-
sensitive dye di-4-ANEPPS (Life Technologies) and given fresh medium consisting 
of DMEM/HAM’s F12 (Life Technologies) without phenol red and serum. Immediately 
afterwards, cultures were optically mapped at 37°C using a MiCAM ULTIMA-L 
imaging system (SciMedia, Costa Mesa, CA, USA). To allow for a fair comparison of 
action potential duration (APD) and conduction velocity (CV), all cultures were locally 
stimulated at 1 Hz using an epoxy-coated bipolar platinum electrode with square 
suprathreshold (i.e. 8 V) electrical stimuli of 10 ms. Parameters of interest were 
calculated using Brain Vision Analyzer 1208 software (Brainvision, Tokyo, Japan). 
Optical signals of 9 pixels were averaged to minimize noise artifacts. To calculate 
CV, two 3 by 3 pixel grids located 2-8 mm apart on a line perpendicular to the 
activation wavefront were used. APD was calculated at 30% (APD30) and 80% 
(APD80) of repolarization. CV and APD values were averages of values obtained 
from 6 different positions equally distributed across the cell cultures. APD30 and 
APD80 dispersion were expressed as the standard deviation (SD) of the mean of the 
APDs. For determining CV, APD and APD dispersion only nr-vCMC cultures with 
uniform activation patterns were used. Occurrence of pro-arrhythmic features was 
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also evaluated after 1-Hz local stimulation. An early afterdepolarization (EAD) was 
defined as a reversal of repolarization during phase 2 or 3 of the AP of more than 
10% of the maximum optical signal amplitude. A focal tachyarrhythmia was defined 
as an activation pattern in which an EAD was followed by 2 or more uninterrupted 
oscillations in membrane potential without giving rise to a reentrant circuit. 
 
Immunocytology 
For immunostaining, 8×104 cells were seeded on fibronectin-coated, round glass 
coverslips (15-mm diameter) in wells of 12-well cell culture plates (Corning Life 
Sciences). At day 9 of culture, cells were fixed by incubation for 30 min in 
phosphate-buffered 4% formaldehyde (Klinipath, Duiven, the Netherlands) and 
permeabilized by a 20-min treatment with 0.1% Triton X-100 in phosphate-buffered 
saline (PBS) both at RT. Next, cells were incubated overnight at 4°C with mouse 
anti-sarcomeric α-actinin (clone: EA-53; Sigma-Aldrich), mouse anti-
sarcoplasmic/endoplasmic reticulum Ca2+ ATPase 2 (Serca2; clone: 2A7-A1; 
Thermo Fisher Scientific, Waltham, MA, USA), rabbit anti-natriuretic peptide 
precursor type A (Nppa; Merck Millipore, order number: AB5490) and rabbit anti-α1-
skeletal muscle actin (Acta1; Abcam, Cambridge, United Kingdom, order number: 
ab52218) primary antibodies diluted 1:200 in PBS + 0.1% donkey serum (Santa Cruz 
Biotechnology, Dallas, TX, USA) followed by a 2-h incubation at RT with appropriate 
Alexa Fluor 488- or 568-conjugated donkey IgG (H+L) secondary antibodies (Life 
Technologies) diluted 1:400 in PBS + 0.1% donkey serum. Nuclei were 
counterstained with 10 µg/ml Hoechst 33342 (Life Technologies) in PBS. Cells were 
washed three times with PBS after fixation, permeabilization and incubation with 
primary antibody, secondary antibody and DNA-binding fluorochrome. To minimize 
photobleaching, coverslips were mounted in VECTASHIELD mounting medium 
(Vector Laboratories, Burlingame, CA, USA). Pictures were taken with a 
fluorescence microscope equipped with a digital color camera (Nikon Eclipse 80i; 
Nikon Instruments Europe, Amstelveen, the Netherlands) using NIS Elements 
software (Nikon Instruments Europe). Cell surface area (CSA) and fluorescent 
intensity were measured using dedicated software (ImageJ, version 4.1 National 
Institutes of Health, USA). 
 
 





Different experimental groups were compared using the unpaired samples t-test. 
Data represented as mean±SD. Differences among means were considered 
significant at P≤0.05. Graphs were prepared in GraphPad Prism version 6 




PMA induces a hypertrophic response in nr-vCMCs  
Immunostaining of control and PMA-treated nr-vCMC cultures for sarcomeric α-
actinin showed the presence of ~13% non-myocytes in the cultures (Figure 1A). 
PMA treatment of nr-vCMC cultures increased mean CSA by 30% (3.5±1.5 [n=81] vs 
2.6±1.0 pixels in control cultures [n=54], P<0.0005) (Figure 1B) and total protein 
content by 80% (1.3±0.1 vs 0.7±0.1 mg/107 cells in control cultures [n=9 for both 






Figure 1. Characterization of PMA-treated nr-vCMC cultures. (A) α-actinin staining showing 
the presence of 13% non-myocytes in the nr-vCMCs cultures. Quantification of (B) CSA and 
(C) protein content of control and PMA-treated nr-vCMCs. CSA and protein level were 
increased in cultures treated with PMA indicative of a hypertrophic response. * P<0.0005 
and ** P<0.0001. 
PMA-treated nr-vCMCs acquire a pathological hypertrophy-related phenotype 
To investigate the nature of the hypertrophic response induced by PMA, control and 
drug-treated nr-vCMC cultures were immunostained for markers distinguishing 
physiological from pathological hypertrophy. The PMA-treated nr-vCMC cultures 
displayed a 42% increase in Nppa level (17.8±2.0 vs 12.5±4.4 arbitrary units, 
P<0.005) (Figure 2A), a 34% increase in Acta1 expression (22.0±4.1 vs 16.4±2.6 
arbitrary units, P<0.0005) (Figure 2B) and a 32% decrease in Serca2a level 
(15.9±2.5 vs 21.1±3.5 arbitrary units, P<0.0001) (Figure 2C) as compared to those in 




control cultures. This indicates that PMA-treated nr-vCMCs obtain properties of 
pathologically hypertrophic cardiac muscle cells. 
 
 
Figure 2. PMA treatment endows nr-vCMCs with features of pathological hypertrophied 
ventricular myocardium including an increase in (A) Nppa (42%) and (B) Acta1 levels (34%) 
and a decrease in (C) Serca2a expression (32%). * P<0.005 and ** P<0.0005. AUs, arbitrary 
units. 
Conduction and repolarization are slowed by PMA treatment of nr-vCMCs cultures  
Optical mapping recordings in 1 Hz-paced, uniformly propagating nr-vCMC cultures 
showed that PMA treatment causes a strong reduction in CV (10±4 vs 21±2 cm/s in 
control cultures, P<0.0001) (Figure 3A). Moreover, the PMA-treated nr-vCMC 
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cultures displayed a large increase in APD30 (306±39 vs 148±18 ms in control 
cultures, P<0.0001) and APD80 (516±53 vs 225±34 ms in control cultures, P<0.0001) 
(Figure 3B,C and Figure 4A). Spatial APD dispersion was also increased in PMA-
treated cultures (APD30 dispersion of 85±19 vs 22±7 ms in control cultures, P<0.0001 
and APD80 dispersion of 50±9 vs 25±2 ms in control cultures, P<0.0001) implying 
increased heterogeneity of repolarization (Figure 3B,C).  
 
 





Figure 3. PMA treatment of nr-vCMC cultures causes conduction slowing and 
heterogeneous APD prolongation. (A) Typical activation maps with 6-ms isochronal spacing 
and corresponding quantitative assessment of control and PMA-treated nr-vCMC cultures 
showing slowing of conduction upon PMA treatment. Typical APD30 (B) and APD80 (C) map 
of control and PMA-treated nr-vCMC cultures and corresponding quantitative assessments 
of APD and APD dispersion showing PMA-induced increases in APD and APD dispersion. 
Cultures were subjected to electrical point stimulation at a frequency of 1-Hz. * P<0.0001. 
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Focal triggered activity is a prominent pro-arrhythmic feature of PMA-treated nr-
vCMC cultures 
The PMA-induced APD prolongation and increase in APD dispersion provided 
enough time and depolarizing force, respectively, for formation of EADs in the drug-
treated cultures, which could oscillate repetitively resulting in focal tachyarrhythmias. 
The incidence of this type of arrhythmias following local 1-Hz stimulation was 53.6% 
in the PMA-treated nr-vCMC cultures (n=82) while control nr-vCMC cultures showed 
4.3% arrhythmias (n=70) (Figure 4A, B). During focal tachyarrhythmias, 
repolarization halted at the initiation site of the EAD (Figure 4C, point 1) followed by 
slow repolarization in areas in the vicinity of the region of sustained depolarization, 
which favored EAD formation (Figure 4,C point 2). 
 





Figure 4. PMA-treated nr-vCMC cultures show a high incidence of focal tachyarrhythmias. 
(A) Typical optical signals from control (red) and PMA-treated cultures showing APD 
prolongation (black) and onset of tachyarrhythmia (green). (B) Quantification of arrhythmia 
incidence (i.e. incidence of focal tachyarrhythmias) in control and PMA-treated nr-vCMC 
cultures. (C) Activation map of a PMA-treated nr-vCMC culture displaying triggered activity. 
Corresponding optical signals showing ceased repolarization (point 1), EAD initiation (point 






The major findings of this study are: (i) Exposure of nr-vCMC cultures for 2 times 24 
hours to PMA induces a hypertrophic response in the cardiac myocytes with 
hallmarks of pathological hypertrophied ventricular myocardium; (ii) Following 
prolonged PMA treatment nr-vCMC cultures undergo electrical remodeling as 
evinced by a decrease in CV and an increase in APD and APD dispersion; (iii) PMA-
treated nr-vCMC cultures display a high incidence of triggered activity causing focal 
tachyarrhythmias; (iv) Mechanistically, the arrhythmias observed in nr-vCMC cultures 
rendered pathologically hypertrophic by prolonged PMA treatment are probably a 
direct consequence of the electrical remodeling process.  
 
In vitro models of PCH 
In recent years much has been learned about the signaling pathways orchestrating 
both physiological and pathological heart growth.24 Through extensive molecular, 
genetic and pharmacological studies, G protein-coupled receptors (GPCRs) and 
their ligands (e.g. AngII, ET-1, noradrenaline [NE]) have been identified as key 
regulators of PCH.25 This has led researchers to use these ligands or synthetic 
analogs hereof (e.g. isoproterenol, phenylephrine [PE]) to develop in vitro and in vivo 
models of PCH and heart failure.9,26-28 In the in vitro models of pathological 
ventricular hypertrophy, an increase in CSA, mRNA and protein content, cell 
capacitance and/or protein synthesis rate was taken as proof of cell growth while 
increases in the expression of Nppa, natriuretic peptide precursor B (Nppb), Acta1, 
β-myosin heavy chain (Myh7) and/or decreases in α-myosin heavy chain (Myh6) and 
Serca2a levels were considered indicative of a pathological rather than a 
physiological hypertrophic response. 
The pro-hypertrophic effects of AngII-, ET-1- and cathecholamine-binding GPCRs 
in the heart are for a large part attributable to the activation of phospholipase C, 
which converts phosphatidylinositol 4,5-bisphosphate (PIP2) into the second 
messengers IP3 and DAG. In this study, PCH was induced by using PMA as a 
synthetic analogue of the second messenger DAG instead of by agonist-induced 
GPCR activation. Possible pro-hypertrophic effects caused by direct ligand-induced 




IP3 receptor (IP3R) activation and subsequent Ca
2+ release are therefore expected to 
be absent in our nr-vCMC-based PCH model. The PMA-treated nr-vCMC cultures 
nevertheless show a very robust hypertrophic response with hallmarks of PCH 
(Figures 1 and 2), which is consistent with the results of previous studies that 
employed (prolonged) PMA treatment to render cardiomyocyte cultures 
hypertrophic.17,20,29,30 This suggests that either IP3R signaling is not necessary for 
inducing PCH-related phenotypic changes in cultured nr-vCMCs or that IP3Rs get 
activated by DAG-dependent signaling. Indeed, several studies have identified the 
DAG receptors PKC and PKD as important mediators of (pathological) cardiac 
hypertrophy and fetal cardiac gene reactivation.14,21,31-34 Consequently, 
overexpression of PKCα35 or PKD336 in nr-vCMCs induced pathological hypertrophic 
growth with increased fetal cardiac gene expression in these cells. 
 
Pro-arrhythmic mechanisms of PCH 
Despite the rapidly increasing knowledge about the molecular pathways involved in 
the development of PCH and heart failure, the mechanisms underlying electrical 
remodeling of the diseased heart are still poorly understood. This is partially due to 
the disparate results obtained in different in vivo studies focusing on PCH-related 
changes in cardiac electrophysiology.37-39 A confounding factor in these studies has 
been the use of different experimental conditions, animal models and/or patient 
groups with distinct contributions of other factors besides PCH to the 
electrophysiological remodeling process. In this study, using a well-defined in vitro 
model system, heterogeneous APD prolongation and EAD-triggered activity were 
identified as likely key players in the development of PCH-associated arrhythmias. 
These findings are consistent with the results of animal and clinical studies 
attributing a prominent role of EADs to the development of ventricular 
tachyarrhythmias.40-43 In our study, we did not investigate the ionic basis of the 
EADs. However, given the pronounced elongation of phase 2 of the AP in the PMA-
treated nr-vCMCs, L-type Ca2+ channels and delayed rectifier K+ channels43 are 
probably involved. In support of this idea, Puglisi et al. recently showed that chronic 
exposure (i.e. for 48-72 hours) of nr-vCMCs to PMA caused a strong decrease in 
normalized IKs.
17 The same researchers also reported a significant decrease in Ito 
and a substantial increase in INa+/Ca2+ while the normalized ICa,L did not change 
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significantly. A decrease in Ito following overnight exposure of nr-vCMCs to PMA has 
also been documented by Walsh et al.44 Another important result was the PMA-
induced 32% decrease in Serca2a protein level. Similar findings were made by 
Porter et al. and Qi et al. following prolonged treatment of nr-vCMCs with PMA.20,21 
In their study, Qi and co-workers found that the reduction in Serca2a expression led 
to a slowing of diastolic Ca2+ uptake into the sarcoplasmic reticulum with possible 
pro-arrhythmic consequences. Besides the reduced repolarization reserve at the 
earlier phases of repolarization (i.e. between -40 and 0 mV) and the increased APD 
dispersion, also the conduction slowing observed in our PMA-treated nr-vCMC 
cultures is a major risk factor for the development of ventricular tachyarrhythmias.45 
The most likely explanation for this conduction slowing is gap junctional remodeling 
in combination with a downregulation of connexin 43 protein level as has been 
observed in patients with PCH or heart failure.46,47  
 
PCH versus heart failure model 
In response to hemodynamic stress and/or myocardial injury (i.e. when cardiac load 
exceeds cardiac output) the heart engages in a process called compensatory 
hypertrophy through the enlargement of cardiomyocytes by the parallel (concentric 
hypertrophy) or serial (eccentric hypertrophy) addition of sarcomeres. This process is 
under neurohormonal control of the adrenergic nervous system and renin-
angiotensin system. At the molecular level, the changes in cardiomyocyte phenotype 
are accompanied by reinduction of the so-called fetal gene program, because 
patterns of gene expression mimic those observed during cardiac development. In 
the continued presence of pathologically stimuli, excessive cardiomyocyte death will 
provoke transition to dilated cardiomyopathy leading to heart failure. The latter 
process is associated with functional perturbations of cellular Ca2+ homeostasis and 
ionic currents resulting in impaired force generation and the development of 
malignant arrhythmias.38,48 The PMA-treated nr-vCMC cultures display many of the 
same electrophysiological changes found in failing ventricular myocardium including 
a reduction in CV, heterogeneous APD prolongation and a high incidence of 
triggered electrical impulses.3 This may suggest that the PMA-treated nr-vCMC 
cultures represent a relatively late stage in the transition from PCH to heart failure. 
Further evidence for this presupposition should come from a comparison of the 




contractile force-generating capacity of control and PMA-treated nr-vCMC cultures 
and from comparative transcriptome analyses. 
 
Conclusion 
In the present study, treatment of nr-vCMCs for 2 times 24 hours with PMA not only 
promoted cardiomyocyte hypertrophy but also led to the reactivation of fetal cardiac 
genes as evinced by PMA-dependent increases in Nppa and Acta1 levels and a 
decrease in Serca2a expression. PMA-treated nr-vCMCs showed a high incidence of 
triggered tachyarrhythmias associated with increases in APD and APD dispersion 
caused by electrical remodeling. To the best of our knowledge, this is the first study 
in which the pro-arrhythmic features of PCH per se have been investigated. Since 
this in vitro model of PCH is highly controllable and provides reproducible results, it 
is ideally suited for testing, in proof-of-concept studies, new therapeutic interventions 
(genetic modifications or pharmacological treatments) targeting specific aspects of 
hypertrophy/heart failure-associated arrhythmias.  
 
Study limitations 
In this study, PCH-related arrhythmias were investigated in 2D cultures of nr-vCMCs. 
Although this in vitro model system has greatly contributed to our current 
understanding of heart structure and function and lends itself very well to 
pharmacological and genetic manipulation, the electrophysiological properties of 
PMA-treated nr-vCMCs will only partially resemble those of cardiomyocytes in the 
pathologically hypertrophied human heart. Also, in isolation, pathological hypertrophy 
may have a different impact on cardiomyocytes’ behaviour than in combination with 
other cardiac pathologies like inflammation, hypoxia and fibrosis. Accordingly, 
discoveries made in PMA-treated nr-vCMC cultures will always have to be verified in 
more clinically relevant settings. Even so, due to the relative ease with which nr-
vCMCs can be obtained, cultured and manipulated they represent a highly useful 
model system for mechanistic and therapy-directed cardiac research. 
 
Funding 
This work was supported by an unrestricted research grant from the Iranian Ministry 





Conceived and designed the experiments: ZN, BOB, DAP, AAF. Performed the 
experiments: ZN. Analyzed the data: ZN, BOB, DAP, AAF. Contributed 
reagents/materials/analysis tools: BOB, MJS, DAP, AAF. Wrote the paper: ZN, MJS, 
DAP, AAF. 
  





1. Grossman W, Jones D, McLaurin LP. Wall stress and patterns of hypertrophy 
in the human left ventricle. J Clin Invest. 1975;56:56-64. 
2. Weber KT, Brilla CG. Pathological hypertrophy and cardiac interstitium. 
Fibrosis and renin-angiotensin-aldosterone system. Circulation. 
1991;83:1849-1865. 
3. Burchfield JS, Xie M, Hill JA. Pathological ventricular remodeling: 
Mechanisms: Part 1 of 2. Circulation. 2013;128:388-400. 
4. Galinier M, Balanescu S, Fourcade J, Dorobantu M, Albenque JP, Massabuau 
P, Doazan JP, Fauvel JM, Bounhoure JP. Prognostic value of arrhythmogenic 
markers in systemic hypertension. Eur Heart J. 1997;18:1484-1491. 
5. Haider AW, Larson MG, Benjamin EJ, Levy D. Increased left ventricular mass 
and hypertrophy are associated with increased risk for sudden death. J Am 
Coll Cardiol. 1998;32:1454-1459. 
6. Arnol M, Starc V, Knap B, Potocnik N, Bren AF, Kandus A. Left ventricular 
mass is associated with ventricular repolarization heterogeneity one year after 
renal transplantation. Am J Transplant. 2008;8:446-451. 
7. McLenachan JM, Dargie HJ. Determinants of ventricular arrhythmias in 
cardiac hypertrophy. J Cardiovasc Pharmacol. 1991;17 Suppl 2:S46-49. 
8. Amano Y, Kitamura M, Tachi M, Takeda M, Mizuno K, Kumita S. Delayed 
enhancement magnetic resonance imaging in hypertrophic cardiomyopathy 
with basal septal hypertrophy and preserved ejection fraction: Relationship 
with ventricular tachyarrhythmia. J Comput Assist Tomogr. 2014;38:67-71. 
9. Schaub MC, Hefti MA, Harder BA, Eppenberger HM. Various hypertrophic 
stimuli induce distinct phenotypes in cardiomyocytes. J Mol Med (Berl). 
1997;75:901-920. 
10. Hohendanner F, McCulloch AD, Blatter LA, Michailova AP. Calcium and IP3 
dynamics in cardiac myocytes: Experimental and computational perspectives 
and approaches. Front Pharmacol. 2014;5:35. 
11. Sin YY, Baillie GS. Protein kinase D in the hypertrophy pathway. Biochem 
Soc Trans. 2012;40:287-289. 




13. Dunnmon PM, Iwaki K, Henderson SA, Sen A, Chien KR. Phorbol esters 
induce immediate-early genes and activate cardiac gene transcription in 
neonatal rat myocardial cells. J Mol Cell Cardiol. 1990;22:901-910. 
14. Shubeita HE, Martinson EA, Van Bilsen M, Chien KR, Brown JH. 
Transcriptional activation of the cardiac myosin light chain 2 and atrial 
natriuretic factor genes by protein kinase C in neonatal rat ventricular 
myocytes. Proc Natl Acad Sci U S A. 1992;89:1305-1309. 
15. Prasad AM, Inesi G. Regulation and rate limiting mechanisms of Ca2+ ATPase 
(SERCA2) expression in cardiac myocytes. Mol Cell Biochem. 2012;361:85-
96. 
16. Shigekawa M, Katanosaka Y, Wakabayashi S. Regulation of the cardiac 
Na+/Ca2+ exchanger by calcineurin and protein kinase C. Ann N Y Acad Sci. 
2007;1099:53-63. 
17. Puglisi JL, Yuan W, Timofeyev V, Myers RE, Chiamvimonvat N, Samarel AM, 
Bers DM. Phorbol ester and endothelin-1 alter functional expression of 
Na+/Ca2+ exchange, K+, and Ca2+ currents in cultured neonatal rat myocytes. 
Am J Physiol Heart Circ Physiol. 2011;300:H617-626. 
18. Kwak BR, van Veen TA, Analbers LJ, Jongsma HJ. TPA increases 
conductance but decreases permeability in neonatal rat cardiomyocyte gap 
junction channels. Exp Cell Res. 1995;220:456-463. 
19. Doble BW, Ping P, Fandrich RR, Cattini PA, Kardami E. Protein kinase C-
epsilon mediates phorbol ester-induced phosphorylation of connexin-43. Cell 
Commun Adhes. 2001;8:253-256. 
20. Qi M, Bassani JW, Bers DM, Samarel AM. Phorbol 12-myristate 13-acetate 
alters SR Ca(2+)-ATPase gene expression in cultured neonatal rat heart cells. 
Am J Physiol. 1996;271:H1031-1039. 
21. Porter MJ, Heidkamp MC, Scully BT, Patel N, Martin JL, Samarel AM. 
Isoenzyme-selective regulation of SERCA2 gene expression by protein kinase 
C in neonatal rat ventricular myocytes. Am J Physiol Cell Physiol. 
2003;285:C39-47. 
22. Blum JL, Samarel AM, Mestril R. Phosphorylation and binding of AUF1 to the 
3'-untranslated region of cardiomyocyte SERCA2a mRNA. Am J Physiol Heart 
Circ Physiol. 2005;289:H2543-2550. 




23. Pijnappels DA, Schalij MJ, Ramkisoensing AA, van Tuyn J, de Vries AA, van 
der Laarse A, Ypey DL, Atsma DE. Forced alignment of mesenchymal stem 
cells undergoing cardiomyogenic differentiation affects functional integration 
with cardiomyocyte cultures. Circ Res. 2008;103:167-176. 
24. Bernardo BC, Weeks KL, Pretorius L, McMullen JR. Molecular distinction 
between physiological and pathological cardiac hypertrophy: Experimental 
findings and therapeutic strategies. Pharmacol Ther. 2010;128:191-227. 
25. Salazar NC, Chen J, Rockman HA. Cardiac GPCRs: GPCR signaling in 
healthy and failing hearts. Biochim Biophys Acta. 2007;1768:1006-1018. 
26. Lijnen P, Petrov V. Renin-angiotensin system, hypertrophy and gene 
expression in cardiac myocytes. J Mol Cell Cardiol. 1999;31:949-970. 
27. Wollert KC, Drexler H. The renin-angiotensin system and experimental heart 
failure. Cardiovasc Res. 1999;43:838-849. 
28. Osadchii OE. Cardiac hypertrophy induced by sustained beta-adrenoreceptor 
activation: Pathophysiological aspects. Heart Fail Rev. 2007;12:66-86. 
29. Allo SN, Carl LL, Morgan HE. Acceleration of growth of cultured 
cardiomyocytes and translocation of protein kinase C. Am J Physiol. 
1992;263:C319-325. 
30. Hartong R, Villarreal FJ, Giordano F, Hilal-Dandan R, McDonough PM, 
Dillmann WH. Phorbol myristate acetate-induced hypertrophy of neonatal rat 
cardiac myocytes is associated with decreased sarcoplasmic reticulum Ca2+ 
ATPase (SERCA2) gene expression and calcium reuptake. J Mol Cell Cardiol. 
1996;28:2467-2477. 
31. Vega RB, Harrison BC, Meadows E, Roberts CR, Papst PJ, Olson EN, 
McKinsey TA. Protein kinases C and D mediate agonist-dependent cardiac 
hypertrophy through nuclear export of histone deacetylase 5. Mol Cell Biol. 
2004;24:8374-8385. 
32. Fielitz J, Kim MS, Shelton JM, Qi X, Hill JA, Richardson JA, Bassel-Duby R, 
Olson EN. Requirement of protein kinase D1 for pathological cardiac 
remodeling. Proc Natl Acad Sci U S A. 2008;105:3059-3063. 
33. Palaniyandi SS, Sun L, Ferreira JC, Mochly-Rosen D. Protein kinase C in 
heart failure: a therapeutic target? Cardiovasc Res. 2009;82:229-239. 
34. Ellwanger K, Hausser A. Physiological functions of protein kinase D in vivo. 
IUBMB Life. 2013;65:98-107. 
110 
 
35. Braz JC, Bueno OF, De Windt LJ, Molkentin JD. PKC alpha regulates the 
hypertrophic growth of cardiomyocytes through extracellular signal-regulated 
kinase1/2 (ERK1/2). J Cell Biol. 2002;156:905-919. 
36. Li C, Li J, Cai X, Sun H, Jiao J, Bai T, Zhou XW, Chen X, Gill DL, Tang XD. 
Protein kinase D3 is a pivotal activator of pathological cardiac hypertrophy by 
selectively increasing the expression of hypertrophic transcription factors. J 
Biol Chem. 2011;286:40782-40791. 
37. Liu HB, Yang BF, Dong DL. Calcineurin and electrical remodeling in 
pathologic cardiac hypertrophy. Trends Cardiovasc Med. 2010;20:148-153. 
38. Wang Y, Hill JA. Electrophysiological remodeling in heart failure. J Mol Cell 
Cardiol. 2010;48:619-632. 
39. Cutler MJ, Jeyaraj D, Rosenbaum DS. Cardiac electrical remodeling in health 
and disease. Trends Pharmacol Sci. 2011;32:174-180. 
40. Yan GX, Rials SJ, Wu Y, Liu T, Xu X, Marinchak RA, Kowey PR. Ventricular 
hypertrophy amplifies transmural repolarization dispersion and induces early 
afterdepolarization. Am J Physiol Heart Circ Physiol. 2001;281:H1968-1975. 
41. Cosin Aguilar J, Hernandiz Martinez A, Andres Conejos F. Mechanisms of 
ventricular arrhythmias in the presence of pathological hypertrophy. Eur Heart 
J. 1993;14 Suppl J:65-70. 
42. Antoons G, Volders PG, Stankovicova T, Bito V, Stengl M, Vos MA, Sipido 
KR. Window Ca2+ current and its modulation by Ca2+ release in hypertrophied 
cardiac myocytes from dogs with chronic atrioventricular block.J Physiol. 
2007;579:147-160. 
43. Weiss JN, Garfinkel A, Karagueuzian HS, Chen PS, Qu Z. Early 
afterdepolarizations and cardiac arrhythmias. Heart Rhythm. 2010;7:1891-
1899. 
44. Walsh KB, Sweet JK, Parks GE, Long KJ. Modulation of outward potassium 
currents in aligned cultures of neonatal rat ventricular myocytes during 
phorbol ester-induced hypertrophy. J Mol Cell Cardiol. 2001;33:1233-1247. 
45. van Rijen HV, Eckardt D, Degen J, Theis M, Ott T, Willecke K, Jongsma HJ, 
Opthof T, de Bakker JM. Slow conduction and enhanced anisotropy increase 
the propensity for ventricular tachyarrhythmias in adult mice with induced 
deletion of connexin43. Circulation. 2004;109:1048-1055. 




46. Severs NJ, Bruce AF, Dupont E, Rothery S. Remodelling of gap junctions and 
connexin expression in diseased myocardium. Cardiovasc Res. 2008;80:9-19. 
47. Kanno S, Saffitz JE. The role of myocardial gap junctions in electrical 
conduction and arrhythmogenesis. Cardiovasc Pathol. 2001;10:169-177. 
48. Diwan A, Dorn GW, 2nd. Decompensation of cardiac hypertrophy: Cellular 
















An In Vitro Model of Early- or No-Reperfusion Scars 
to Explain How Clinical Reentrant Arrhythmia 
Characteristics May Relate to Therapeutic Efficacy 
 
 
Saïd F. A. Askar*, Zeinab Neshati*, Brian O. Bingen, Sebastiaan R.D. 




* Equal contribution 
 





Purpose: Early-reperfusion during acute myocardial infarction causes scars with a 
patchy aspect, whereas no reperfusion causes compact scars. Patchy scars show a 
lower inducibility and shorter cycle length of arrhythmias compared to compact 
scars. Despite increasing numbers of early-reperfused patients, little data on 
arrhythmic mechanisms is available. We therefore developed an in vitro model of 
patchy and compact scar patterns to gain a mechanistic understanding of associated 
arrhythmia characteristics and how these affect the efficacy of anti-arrhythmic 
interventions. 
Methods: Neonatal rat Ventricular monolayers were locally ablated at day 6-7 of 
culture by a laser-cut plexiglass stamp that produced an anatomical obstruction to 
mimic a compact scar or a stamp that produced multiple smaller anatomical 
obstructions with an equal total outer obstruction diameter to mimic patchy scars. 
One day later, optical mapping was performed.  
Results: Inducibility of reentry was slightly lower in patchy cultures compared to 
compact cultures (41%, n=34 vs 52%, n=23, P<0.05) and cycle length of reentry was 
shorter (234±52 vs 288±38 ms, P<0.05). Reentry was less frequently sustained in 
patchy cultures (40% vs 88% in compact cultures) while the percentage of complex 
arrhythmias was higher (31% vs 11%). Meandering was only found in patchy 
cultures and could result in local polymorphic pseudo-electrograms. A gradient of 
excitability during reentrant arrhythmias was only detectable in patchy cultures. 
Termination of reentry by electrical stimulation was more easily achieved in compact 
cultures (82% vs 20% in patchy cultures) while Nav1.5 blockade by tetrodotoxin only 
induced meandering in patchy cultures (67% of arrhythmic cultures). In smaller 
cultures, this resulted in more frequent termination of reentry in patchy cultures.  
Conclusions: An in vitro model of patchy and compact obstructions reproduces 
arrhythmic characteristics observed after early- and non-reperfused myocardial 
infarctions. Furthermore, it may provide mechanistic insights into the efficacy of anti-
arrhythmic interventions in different anatomical substrates. 
  





Over the past decades, treatment of acute myocardial infarction (AMI) has become 
increasingly effective by focusing on restoring cardiac blood supply as early as 
possible.  During AMI, time-to-reperfusion is not only a critical determinant of 
survival, but also ultimately affects scar composition and size.1-3 By early 
reperfusion, cardiomyocyte (CMC) survival is improved and as a result, post-
infarction scars are smaller and contain surviving myocardial fibers that gives the 
scars a patchy aspect.2 This is opposed to the compact, fibrous scars that are rich in 
fibroblasts and extracellular matrix that do not contain large amounts of CMCs. As 
early reperfusion is becoming increasingly widespread due to adherence to 
constantly improving guidelines that focus on early treatment of AMI, the patient 
population with patchy scars is vastly growing.4-6 Nevertheless, how scar 
composition affects arrhythmogenicity and arrhythmic phenotype is not completely 
clear. Recent clinical evidence suggests that inducibility of arrhythmias in early-
reperfused patients was lower compared to non-reperfused patients.7 Moreover, 
reentrant cycle length (CL) is shorter in early-reperfused patients. However, the 
electrophysiological mechanisms for these observations have not been fully 
elucidated. More importantly, it is there unknown whether these different scar 
compositions can influence the efficacy of pharmacological or electrical defibrillatory 
treatment modalities. Therefore, the current study set out to 1) develop a simplified in 
vitro model to reproduce clinical findings of these different scar compositions and 2) 
utilize this model to investigate the mechanisms behind the different clinical findings 
to subsequently 3) investigate how these mechanisms influence therapeutic efficacy 





All animal experiments were approved by the Animal Experiments Committee of the 
Leiden University Medical Center and conformed to the Guide for the Care and Use 
of Laboratory Animals as stated by the US National Institutes of Health. 
 
Cell isolation and culture 
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Neonatal cardiomyocytes were isolated from 2-day old wistar rats as described 
previously.8,9 Animals were anesthesized by inhalation of 4-5% isoflurane. After pain 
reflexes were assured to be absent, hearts were rapidly excised and the ventricular 
tissue was minced and digested with collagenase I (450 units/ml; Worthington, NJ, 
USA) under gentle agitation. After a pre-plating step to minimize fibroblast 
contamination of cardiac cultures, cells were plated out on fibronectin-coated, round 
glass coverslips (22 mm) at a cell density of 1x106 cells/well in 12-well plates 
(Corning Life Sciences, Amsterdam, the Netherlands). In another subset of 
experiments, 15 mm coverslips were used in 24-wells plates (Corning Life Sciences) 
and cell density was 5x105 cells/well. Proliferation of endogenously present 
myofibroblasts was inhibited by administration of 10 µg/mL Mitomycin-C (Sigma-
Aldrich, St. Louis, MO, USA) at day 1 for 2 hours.8 
 
Preparation of anatomical obstructions 
To produce pre-defined configurations of cardiac tissue, a method of inducing local 
cell death using specialized stamps was utilized to mimic scar compositions from 
early or non-reperfused myocardium. Stamps were designed using CAD-software 
(Solidworks, Dassault Systèmes, Velizy-Villacoublay, France). Designs were laser-
cut into plexiglass using a PLS3.60 Laser (Universal Lasersystems, Scottsdale, AZ, 
USA). Bottom surfaces were gently polished with 9 µm polishing paper to equalize 
surfaces. By carefully pressing these stamps onto cardiac cultures at day 6-7 of 
culture, these stamps formed the desired pattern in the cardiac cultures. Cultures 
were allowed to adjust for ≥6h after ablation before optical mapping was performed. 
Stamps that mimicked the compact scar composition had an outer diameter of 11.5 
mm and lacked any clefts in order to ablate cells over the entire surface area of the 
stamp. In contrast, stamps to mimic patchy composition had the same outer 
diameter of 11.5 mm, but were comprised of smaller circles with a diameter of 1 mm 
and interpositioned clefts that allowed for the survival of myocardial cells throughout 
the ablated area. 
 
Optical mapping 
Arrhythmogenicity of cultures was evaluated using optical mapping as described 
previously.8,9 At day 7-8, cultures were loaded with 6 µmol/L of the voltage-sensitive 
dye Di-4-ANEPPS (Invitrogen, Breda, the Netherlands) diluted in DMEM/Hams’ F12 




(Invitrogen) for 10 minutes at 37oC. Next, cultures were refreshed with warm (37oC) 
DMEM/HAMS F12 and immediately mapped. Cultures were never exposed to 
mapping conditions for >30 minutes, and cumulative exposure time to excitation light 
never exceeded 1 minute. Electrical stimulation was delivered for 10 ms at ≥1.5x 
diastolic threshold using custom-made platinum electrodes spaced either 1 mm 
(narrow bipolar) or 20 mm (wide bipolar) apart. Narrow bipolar stimulation was used 
to investigate conduction velocity (CV) and action potential duration (APD), while 
wide bipolar stimulation was used to induce or terminate reentry. To investigate the 
inducibility of reentry, burst stimulation was performed by wide bipolar 14 Hz 10 ms 
pulses. Reentry was defined as at least 3 consecutive circular activations. Reentry 
was considered not inducible after 6 unsuccessful attempts at induction with burst 
stimulation. Electrical termination of reentry was performed by wide bipolar burst 
stimulation. Optical signals were recorded using a 100 by 100 pixels CMOS camera 
(MiCAM Ultima-L, Scimedia ltd, Costa Mesa, CA, USA) and several parameters 
were analyzed offline with Brainvision Analyze 1201 (Brainvision, Scimedia, Tokyo, 
Japan). CV was determined at least 3 times, directly perpendicular to the activational 
wavefront. Pharmacological interventions (tetrodotoxin (TTX), Alomone Labs, 
Jerusalem, Israel) were pipetted directly into the middle of the well, after which wells 
were gently agitated for 5 seconds to enhance distribution of the pharmacological 
agent. Excitability gradients were determined as the difference between CV at the 
spiral tip during an arrhythmia and the CV at the periphery. 
 
Statistical analysis 
Student t-tests were performed where appropriate. Statistical analyses were 
performed using SPSS 11.0 for Windows (SPSS, Inc., Chicago, IL, USA). 




Partial or complete conduction block in cultures with patchy or compact obstructions 
Neonatal rat ventricular monolayers were confluent and spontaneously beating by 
day 2 of culture and contained roughly 15% of non-myocytes as described 
previously.8 At day 5, cultures were ablated with custom-made probes to form either 
patchy or compact obstructions (Figure 1A). These ablations produced local areas of 
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cell death with smooth, circular edges and often removed the ablated cells altogether 
(Figure 1B). Cultures are referred to as “patchy” or “compact” cultures depending on 
the obstruction pattern produced by the ablations. Optical mapping at day 8 of 
culture showed that APD80 did not significantly differ between any of the groups 
(233±76 ms and 249±31 ms for patchy and compact cultures, respectively, P>0.05, 
Figure 1D). In addition, CV was similar for patchy and compact cultures (21.5±2.1 
cm/s and 21.1±1.7 cm/s, respectively, P>0.05, Figure 1E). Therefore, the basic 
electrophysiology of these cultures was considered to be equal. However, the 
structural differences as produced by the ablations did cause different degrees of 
dyssynchrony across the ablated areas, as conduction was possible across the 
ablated area in patchy cultures but not in compact cultures. This resulted in a 
conduction delay of 70±8 ms in patchy cultures vs 89±6 ms in compact cultures 
across equal distances (P<0.05, Figure 1F). Thereby, partial or complete local 
conduction block was established in this culture model to mimic scar compositions 
after early- or no reperfusion of myocardial infarctions, respectively. 
  





Figure 1. Local ablations in neonatal rat monolayers cause anatomical obstructions of 
conduction that do not affect basic electrophysiological parameters. (A) Pictures of the laser-
cut plexiglass stamp that are used to perform (B) ablations of neonatal rat ventricular 
cardiomyocyte monolayers that produce surviving strands of cardiomyocytes and (C) non-
conducting local anatomical obstructions as visualized by optical mapping. The (*) marks the 
site of electrical stimulation. Green, yellow and red signify activating tissue while gray marks 
inactive tissue. (D) APD80 and (E) CV do not significantly differ between cultures treated with 
the compact probe and cultures treated with the patchy probe. (F) Conduction delay 
between edges across the ablated area is significantly higher in the cultures treated with the 
compact probe. *: P<0.05 vs patchy cultures. 
 
Patchy or compact obstructions reproduce clinical findings of differing inducibility, 
reentrant cycle length and complexity 
In vivo, reentry in early reperfused hearts with patchy scars is less frequently 
inducible but has a shorter cycle. To investigate reproducibility of these findings in 
the current in vitro model, we performed burst stimulation during optical mapping 
experiments to induce reentrant tachyarrhythmias (Figure 2A, B). Inducibility of 
reentry was 41% in patchy (n=34) and 52% in compact scar cultures (n=23, Figure 
2C). Moreover, while most of the reentry episodes in compact scar cultures were 
sustained (7 out of 8 reentry induction episodes), reentry in patchy scars was less 
frequently sustained (6 out of 15 episodes). Reentrant CL was shorter in patchy scar 
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cultures compared to compact scar cultures (234±52 ms vs 288±38 ms, P<0.05, 
Figure 2D). Of these CLs, 62% of reentry in patchy cultures was <250 ms, whereas 
in compact cultures, 24% was faster than 250 ms. Furthermore, CL adaptation was 
most pronounced in patchy cultures (decrease in CL within 1 minute of 50±29 ms 
versus 24±17 ms in compact scar cultures, P<0.05).  
 
 
Figure 2. Reentrant tachyarrhythmias in cultures with patchy or compact obstructions. (A) 
Typical activation map of induced reentry in a culture with patchy obstructions. Isochronal 
spacing = 6 ms. The (*) marks the positions of the electrodes used to induce reentry by burst 
stimulation. (B) Typical activation map of induced reentry in a culture with a compact 
obstruction. Isochronal spacing = 6 ms. (C) Inducibility of reentry was slightly lower in patchy 
cultures. (D) Reentrant cycle length is shorter during reentry in cultures with patchy 
obstructions. *: P<0.05. 
 
 




Excitability gradient from core to periphery is only present during arrhythmias in 
patchy cultures  
Next, to utilize the model and investigate electrophysiological parameters that are 
difficult to measure in vivo, more in-depth analyses of arrhythmias were performed. 
Complexity of arrhythmias was assessed within the first minute of induction. 
Interestingly, complexity of observed reentry in compact cultures rarely consisted of 
more than one activating wavefront (1 out of 9 reentry episodes, Figure 3A). In 
contrast, reentrant arrhythmias in patchy cultures could consist of multiple 
wavefronts (5 out of 16 reentry episodes, Figure 3B, C). Moreover, reentrant 
arrhythmias within patchy cultures were shown to meander following induction (15 
reentry induction episodes with meandering found in 11 episodes, Figure 4A) while 
none out of 8 reentry induction episodes in compact cultures revealed any 
meandering as reentrant arrhythmias immediately stabilized. During meandering in 
patchy cultures, local pseudo-electrograms had a polymorphic appearance (Figure 
4B). In contrast, all observed reentrant arrhythmias in compact cultures showed a 
monomorphic pseudo-electrogram (Figure 4C). Out of 9 non-sustained episodes of 
reentry induction in patchy cultures, 7 showed meandering which implied a role of 






Figure 3. Complexity of reentrant arrhythmias. (A) Typical example of a complex reentrant 
arrhythmia in a culture with a compact obstruction showing multiple activational fronts. The 
(*) marks the locations of the electrodes that were used to induced reentry. (B) Typical 
activation map of a complex reentrant arrhythmia in a culture with patchy obstructions. 
Isochronal spacing = 6 ms. (C) Incidence of complex forms of reentrant arrhythmias was 
higher in cultures with patchy obstructions. 
 
Figure 4. Rotor meandering in cultures with patchy obstructions gives rise to polymorphic 
pseudo-electrograms. (A) High-pass filtered pseudo-voltage map sequence showing 
meandering of a reentrant arrhythmia through the culture. The (O) marks the pivot point of 
reentry. Green, yellow and red signify activating tissue while gray signifies inactive tissue. 
Blue marks depolarizing tissue. (B) High-pass filtered pseudo-electrogram during 
meandering reentry in a culture with patchy obstructions shows a polymorphic appearance. 
(C) High-pass filtered pseudo-electrogram during non-meandering reentry, the only type of 
sustained reentry in compact cultures. These pseudo-electrograms were typically 
monomorphic. 
 




During reentrant arrhythmias in patchy cultures, it was observed that the 
amplitude of the optical pseudo-voltage differed throughout the culture (Figure 5A). 
As changes in fluorescence of the used voltage-sensitive dye are an indication of 
changes in membrane potential, it appeared there was an excitability gradient during 
reentry in patchy cultures that was absent during reentry in compact cultures (Figure 
5B).10 To substantiate this claim, CV was determined at locations nearest to the pivot 
point of reentry and peripheral to the pivot point in reentry, as CV is highly dependent 
on the excitability of cardiac tissue. A significant difference between these values 
was only detected for reentrant arrhythmias in patchy cultures. Moreover, values of 
these differences were (5.8±0.3 cm/s) in patchy cultures vs (0.8±1.1 cm/s) in 






Figure 5. An excitability gradient during reentrant arrhythmias is only found in cultures with 
patchy obstructions. (A) Typical example of a high-pass filtered pseudo-voltage map with 
corresponding optical signals shows that optical signal amplitude increases from core to 
periphery during reentry in a patchy culture. Green, yellow and red signify activating tissue 
while gray marks inactive tissue. (B) Typical example of a high-pass filtered pseudo-voltage 
map with corresponding pseudo-voltage signals show that optical signal amplitude does not 
differ between the tissue nearest to the core of reentry or outer ring of tissue during reentry 
in a compact culture. Green, yellow and red signify activating tissue while gray marks 
inactive tissue. (C) During reentry, only patchy cultures showed a significant difference 
between the CV at the tissue nearest to the core of reentry and CV at the periphery. *P: 
<0.05. 
 
Anti-arrhythmic efficacy of fast-sodium channel blockade and electrical stimulation 
depends on the anatomical configuration 
To investigate the efficacy of fast sodium channel blockade, 20 µM TTX was 
administered during arrhythmias. After arrhythmias were confirmed to be stable and 
sustained for at least 30 seconds, TTX was directly pipetted in the middle of the 
culture. After such an intervention in patchy cultures, reentry started to wander 




throughout the culture in 67% of 12 cultures, whereas 14 compact cultures did not 
show  such an activity (Figure 6A). Interestingly, only 1 out of 12 arrhythmias 
terminated in patchy cultures despite strong meandering. Moreover, 2 out of 14 
arrhythmias terminated in compact cultures after TTX administration. To investigate 
whether this may have been due to the size of the culture and multitude of small 
obstructions in these cultures that provide re-anchoring points for these arrhythmias, 
we performed the same intervention in smaller cultures (15 mm in diameter) with 
smaller and less obstructions (6 mm outer diameter). In these smaller patchy 
cultures, TTX administration often resulted in termination (88%, n=8 arrhythmias, 
Figure 6B). In contrast, TTX was less effective in compact cultures (25% terminated 





Figure 6. Effect of obstruction pattern on termination of reentry by sodium channel blockade 
or electrical stimulation. (A) Quantification of the percentage of arrhythmias that meander 
after TTX administration. (B) Quantification of the percentage of arrhythmias that terminate 
after administration of TTX in smaller cultures (total diameter of 15 mm and 6 mm outer 
diameter of the area of ablation) which shows that the induced meandering by TTX can be 
important for terminating arrhythmias. (C) Quantification of the percentage of reentrant 
arrhythmias that could be terminated by application of a bipolar 14 Hz electrical stimulation 
protocol. (D) Quantification of the number of attempts necessary to terminate reentry. *: 
P<0.05. 
 




Alternatively, electrical stimulation was investigated for its anti-arrhythmic efficacy. 
In compact cultures, reentry was terminated by burst stimulation in 9 out of 11 
cultures (Figure 6C). In patchy cultures, 1 out of 5 reentrant arrhythmias terminated 
by a single attempt at burst stimulation. Overall, 2.2±1 attempts of reentry 
termination by burst stimulation were necessary for successful reentry termination in 
patchy cultures, whereas 1.1±0.3 attempts were necessary in compact cultures 




Key findings of this study are 1) patchy or compact obstructions in a 2D cardiac 
model can reproduce clinical arrhythmic findings of early or non-reperfused 
myocardial scars and 2) reveal an excitability gradient that is only present during 
reentrant arrhythmias in patchy scar cultures and 3) the absence or presence of this 
excitability gradient is responsible for differences in anti-arrhythmic outcome of 
electrical and pharmacological defibrillation. 
 
Reproducibility of clinical findings in a simplified in vitro model 
Over the past decades, timely reperfusion during AMI has been proven to be crucial 
in improving acute but also chronic survival.1,3 Duration of coronary artery occlusion 
is directly related to myocardial cell death, the transmural extent and size of the 
myocardial scar that develops.11,12 As early reperfusion strongly limits myocardial 
damage, the subsequent myocardial scar contains a lower collagen density than 
non-reperfused scars. Importantly, early reperfusion also increases the amount of 
surviving cardiomyocytes within the infarction area which results in a patchy aspect 
of the scar.2 Moreover, the pro-arrhythmic substrate that is formed by post-MI scars 
is altered in such a way that different arrhythmic characteristics are present in early- 
or non-reperfused patients.7 However, it is unknown how early reperfusion affects 
the efficacy of electrical and pharmacological anti-arrhythmic interventions, despite a 
growing patient population due to better care and management of AMI. In the current 
study, an in vitro model of these patchy or compact scar compositions was 
developed to gain more insight into the mechanisms of differing arrhythmogenicity. 
By locally inducing cell death, anatomical obstructions were prepared in 2D neonatal 
rat cultures that allowed for surviving myocardial strands capable of conduction 
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through the scar in the patchy group but formed a solid, compact obstruction that 
blocked conduction in the compact scar group. As a result, dyssynchrony across the 
scar was higher in the compact group than in the patchy group. In the clinical setting, 
dyssynchrony also corresponds to obstruction size.13 Moreover, this model 
reproduced the difference in reentrant CL and due to the use of optical mapping, 
showed that this difference in CL can be explained by differing path lengths.7 While 
non-reperfused and early-reperfused patients without prior arrhythmias do not show 
a difference in the inducibility of reentry, inducibility is lower for early-reperfused 
patients that had prior arrhythmic episodes compared to non-reperfused patients 
with prior arrhythmic episodes.7 Remarkably, the inducibility of reentry in the current 
study can be positioned in between these findings as the inducibility of reentry in 
patchy cultures was slightly lower than in compact cultures. However, the 
electrophysiological equality of both groups in our model regarding APD and CV at 
1Hz activation rate, and the observation that arrhythmic episodes can modify the 
electrical behavior of myocardial tissue to favor arrhythmias14 are arguments that 
suggest our model may be most relevant to patients without prior arrhythmias. 
Though the current model is based on neonatal rat cardiomyocytes and any direct 
comparison of parameters may appear arbitrary, it is peculiar that the clinically 
established criterion of “fast VT” with a CL below 250 ms can be applied to our 
model with similar outcomes.7 Besides the high degree of reproducibility of clinical 
findings in this in vitro model, the most promising implications of such a model lie in 
the potential for in-depth investigation of arrhythmic mechanisms. 
 
Anatomical versus functional reentry and the relevance of an excitability gradient 
Using the optical mapping technique, arrhythmic dynamics can be studied in detail 
with a high spatial and temporal resolution.15,16 Therefore, this technique was 
perfectly suited to further investigate arrhythmic mechanisms of reentry in cultures 
with patchy or compact obstructions in a manner that is currently difficult to realize in 
vivo. By visualizing conduction, it was found that reentry in patchy cultures exhibited 
features of a functional type of reentry, as wandering of the arrhythmia throughout 
the culture was observed in a relatively large portion of the cultures.17,18 In contrast, 
reentry in compact cultures did not show meandering and adhered more to the 
specifications of anatomical reentry.19 These differences can be explained by the 
differences in minimal obstacle size to which these arrhythmias pin to in patchy or in 




compact cultures.20 Therefore, the distinction between functional and anatomical 
reentry is based on a gradient rather than strictly separate phenomena.21 The 
smaller the object, the higher the degree of head-to-tail wave interaction and the 
more the arrhythmia resembles functional reentry. Moreover, the degree of head-to-
tail wave interaction determines the excitability of the affected tissue by interfering 
with recovering ion channel dynamics. This also explains the presence of the 
excitability gradient in patchy cultures and its absence in compact cultures, as during 
functional reentry, the head-to-tail wave interaction is maximal at the pivot point of 
reentry and decreases towards the periphery. The relevance of such a gradient was 
demonstrated in the current study, as Nav1.5 blockade using TTX altered culture 
excitability and increased the probability of meandering in patchy cultures, but did 
not strongly affect arrhythmias in compact cultures apart from increasing the CL. The 
mechanism behind this destabilization depends on the altered source-sink 
relationships due to decreased excitability of the tissue by Nav1.5 blockade, which 
forces an increase in the minimal pivoting radius of the reentrant arrhythmia and 
detachment of the anatomical obstruction.22-25 By inducing meandering, reentry may 
be terminated as the core encounters inexcitable boundaries.20,26 Indeed, this was 
confirmed in the current study by repeating the same experiment in smaller cultures 
that made it more likely for the arrhythmia to encounter inexcitable boundaries. In 
addition, the excitability gradient also determines the excitable state of a culture. Due 
to the absence of a fully excitable gap during functional reentry, electrical stimulation 
during reentry in patchy cultures was less successful at termination than in compact 
cultures.19 This electrical stimulation was delivered with bipolar electrodes at a high 
frequency, so that it bears resemblance to anti-tachycardia pacing and defibrillation 
protocols. Taken together, this model may provide a useful tool to improve our 
current understanding of reentrant arrhythmia dynamics and to know how they 
influence therapeutic efficacy in early or non-reperfused patients.  
 
Future perspectives and limitations 
Despite the high reproducibility of clinical findings with the currently presented in vitro 
model, the authors recognize that its relevance to clinical situations needs to be 
substantially increased. While the current study made a clear distinction between the 
patchy anatomical composition after early reperfusion or the clear-cut compact scar 
composition without reperfusion for standardization purposes, the in vivo setting is 
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more complex, with for example borderzones that may exhibit features of both 
patchy and compact fibrosis. By gradually increasing the complexity of the 
anatomical configurations in this model, the model can be more tailored to such 
specific clinical situations in the future. Currently, ventricular cardiomyocytes from 
neonatal rats have been used to create a 2D monolayer of cells in which arrhythmic 
dynamics can be more easily interpreted than in 3D tissue preparations. These cells 
were utilized due to their ability to stay in culture for extended periods of time, to form 
confluent beating monolayers and their availability, as human adult CMCs cannot, 
despite their superior clinical relevance. However, with the recent discovery of 
induced pluripotent stem cells (iPS cells) that allow for the genetic reprogramming of 
somatic cells into cell types of different lineages such as cardiomyocytes, future 
studies will benefit from utilizing iPS-derived CMCs for their confluent monolayers.27 
Despite reported impurities and inefficiencies of cardiac differentiation of such 
reprogrammed cells,28 very recent technological advancements29 make it likely that 
purified human cardiac monolayers can be utilized to increase the relevance of in 
vitro models for the clinical setting in the near future. As these iPS-derived human 
cardiomyocytes may more accurately represent the patient-specific ion channel 
expression profile, such cells have already been used to demonstrate the feasibility 
of patient-specific drug-screening techniques.30 The combination of human 
cardiomyocytes in monolayers with the anatomical compositions of their respective 
pro-arrhythmic substrate may therefore not only elucidate pro-arrhythmic 
mechanisms, but also provide a very powerful patient-specific anti-arrhythmic drug-
screening tool in the near future. 
 
Conclusions 
An in vitro model of early- or non-reperfused post-myocardial infarction scars 
reproduces clinical arrhythmic findings. Importantly, this model allows for the 
investigation of arrhythmic mechanisms such as meandering and complexity of 
arrhythmias that is more difficult to realize in a clinical setting. Finally, this model may 
provide mechanistic insight in how these arrhythmic mechanisms influence the 









We wish to thank H. van der Stadt and R. van Leeuwen for excellent technical 
support.  
 
Sources of Funding 
This work was supported by the Dutch Heart Foundation (2008/B119) and the 
Netherlands Organization for Scientific Research (NWO; VENI grant (91611070), 
D.A.P). 
 




















1. The effects of tissue plasminogen activator, streptokinase, or both on 
coronary-artery patency, ventricular function, and survival after acute 
myocardial infarction. The GUSTO Angiographic Investigators. N Engl J Med. 
1993;329:1615-1622. 
2. Wijnmaalen AP, Schalij MJ, von der Thusen JH, Klautz RJ, Zeppenfeld K. 
Early reperfusion during acute myocardial infarction affects ventricular 
tachycardia characteristics and the chronic electroanatomic and histological 
substrate. Circulation. 2010;121:1887-1895. 
3. Lambert L, Brown K, Segal E, Brophy J, Rodes-Cabau J, Bogaty P. 
Association between timeliness of reperfusion therapy and clinical outcomes 
in ST-elevation myocardial infarction. JAMA. 2010;303:2148-2155. 
4. Filardo G, Nicewander D, Ballard DJ. Changes over six years in 
administration of aspirin and beta blockers on arrival and timely reperfusion 
and in in-hospital and 30-day postadmission mortality in patients with acute 
myocardial infarction. Am J Cardiol. 2011;107:1421-1425. 
5. Bassand JP, Danchin N, Filippatos G, Gitt A, Hamm C, Silber S, Tubaro M, 
Weidinger F. Implementation of reperfusion therapy in acute myocardial 
infarction. A policy statement from the European Society of Cardiology. Eur 
Heart J. 2005;26:2733-2741. 
6. Schiele F, Hochadel M, Tubaro M, Meneveau N, Wojakowski W, Gierlotka M, 
Polonski L, Bassand JP, Fox KA, Gitt AK. Reperfusion strategy in Europe: 
temporal trends in performance measures for reperfusion therapy in ST-
elevation myocardial infarction. Eur Heart J. 2010;31:2614-2624. 
7. Piers SR, Wijnmaalen AP, Borleffs CJ, van Huls van Taxis CF, Thijssen J, 
van Rees JB, Cannegieter SC, Bax JJ, Schalij MJ, Zeppenfeld K. Early 
reperfusion therapy affects inducibility, cycle length, and occurrence of 
ventricular tachycardia late after myocardial infarction. Circ Arrhythm 
Electrophysiol. 2011;4:195-201. 
8. Askar SF, Ramkisoensing AA, Schalij MJ, Bingen BO, Swildens J, van der 
Laarse A, Atsma DE, de Vries AA, Ypey DL, Pijnappels DA. Antiproliferative 
treatment of myofibroblasts prevents arrhythmias in vitro by limiting 
myofibroblast-induced depolarization. Cardiovasc Res. 2011; 90(2):295-304. 




9. Askar SF, Bingen BO, Swildens J, Ypey DL, van der Laarse A, Atsma DE, 
Zeppenfeld K, Schalij MJ, de Vries AA, Pijnappels DA. Connexin43 silencing 
in myofibroblasts prevents arrhythmias in myocardial cultures: role of maximal 
diastolic potential. Cardiovasc Res. 2012;93:434-444. 
10. Loew LM, Cohen LB, Dix J, Fluhler EN, Montana V, Salama G, Wu JY. A 
naphthyl analog of the aminostyryl pyridinium class of potentiometric 
membrane dyes shows consistent sensitivity in a variety of tissue, cell, and 
model membrane preparations. J Membr Biol. 1992;130:1-10. 
11. Reimer KA, Lowe JE, Rasmussen MM, Jennings RB. The wavefront 
phenomenon of ischemic cell death. 1. Myocardial infarct size vs duration of 
coronary occlusion in dogs. Circulation. 1977;56:786-794. 
12. Miyazaki S, Fujiwara H, Onodera T, Kihara Y, Matsuda M, Wu DJ, Nakamura 
Y, Kumada T, Sasayama S, Kawai C. Quantitative analysis of contraction 
band and coagulation necrosis after ischemia and reperfusion in the porcine 
heart. Circulation. 1987;75:1074-1082. 
13. Nucifora G, Bertini M, Marsan NA, Delgado V, Scholte AJ, Ng AC, van 
Werkhoven JM, Siebelink HM, Holman ER, Schalij MJ, van der Wall EE, Bax 
JJ. Impact of left ventricular dyssynchrony early on left ventricular function 
after first acute myocardial infarction. Am J Cardiol. 2010;105:306-311. 
14. Rostock T, Steven D, Lutomsky B, Servatius H, Drewitz I, Klemm H, 
Mullerleile K, Ventura R, Meinertz T, Willems S. Atrial fibrillation begets atrial 
fibrillation in the pulmonary veins on the impact of atrial fibrillation on the 
electrophysiological properties of the pulmonary veins in humans. J Am Coll 
Cardiol. 2008;51:2153-2160. 
15. Chang MG, Zhang Y, Chang CY, Xu L, Emokpae R, Tung L, Marban E, 
Abraham MR. Spiral waves and reentry dynamics in an in vitro model of the 
healed infarct border zone. Circ Res. 2009;105:1062-1071. 
16. Entcheva E, Lu SN, Troppman RH, Sharma V, Tung L. Contact fluorescence 
imaging of reentry in monolayers of cultured neonatal rat ventricular 
myocytes. J Cardiovasc Electrophysiol. 2000;11:665-676. 
17. Pertsov AM, Davidenko JM, Salomonsz R, Baxter WT, Jalife J. Spiral waves 




18. Fenton FH, Cherry EM, Hastings HM, Evans SJ. Multiple mechanisms of 
spiral wave breakup in a model of cardiac electrical activity. Chaos. 
2002;12:852-892. 
19. Rudy Y. Reentry: insights from theoretical simulations in a fixed pathway. J 
Cardiovasc Electrophysiol. 1995;6:294-312. 
20. Lim ZY, Maskara B, Aguel F, Emokpae R, Jr., Tung L. Spiral wave attachment 
to millimeter-sized obstacles. Circulation. 2006;114:2113-2121. 
21. Xie F, Qu Z, Garfinkel A. Dynamics of reentry around a circular obstacle in 
cardiac tissue. Phys Rev E. 1998;58:6355-6358. 
22. Cabo C, Pertsov AM, Davidenko JM, Jalife J. Electrical turbulence as a result 
of the critical curvature for propagation in cardiac tissue. Chaos. 1998;8:116-
126. 
23. Cabo C, Pertsov AM, Davidenko JM, Baxter WT, Gray RA, Jalife J. Vortex 
shedding as a precursor of turbulent electrical activity in cardiac muscle. 
Biophys J. 1996;70:1105-1111. 
24. Athill CA, Ikeda T, Kim YH, Wu TJ, Fishbein MC, Karagueuzian HS, Chen PS. 
Transmembrane potential properties at the core of functional reentrant wave 
fronts in isolated canine right atria. Circulation. 1998;98:1556-1567. 
25. Karagueuzian HS, Athill CA, Yashima M, Ikeda T, Wu TJ, Mandel WJ, Chen 
PS. Transmembrane potential properties of atrial cells at different sites of a 
spiral wave reentry: cellular evidence for an excitable but nonexcited core. 
Pacing Clin Electrophysiol. 1998;21:2360-2365. 
26. Takemoto Y, Takanari H, Honjo H, Ueda N, Harada M, Kato S, Yamazaki M, 
Sakuma I, Opthof T, Kodama I, Kamiya K. Inhibition of intercellular coupling 
stabilizes spiral-wave reentry, whereas enhancement of the coupling 
destabilizes the reentry in favor of early termination. Am J Physiol Heart Circ 
Physiol. 2012;303:H578-H586. 
27. Lee P, Klos M, Bollensdorff C, Hou L, Ewart P, Kamp TJ, Zhang J, Bizy A, 
Guerrero-Serna G, Kohl P, Jalife J, Herron TJ. Simultaneous voltage and 
calcium mapping of genetically purified human induced pluripotent stem cell-
derived cardiac myocyte monolayers. Circ Res. 2012;110:1556-1563. 
28. Chen JX, Krane M, Deutsch MA, Wang L, Rav-Acha M, Gregoire S, Engels 
MC, Rajarajan K, Karra R, Abel ED, Wu JC, Milan D, Wu SM. Inefficient 




reprogramming of fibroblasts into cardiomyocytes using Gata4, Mef2c, and 
Tbx5. Circ Res. 2012;111:50-55. 
29. Zhang J, Klos M, Wilson GF, Herman AM, Lian X, Raval KK, Barron MR, Hou 
L, Soerens AG, Yu J, Palecek SP, Lyons GE, Thomson JA, Herron TJ, Jalife 
J, Kamp TJ. Extracellular matrix promotes highly efficient cardiac 
differentiation of human pluripotent stem cells: the matrix sandwich method. 
Circ Res. 2012;111:1125-1136. 
30. Malan D, Friedrichs S, Fleischmann BK, Sasse P. Cardiomyocytes obtained 
from induced pluripotent stem cells with long-QT syndrome 3 recapitulate 















Atrium-Specific Kir3.x Determines Inducibility, 
Dynamics, and Termination of Fibrillation by 
Regulating Restitution-Driven Alternans 
 
 
Brian O. Bingen, Zeinab Neshati, Saïd F.A. Askar, Ivan V. Kazbanov, 
Dirk L. Ypey, Alexander V. Panfilov, Martin J. Schalij, Antoine A.F. de 








Background—Atrial fibrillation is the most common cardiac arrhythmia. Ventricular 
proarrhythmia hinders pharmacological atrial fibrillation treatment. Modulation of 
atrium-specific Kir3.x channels, which generate a constitutively active current (IK,ACh-
c) after atrial remodeling, might circumvent this problem. However, it is unknown 
whether and how IK,ACh-c contributes to atrial fibrillation induction, dynamics, and 
termination. Therefore, we investigated the effects of IK,ACh-c blockade and Kir3.x 
downregulation on atrial fibrillation. 
Methods and Results—Neonatal rat atrial cardiomyocyte cultures and intact atria 
were burst paced to induce reentry. To study the effects of Kir3.x on action potential 
characteristics and propagation patterns, cultures were treated with tertiapin or 
transduced with lentiviral vectors encoding Kcnj3- or Kcnj5-specific shRNAs. Kir3.1 
and Kir3.4 were expressed in atrial but not in ventricular cardiomyocyte cultures. 
Tertiapin prolonged action potential duration (APD; 54.7±24.0 to 128.8±16.9 
milliseconds; P<0.0001) in atrial cultures during reentry, indicating the presence 
of IK,ACh-c. Furthermore, tertiapin decreased rotor frequency (14.4±7.4 to 6.6±2.0 
Hz; P<0.05) and complexity (6.6±7.7 to 0.6±0.8 phase singularities; P<0.0001). 
Knockdown of Kcnj3 or Kcnj5 gave similar results. Blockade of IK,ACh-
c prevented/terminated reentry by prolonging APD and changing APD and 
conduction velocity restitution slopes, thereby altering the probability of APD 
alternans and rotor destabilization. Whole-heart mapping experiments confirmed key 
findings (eg, >50% reduction in atrial fibrillation inducibility after IK,ACh-c blockade). 
Conclusions—Atrium-specific Kir3.x controls the induction, dynamics, and 
termination of fibrillation by modulating APD and APD/conduction velocity restitution 
slopes in atrial tissue with IK,ACh-c. This study provides new molecular and 
mechanistic insights into atrial tachyarrhythmias and identifies Kir3.x as a promising 
atrium-specific target for antiarrhythmic strategies.   
 
Keywords: action potentials, arrhythmia, atrial fibrillation, cardiomyocyte, G protein-
coupled inwardly rectifying potassium channels, RNA interference, voltage-sensitive 
dye imaging 





Atrial fibrillation (AF), the most common cardiac rhythm disorder in humans, 
contributes substantially to morbidity, mortality, and healthcare costs.1-3 Ablation 
techniques, breaking up AF circuits or triggers, have improved the outcome of AF in 
the past decades.4 Although the success rate of AF ablation is relatively high in 
paroxysmal AF, in permanent AF, ablation restores sinus rhythm in only a fraction of 
patients by altering the underlying mechanisms and structural changes of the atrial 
myocardium. Importantly, there is a lack of consensus on the optimal ablation 
strategy in these patients, and this population is vastly growing.5,6 In addition, 
ablation procedures are associated with a risk of complications because of their 
invasive nature.7 Furthermore, long-term maintenance of sinus rhythm requires 
repeated procedures or continuation of antiarrhythmic drugs in a significant 
proportion of chronic AF patients.8 Hence, the first-line treatment of AF is still 
pharmacological.4 However, the use of antiarrhythmic agents is hampered by 
potentially lethal ventricular proarrhythmia, lack of efficacy, and serious side effects.9-
13 Thus, research on AF treatment has focused on finding atrium-selective drugs with 
higher efficacy in AF rhythm control but fewer side effects such as ventricular 
proarrhythmia. 
In the heart of most mammals, including humans, the acetylcholine-activated 
potassium current (IK,ACh) is found exclusively in the atrium.
14 Hence, IK,ACh is one of 
the novel candidates for atrium-specific drug treatment. Activation ofIK,ACh by 
acetylcholine has been shown to shorten action potential (AP) duration (APD) in the 
atria.15 In patients suffering from persistent AF and atrial remodeling,IK,ACh can 
become constitutively active.16,17 Whether this constitutively active acetylcholine-
inducible current (IK,ACh-c) affects AF induction, dynamics, or termination, the 
mechanisms by which it could do so, and the channels involved in this process 
remain to be elucidated. 
To test whether and how IK,ACh-c affects fibrillation, a 2-dimensional in vitro model 
of atrial tissue and a whole-heart model of AF were developed using atrial neonatal 
rat cardiomyocytes (nrCMCs) and hearts with endogenous IK,ACh-c. With these 
models, fibrillation could be systematically and reproducibly studied. Inhibition of 
Kir3.1 or Kir3.4 activity by the highly specific drug tertiapin or lentiviral vector (LV)–
mediated RNA interference (RNAi) was used to study the role of IK,ACh-c in AF 





Noninvasive atrial fibrillation (AF) therapies are based on 2 separate strategies: rate 
or rhythm control aiming to slow ventricular rate to normal or to restore sinus rhythm, 
respectively. Hence, in rate control, AF itself is not resolved, whereas the curtailment 
of ventricular frequency reduces exercise tolerance. Rhythm control, on the other 
hand, is hampered by adverse effects such as ventricular proarrhythmia. Therefore, 
better insight into the contribution of ion channels, present in the atria but not the 
ventricles, to AF and the concordant exploration of possible atrium-specific therapies 
are essential if we are to diminish the burden of adverse effects in AF treatment. 
Previous studies showed that the acetylcholine-dependent potassium current (IK,ACh), 
governed by the atrium-specific Kir3.x channels, can become constitutively active 
(IK,ACh-C) in patients with AF. In the present study, we demonstrate the contribution 
of IK,ACh-Cand Kir3.x to the initiation, maintenance, and termination of AF. We show 
for the first time that IK,ACh-C increases the chance of AF initiation through its 
steepening effects on the action potential duration and conduction velocity restitution 
curves, causing action potential duration and amplitude alternans. In addition, IK,ACh-
C is shown to facilitate AF maintenance by stabilizing rotor dynamics, whereas AF 
termination can be elicited by blockade of IK,ACh-C, causing alternans-mediated rotor 
destabilization. Our findings provide evidence for a causal relationship 
between IK,ACh-C, alternans, and the initiation, maintenance, and termination of AF. 
Thus, not only IK,ACh-C or Kir3.x but also its consequent alternans might be an 





A detailed description of materials and methods can be found in the online-only Data 
Supplement. 
All animal experiments were approved by the Animal Experiments Committee of 
the Leiden University Medical Center and conformed to the Guide for the Care and 
Use of Laboratory Animals as stated by the US National Institutes of Health. 
 
  




Cell Isolation and Culture 
After careful separation of the atria and ventricles of neonatal Wistar rat hearts, 
cardiomyocytes were isolated by collagenase digestion and plated on fibronectin-
coated, round glass coverslips (15-mm diameter) at a density of 2 to 8×105 cells per 
well in 24-well cell culture plates, as described previously.18 To restrict unwanted 
expansion of the remaining nonmyocytes, cell proliferation was inhibited by 
incubation with mitomycin-C (10 µg/mL; Sigma-Aldrich, St. Louis, MO) for 2 hour at 
day 1 of culture.19 
 
Western Blotting 
Cardiomyocytes were lysed in 50 mmol/L Tris-HCl (pH 8.0), 150 mmol/L NaCl, 1% 
Triton X-100, 0.5% sodium deoxycholate, and 0.1% sodium dodecyl sulfate. Three 
15-mm wells, each seeded with 8×105 cells, were used for each sample, and each 
experiment consisted of at least 4 samples. The proteins in the lysate were size 
fractionated in NuPage Novex 12% Bis-Tris gels (Life Technologies, Bleiswijk, the 
Netherlands) and transferred to Hybond polyvinylidene difluoride membranes (GE 
Healthcare, Diegem, Belgium). Membranes were blocked in Tris-based saline, 0.1% 
Tween-20, and 5% BSA (Sigma-Aldrich) for 1 hour. Next, membranes were 
incubated with antibodies directed against Kir3.1 (Alomone Labs, Jerusalem, Israel), 
Kir3.4 (Santa Cruz Biotechnology, Dallas, TX), or GAPDH (loading control; Merck 
Millipore, Billerica, MA) and corresponding horseradish peroxidase–conjugated 
secondary antibodies (Santa Cruz Biotechnology) for 1 hour. Chemiluminescence 
was detected with the ECL Prime Western Blotting Detection Reagent (GE 
Healthcare).  
 
Optical Mapping  
At day 9 of culture, investigation of AP propagation on a whole- culture scale by 
optical mapping (with di-4-ANEPPS [Life Technologies] as a voltage-sensitive dye) 
and subsequent data analyses were performed as described previously.18 During 
optical mapping, cells were stimulated electrically with a custom-made, epoxy-coated 
unipolar platinum electrode with square suprathreshold electric stimuli at 1 and 2 to 
20 Hz (2-Hz increments). Burst pacing with a cycle length of 20 to 100 milliseconds 
was used to induce reentry. Complexity was defined as the number of phase 
singularities (PSs) per 1 cm2, determined by using the phase space method, as 
142 
 
described previously.18 The effect of several drugs (100 nmol/L tertiapin [Alomone 
Labs], 200 nmol/L atropine [Sigma-Aldrich], and 2 µmol/L carbachol [Sigma-
Aldrich])16 was studied by pipetting them directly into the medium and dispersing 
them by gentle agitation, followed immediately by optical mapping. 
Whole-heart mapping was performed by incubating neonatal rat hearts with 2 µmol/L 
di-4-ANEPPS in a tissue bath containing oxygenated Tyrode solution (comprising [in 
mmol/L] NaCl 130, CaCl2 1.8, KCl 4.0, MgCl2 1.0, NaH2PO4 1.2, NaHCO3 24, and 
glucose 5.5, pH 7.4). Before excision of the heart, the left ventricle was injected with 
Tyrode solution supplemented with 20 mmol/L 2,3-butanedione monoxime (Sigma-
Aldrich) to minimize motion artifacts with or without 200 nmol/L tertiapin to block the 
Kir3.x channels. During whole-heart mapping, AF was induced by burst pacing at a 




Kir3.1 and Kir3.4 expression in neonatal rat atrial cell cultures was selectively 
inhibited with self-inactivating LVs encoding shRNAs specific for rat Kcnj3 (LV-
Kir3.1↓) and Kcnj5 (LV-Kir3.4↓), respectively. The shuttle constructs to generate 
these LVs are derivatives of plasmid SHC007 from the Mission shRNA library 
(Sigma-Aldrich) in which the Photinus pyralis luciferase (PpLuc)–specific shRNA-
coding sequence was replaced by a rat Kcnj3- or Kcnj5-specific shRNA-coding 
sequence, and the marker gene cassette consisting of the humanphosphoglycerate 
kinase 1 gene promoter and the puromycin-N-acetyltransferase-coding sequence 
was substituted by the human eukaryotic translation elongation factor 1 alpha 1 gene 
promoter and the Aequorea victoriaenhanced green fluorescent protein-coding 
sequence. The negative control vector (LV-PpLuc↓) had the same genetic makeup 
except that it contained the aforementioned PpLuc-specific shRNA-coding sequence. 
 
Statistical Analysis 
Statistical analyses were performed with SPSS11.0 for Windows (SPSS, Chicago, 
IL). Comparison between 2 groups was performed with the Mann-Whitney U test, the 
Wilcoxon signed-rank test, or the Fisher exact test as appropriate. Kruskal-Wallis 
testing with Bonferroni post hoc correction was used for multiple groups and 
comparisons. Data were expressed as mean±SD for a number of observations. 




Differences were considered statistically significant at P<0.05. Nonlinear regression 
curves were constructed by using a robust exponential 1-phase decay curve fit. 
Accuracy of these curves was expressed as the coefficient of determination 
(R2). R2 was calculated by the formula R2= 1−(SSreg/SStot), where SSreg is the 
regression sum of squares (the sum of the square vertical distances of individual 
points to the regression curve) and SStot is the total sum of squares (the sum of the 




Cell Culture Characteristics 
A detailed characterization of atrial and ventricular nrCMC cultures by 
immunocytology and Western blotting can be found in Supplemental Figure I in the 





Supplemental Figure I. Typical examples of immunocytological double staining of (A) 
MLC2a (green) and α-actinin (red) and (B) NPPA (green) and α-actinin (red) in atrial (upper 
panels) and ventricular (lower panels) neonatal rat CMC cultures. (C) Quantification of 
MLC2a and α-actinin double-positive cells in atrial and ventricular neonatal rat CMC 
cultures. (D) Western blot analysis (left) and quantification (right) of NPPA, MLC2v, MLC2a, 
Cx43 and Cx40 levels in atrial and ventricular neonatal rat CMC cultures using GAPDH as 
loading control. (E) Immunocytological double staining of Cx40 (green) and α-actinin (red) 
and of Cx43 (green) and α-actinin (red) in atrial (1st and 3rd panel from the left, respectively) 
and ventricular (2nd and 4th panel from the left, respectively) neonatal rat CMC cultures. (F) 
Immunocytological double staining of collagen type I (green, left) and PECAM-1 (green, 
middle) with α-actinin (red) and of MLC2a (green, right) with smMHC (red, right). The 
corresponding quantification of fibroblasts (FB), endothelial cells (EC) and smooth muscle 
cells (SMC) is depicted on the far right. #: p<0.05 vs ventricular cultures, ND: not detected. 




Activation Pattern Characteristics in Atrial nrCMC Cultures 
During optical mapping, atrial cultures showed uniform, convex, and fast activation 
originating from the electrode on 1-Hz stimulation (Figure 1A). After burst pacing, 
reentry was induced in the vast majority of atrial cultures. In 46 of 49 of these 
arrhythmic cultures, the activation patterns remained stable during each cycle of 
reentry, and the number and spatial dispersion of PSs did not change during 6 
seconds of mapping (Figure 1B and Movie 1 in the online-only Data Supplement). 
Return mapping (plotting a peak-to-peak interval against the subsequent peak-to-
peak interval) and time series of the peak-to-peak intervals showed that through 
such a fixed activation pattern and PS position, these arrhythmias had period-1 (P-1) 
oscillatory dynamics (ie, all rotor periods had approximately the same length; Figure 
IIA, IIC, and IIE in the online-only Data Supplement). Interestingly, the remaining 6% 
of cultures showed changes in activation pattern, PS number, and PS position for 
each reentrant cycle (Figure 1C and Movie 2 in the online-only Data Supplement). 
Return mapping and time series of the peak-to-peak intervals in these cultures 
showed period >1 or aperiodical oscillatory dynamics (ie, the wave front rotation 
alternated between >1 different periods or showed a different period during each 









Figure 1. Activation maps (top; 6-millisecond isochrone spacing) and corresponding phase 
maps (bottom) of atrial neonatal rat cardiomyocyte cultures during (A) 1-Hz activation 
showing uniform propagation, (B) 3 subsequent reentrant cycles after burst pacing showing 
a stable activation pattern and phase singularity (PS) density and localization during each 
cycle, and (C) 5 subsequent reentrant cycles after burst pacing showing changes in 
activation pattern and PS density and localization during each cycle. The direction of 
activation is indicated by the white arrows; PSs are depicted as white circles. Relationship 
etween rotor frequency and (D) APD80, (E) conduction velocity (CV), and (F) wavelength 
and between complexity of reentry and (G) APD80, (H) CV, and (I) wavelength. 





Supplemental Figure II. Typical examples of the optical signal in neonatal rat atrial CMC 
cultures with (A) period-1 and (B) aperiodical reentry after burst pacing. Return maps of the 
peak-to-peak interval (PPI) sequences in an atrial CMC culture after burst pacing with (C) 
period-1 reentry, characterized by monofocal clustering in the return map and (D) aperiodical 
reentry, characterized by the absence of clustering in the return map. Time series of the 
PPIs in an atrial CMC culture with (E) period-1 (corresponding with Supplemental Figure 
IIA,C and Figure 1B in the main manuscript) and (F) aperiodical reentry (corresponding with 
Supplemental Figure IIB,D and Figure 1C in the main manuscript). The red dotted lines 




During burst pacing–induced reentry (including both the stable and unstable cases of 
reentry, n=49), rotor frequency showed a hyperbolic-like relationship with both 
APD80 (R
2=0.91) and wavelength (R2=0.63). No apparent relation was found 
between rotor frequency and conduction velocity (CV; Figure 1D–1F). Moreover, the 
number of rotors negatively correlated with wavelength (R2=0.73) and 
APD80(R
2=0.70). Again, CV, other than its effects on wavelength, did not show a 
strong individual correlation with the number of PSs during reentry (Figure 1G–1I). 
These results show that fibrillatory activation in this model can be maintained by P-1 
or period >1/aperiodical reentry. Furthermore, the correlation analyses suggest that 
prolongation of atrial APD and wavelength during AF could decrease rotor frequency 
and complexity, possibly leading to the prevention or termination of AF. 
 
Blockade of Atrium-Specific IK,ACh Decreases Rotor Frequency, Complexity, and 
Inducibility of Reentry 
Atrial nrCMCs abundantly expressed Kir3.1 and Kir3.4 compared with ventricular 
nrCMCs (100.0±6.3% versus 18.3±0.7% and 100±2.8% versus 7.8±2.0%, 
respectively; P<0.05; n=4 per group) as judged by Western blot analyses (Figure 
2A). Therefore, Kir3.x could be a target for blockade in an attempt to selectively 
prolong atrial APD, thereby preventing or terminating AF. To test this hypothesis, 
both atrial and ventricular nrCMC cultures were treated with 100 nmol/L tertiapin, a 
specific blocker of IK,ACh.
16 Tertiapin significantly increased APD80 in atrial nrCMCs 
during 1-Hz pacing (from 56.5±12.5 to 145.5±20.6 milliseconds;P<0.0001; 
n=33; Figure 2B) in the absence of exogenous acetylcholine, showing the presence 
of IK,ACh-c in these cells (see also Results and Supplemetal Figure III in the online-
only Data Supplement). Tertiapin had no significant effect on APD in ventricular 
nrCMCs (n=12; Figure 2C). Hence, the increase in APD80 induced by tertiapin was 
significantly larger in atrial nrCMCs (86.7±19.6 versus 9.5±9.9 milliseconds in 
ventricular nrCMCs; Figure 2D). 





Figure 2. A, Western blot analysis of Kir3.1 and Kir3.4 levels in atrial and ventricular 
neonatal rat cardiomyocyte (nrCMC) cultures using GAPDH as a loading control. B and C, 
Typical optical action potential (AP) records of untreated (red) and tertiapin-treated (blue) 
atrial and ventricular nrCMC cultures, respectively. D, Quantification of ΔAPD80 after tertiapin 
treatment in atrial vs ventricular nrCMC cultures. E, Typical optical signal records of 
untreated (red) and tertiapin-treated (blue) atrial nrCMC cultures after induction of atrial 
fibrillation by burst pacing. F, Typical phase maps of untreated (left) and tertiapin-treated 
(right) cultures after burst pacing. White circles indicate phase singularities. Quantification of 
(G) APD80 during reentry, (H) rotor frequency, (I) complexity of reentry, (J) inducibility of 
reentry, and (K) complete rotor termination in control and tertiapin-treated atrial nrCMC 




Supplemental Figure III. (A) Typical examples of optical signal traces in a neonatal rat 
atrial CMC culture before (control) and after the cumulative treatment with 200 nmol/L 
atropine and 100 nmol/L tertiapin during 1-Hz pacing. (B) Typical examples of optical signal 
traces in a neonatal rat atrial CMC culture before (control) and after the cumulative treatment 
with 2 μmol/L carbachol, 200 nmol/L atropine and 100 nmol/L tertiapin during 1-Hz pacing. 
(C) Quantification of APD80 at a 1-Hz pacing frequency in untreated atrial CMC cultures and 
in atrial CMC cultures treated with atropine and tertiapin, respectively. (D) Quantification of 
APD80 at a 1-Hz pacing frequency in untreated atrial CMC cultures and in atrial CMC 
cultures treated with carbachol, atropine and tertiapin, respectively. *: p<0.05 vs control, #: 
p<0.05 vs atropine, ǂ: p<0.05 vs carbachol. 
Blockade of IK,ACh-c by tertiapin increased APD80 during reentry (from 54.7±24.0 to 
128.8±16.9 milliseconds; n=42; Figure 2E–2G), which significantly decreased rotor 
frequency (from 14.1±7.4 to 5.9±1.7 Hz) and complexity (from 6.7±7.7 to 0.58±0.83 
PSs; Figure 2H and 2I). Interestingly, the inducibility of reentry also decreased (from 
89.2% to 27.2%) after tertiapin treatment (Figure 2J). Concomitantly, tertiapin led to 
complete termination of all rotors in 67.4% of cultures, whereas rotor termination 
occurred in only 7.0% of control cultures (Figure 2K).  





Kcnj3/5 Knockdown in Atrial nrCMC Cultures 
To investigate the individual contribution of the molecular determinants of IK,ACh-
c (Kir3.1 and Kir3.4) to the induction and dynamics of AF, expression 
of Kcnj3 andKcnj5 was specifically downregulated in atrial nrCMC cultures by means 
of lentiviral, shRNA-mediated RNAi. Kir3.1 and Kir3.4 protein levels were 
significantly lowered in cultures transduced with LV-Kir3.1↓ and LV-Kir3.4↓, 
respectively, compared with those in LV-PpLuc↓-treated control cultures (20.2±1.7% 
versus 100.0±2.4% and 34.6±3.5% versus 100.0±34.6%, respectively; n=4 per 
group;Figure 3A–3C). As expected, transduction with LV-Kir3.1↓ (n=11) and LV-
Kir3.4↓ (n=20) resulted in significant APD prolongation compared with LV-PpLuc↓-
treated control cultures (n=11; Figure 3D). APD80 was significantly increased 
throughout all pacing cycle lengths (PCLs; Figure 3E). In addition, CV was lowered 
significantly by both Kcnj3 and Kcnj5 knockdown (Figure 3F), possibly caused by a 






Figure 3. Western blot of (A) Kir3.1 levels in LV-PpLuc↓ (ie, control lentiviral vector)-and LV-
Kir3.1↓–transduced atrial neonatal rat cardiomyocyte (nrCMC) cultures and (B) Kir3.4 levels 
in LV-PpLuc↓– and LV-Kir3.4↓–transduced atrial nrCMC cultures with GAPDH used as a 
loading control and (C) their quantification. D, Typical optical signal in atrial nrCMC cultures 
transduced with the control vector LV-PpLuc↓ or with LV-Kir3.1↓ or LV-Kir3.4↓. 
Quantification of (E) action potential duration and (F) conduction velocity restitution in atrial 
nrCMC cultures transduced with the control vector LV-PpLuc↓ or with LV-Kir3.1↓ or LV-
Kir3.4↓. a.u. indicates arbitrary units. *P<0.05 vs LV-PpLuc↓. 
Effect of Kcnj3/5 Knockdown on Reentry in Atrial nrCMC Cultures 
Next, reentry was induced in cultures transduced with LV-Kir3.1↓ (n=14), LV-Kir3.4↓ 
(n=12), or the control LV (n=19) to investigate the effect of Kir3.x-dependent APD 
prolongation on spiral waves. As expected, reentrant cycle length was significantly 
increased after knockdown of either Kcnj3 or Kcnj5 (Figure 4A–4D and 4F), 
consistent with prolongation of APD80 during reentry (Figure 4E). Similarly, activation 
frequency and complexity were significantly decreased (Figure 4G and 4I and Movie 
3 in the online-only Data Supplement). In addition, inducibility of reentry was clearly 
reduced by Kcnj3 or Kcnj5 knockdown (Figure 4H). Together, these results show 
that the effect of tertiapin on reentry induction and dynamics can be reproduced by 
RNAi-mediated reduction of Kir3.1 or Kir3.4 protein levels. 






Figure 4. A, Activation maps and corresponding phase maps during reentry in atrial 
neonatal rat cardiomyocyte (nrCMC) cultures transduced with LV-PpLuc↓ (ie, control 
lentiviral vector), LV-Kir3.1↓, or LV-Kir3.4↓. White arrows indicate the direction of action 
potential (AP) propagation; white circles depict phase singularity position. Optical signal 
traces during reentry in atrial nrCMC cultures transduced with (B) LV-PpLuc↓, (C) LV-
Kir3.1↓, or (D) LV-Kir3.4↓. Quantification of (E) AP duration (APD), (F) cycle length, (G) 
activation frequency, (H) inducibility of reentry, and (I) complexity of reentry after burst 
pacing in control (red), LV-Kir3.1↓–transduced (blue), and LV-Kir3.4↓–treated (black) atrial 
nrCMC cultures. a.u. indicates arbitrary units. *P<0.05 vs LV-PpLuc↓. 
154 
 
IK,ACh-c Blockade Prevents APD Alternans by Decreasing APD and CV Restitution 
Slope 
To investigate how IK,ACh-c blockade or downregulation prevents reentry induction, we 
studied the effect of tertiapin on APD and CV restitution. During pacing at 1 to 20 Hz, 
Kir3.x blockade by tertiapin increased APD80 throughout all PCLs compared with 
control cultures (n=8 per group; Figure 5A). CV was unaltered after 1- to 2-Hz pacing 
after tertiapin treatment. However, at higher pacing frequencies, CV was significantly 
lower in cultures treated with tertiapin (Figure 5B). This was possibly attributable to a 
change in the maximal diastolic potential, which gets more depolarized at higher 
pacing frequencies if the APD is prolonged by IK,ACh-c blockade.
20 Furthermore, 
wavelength was significantly increased by tertiapin at all activation frequencies 
(Figure 5C). Interestingly, the slopes of the APD and CV restitution curves were 
strongly flattened by tertiapin treatment as a consequence of significantly increased 
minimal APD80 and decreased maximal activation frequency (Figure 5D and 5E). 
Because the restitution curves naturally become steeper at shorter diastolic intervals 
(Figure 5A–5C), prolonging minimal APD (and thereby decreasing maximal 
activation frequency) prevents steepening in APD and CV restitution. Tertiapin 
treatment decreased the maximal APD restitution slope from 1.0±0.4 to 0.3±0.2 
(Supplemental Figure IVA and IVB in the online-only Data Supplement), whereas the 
percentage of cultures with a maximal APD restitution slope above the critical 
value21 of 1 decreased from 71.4% to 0% (Supplemental Figure IVC in the online-
only Data Supplement). 
 





Figure 5. Restitution of (A) APD80, (B) conduction velocity, and (C) wavelength during 1- to 
20-Hz pacing in control (red) and tertiapin-treated (blue) atrial neonatal rat cardiomyocyte 
(nrCMC) cultures. Red and blue dotted lines indicate the maximal slopes in the restitution 
curves; solid black line indicates slope=1. Quantification of (D) minimal action potential 
duration (APD) and (E) maximal activation frequency in control and tertiapin-treated atrial 
nrCMC cultures. F, APD80 maps of untreated (left) and tertiapin-treated (right) atrial nrCMC 
cultures. G, Typical optical signal traces during pacing at maximal activation frequency in 
control cultures (left) showing alternating APDs (red double arrows) on equal pacing cycle 
lengths (PCLs; green double arrows) and tertiapin-treated cultures showing stable APDs 
(red double arrows) on equal PCLs (green double arrows). Quantification of (H) temporal 
APD80 dispersion, (I) spatial APD80dispersion, and (J) temporal amplitude dispersion. a.u. 




Supplemental Figure IV. (A) Typical examples of APD restitution curves of a single control 
(left) and a single tertiapin-treated (right) culture of neonatal rat atrial CMCs, showing that 
the maximal slope of the curve in the control culture exceeds 1, while the slope in the 
tertiapin-treated culture remains well below 1. Black dotted lines indicate slope=1. Colored 
dotted lines indicate the maximal slope in control (red) and tertiapin-treated (blue) cultures. 
(B) Quantification of the maximal slope in the APD restitution curve of control and tertiapin-
treated cultures. (C) Quantification of the percentage of cultures with a maximal slope in the 
APD restitution curve ≥1.  
As a consequence of restitution moderation, spatial dispersion (21.7±8.0% versus 
56.5±4.4% in control cultures) and temporal dispersion (7.8±6.5% versus 38.1±8.0% 
in control cultures) in APD were significantly decreased by Kir3.x blockade (Figure 
5F–5I). Because steepening in APD and CV restitution causes small PCL changes to 
result in large APD and CV changes, APD alternans occurred in control but not in 
tertiapin-treated cultures. During APD alternans at stable PCL in a control culture, as 
a consequence of the relationship between APD and diastolic interval (see 
also Figure 5A), a long APD was repeatedly followed by a short APD because the 
diastolic interval is shortened after the long APD (Figure 5G). Since the short APD 




follows after incomplete repolarization during the long AP, amplitude alternans was 
observed (likely because of inactivation of Na+ channels as a result of incomplete 
repolarization). Therefore, blockade of IK,ACh-c leads to a significant decrease in 
temporal amplitude dispersion (Figure 5G and 5J). Together, these findings suggest 
that IK,ACh-c-dependent alternans is linked to restitution kinetics (see also Results and 
Supplemental Figure V in the online-only Data Supplement). 
 
 
Supplemental Figure V. (A) Typical examples of optical signal traces of control (left) and 
BAPTA-AM-treated (right) neonatal rat atrial CMC cultures at maximal activation frequency 
in areas showing APD alternans (B) Quantification of reentry inducibility in control cultures 
and in cultures treated with 10 μmol/L, 50 μmol/L or 100 μmol/L BAPTA-AM showing no 
difference in the induction of reentry by burst pacing during buffering of intracellular Ca2+. 
Role of APD Alternans in Reentry 
In control atrial cultures, reentry initiation after burst pacing was found to be a 
consequence of highly incident APD alternans, during which a long AP was 
repeatedly followed by a short AP (Figure 6, left). Typically, the long AP was 
uniformly propagated throughout the culture (Figure 6, right, long AP). However, 
because of the spatial heterogeneity in APD, the short AP frequently underwent 
conduction block when propagated from an area with short-long APD to an area with 
long-long APD. This caused PSs to arise adjacent to the area of conduction block 
(Figure 6, left and right, short AP). The AP was subsequently propagated around the 
PS. This could lead to reentry if the area in which the conduction block occurred 
repolarized before return of the wave front, which then circled the PS in a retrograde 
fashion (Figure 6, right, short AP). These results show that APD alternans, which can 





Figure 6. Typical optical signal traces (graph, left) in a 9-mm2 square in a control atrial 
neonatal rat cardiomyocyte culture during action potential (AP) duration (APD) alternans 
leading to reentry. Green and red dotted lines indicate pacing cycle length and alternating 
APD, respectively. Corresponding phase maps (right) during uniform propagation of the 
long AP (top) and conduction block, followed by circular propagation of the short AP 
(bottom). Arrows, double lines (blue in the optical signal traces and black in the phase 
maps), and white circles indicate the direction of AP propagation, conduction block, and the 
phase singularity position, respectively. The positions of points I and II in the culture are 
indicated in the top left phase map. 
Mechanism of Rotor Termination After IK,ACh Blockade 
In addition to preventing reentry induction, blockade of IK,ACh terminated a large 
portion of rotors initiated by burst pacing. Atrial cultures were mapped during the 
addition of tertiapin to study how IK,ACh blockade led to rotor termination. 
Interestingly, during tertiapin incubation, rotors with P-1 oscillatory dynamics 
destabilized into period-2 (P-2) and aperiodical reentry before termination (Figure 
7 and Supplemental Figure VI in the online-only Data Supplement). As shown 
in Figure 5A, incubation of atrial cultures with tertiapin led to an increase in minimal 
APD and a decrease in the maximal slope of the APD restitution curve. The 
increased steepness of the restitution slope at long PCLs in the tertiapin-treated 




cultures suggests that this slope becomes critically steep before tertiapin has 
completely increased minimal APD. This caused APD alternans in vulnerable spots 
during reentry, leading to P-2 oscillatory dynamics (Figure 7, middle, and 
Supplemental Figure VIB and VID in the online-only Data Supplement). 
Subsequently, APD prolonged further and refractory periods around the PSs 
increased. Consequently, if the refractory period got critically long, the reentrant 
wave had to alter its path from the previous cycle to be sustained. Therefore, PSs 
tended to shift position after incubation with tertiapin, leading to aperiodical reentry 
dynamics (Figure 7, bottom, and Supplemental Figure VIC and VID in the online-only 
Data Supplement), which simultaneously increased the chance for these PSs to 
meet a boundary, followed by rotor termination (Figure 7, bottom, and Supplemental 
Figure VIC and VID in the online-only Data Supplement). Because tertiapin 
increased wavelength and decreased the incidence of APD alternans after full 
incubation, new rotors were not formed, resulting in a net decrease in complexity of 
conduction patterns after tertiapin treatment, ultimately leading to termination of AF 
(Movie 4 in the online-only Data Supplement). These results show that in addition to 
affecting reentry initiation and global reentry characteristics, IK,ACh-c determines the 
period dynamics and propensity toward rotor termination by controlling the onset of 





Figure 7. Phase map sequence of an atrial neonatal rat cardiomyocyte culture during 
tertiapin incubation. The top row shows the initial period (P)-1 reentrant arrhythmia rotating 
around a single stable phase singularity (PS) and its corresponding optical signals. The 
second row shows the change into a P-2 reentry (≈4 seconds after tertiapin addition) with 
meandering, disappearing, and reappearing PSs and its corresponding optical signals 
showing action potential (AP) duration (APD) alternans in critical areas. The bottom 2 rows 
show the shift to aperiodical reentry (≈9 seconds after tertiapin addition) followed by the 
termination of rotors as a consequence of PS drift toward the edge of the culture as the 
wave front increasingly meets refractory tissue. The white circles indicate PSs; translucent 
white circles, the PS position in the previous frame. Bottom right, The corresponding AP 
between points I and II in the culture. The blue arrow indicates the propagation of the final 
AP leading to conduction block. a.u. indicates arbitrary units. 





Supplemental Figure VI. Return maps of the PPI sequences in an atrial CMC culture during 
(A) typical period-1 reentry showing a single cluster in the return map, (B) the early phase of 
tertiapin incubation leading to a change into period-2 reentry showing two clusters (red) as a 
result of APD alternans (See Figure 7 in the main manuscript, second row) and a third 
cluster (blue) corresponding to the subsequent prolonged reentrant cycle length (temporary 
2:1 conduction) starting at the arrow in both subfigures B and D, (C) the late phase of 
tertiapin incubation leading to aperiodical reentry lacking any clustering in the return map. 
Dotted red circles indicate clustering of PPI sequences. (D) Time series of the PPIs during 
the incubation with tertiapin, showing the progression of period-1, to period>1, to aperiodical 
reentry and eventually termination. The return maps in A-C are each based on a part of the 
time series separated by the gray rectangles. 
Kir3.x Blockade in Whole-Heart Mapping  
Our novel 2-dimensional model of atrial tissue appeared to be crucial for a 
mechanistic understanding of the role of IK,ACh-c in rotor formation, dynamics, and 
termination because these events are likely to occur subepicardially in the intact 
atria, which precludes their direct readout and interpretation. However, whole-heart 
data are needed to show the effects of IK,ACh-c on actual AF in a more complex and 
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relevant setting. We thus studied the effects of tertiapin in a whole-heart model of AF 
using neonatal rat hearts. In these hearts, immunocytological analyses confirmed the 
expression of myosin light chain 2a in the atria only (Supplemental Figure VIIA in the 
online-only Data Supplement). The atria consisted of 37.9±12.1% nonmyocytes, 
which were predominantly fibroblasts as judged by α-actinin/collagen-I double 
staining (Supplemental Figure VIIB and VIIC in the online-only Data Supplement). 
Consistent with the in vitro results, Western blot analyses showed a significantly 
higher expression of Kir3.1 and Kir3.4 in the atrium compared with the ventricle 
(100.0±21.3% versus 13.7±6.0% [P<0.05] and 100.0±24.2% versus 22.4±5.2% 




Supplemental Figure VII. Immunohistological double staining of whole neonatal rat hearts 
for (A) MLC2a (green) and α-actinin (red) and (B) collagen type I (green) and α-actinin (red). 
(C) Quantification of the number of α-actinin-positive (i.e. CMCs) and -negative cells (i.e. 
non-myocytes) as judged by immunohistology. (D) Western blot analysis and quantification 
of Kir3.1 and Kir3.4 levels in the neonatal rat atrium and ventricle using GAPDH as loading 
control. LA: left atrium, RA: right atrium, LV: left ventricle, RV: right ventricle, *: p<0.05 vs 
control.  




During optical mapping of whole neonatal rat hearts, blockade of Kir3.x channels 
by tertiapin significantly increased atrial APD (62.8±20.9 versus 111.0±32.9 
milliseconds; P<0.05) in sinus rhythm, whereas the APD in the ventricles was not 
significantly altered (219.7±57.6 versus 211.8±42.7 milliseconds; P<0.05; n=10 per 
group; Figure 8A–8C). Atropine treatment had no significant effect on atrial APD 
(54.7±13.9 versus 62.8±20.9 milliseconds in control hearts; Supplemental Figure 
VIIIA–VIIIC in the online-only Data Supplement), confirming the M2 receptor–
independent, constitutive activation of IK,ACh in neonatal rat atria. After burst pacing, 
AF was maintained by P-1 oscillatory dynamics in both control and tertiapin-treated 
hearts. In hearts treated with tertiapin, APD during AF was significantly longer 
compared with control hearts (54.8±14.2 versus 38.8±7.9 
milliseconds; P<0.05; Figure 8D and 8E). As a consequence, AF cycle length was 
significantly increased (106.5±10.3 versus 81.3±11.3 milliseconds; P<0.05; Figure 
8F), whereas the inducibility of AF showed a significant decrease after tertiapin 
incubation (90% versus 40%; P<0.05; Figure 8G). Together, these results support 






Figure 8. A, Typical examples of a control neonatal rat heart during optical mapping 
showing its orientation (left), a map of the atrial activation sequence during sinus rhythm 
(middle; 6-millisecond isochrone spacing), and a map of the atrial activation sequence 
during atrial fibrillation (AF) induced by burst pacing (right; 6-millisecond isochrone spacing) 
showing circular activation in the atrial epicardium (white arrow). The white squares indicate 
the areas from which typical optical signals were derived. LA indicates left atrial; RA, right 
atrial, and V, ventricle. B, Examples of the optical signal traces in the atrium (red) and 
ventricle (black) in control hearts (left) and tertiapin-treated hearts (right). Quantification of 
(C) APD80 in atria and ventricles of control and tertiapin-treated hearts during sinus rhythm 
and (D) the atrial APD80 during AF. E, Examples of the optical signal traces during AF after 
burst pacing in the atrium (red) and ventricle (black) in control and tertiapin-treated hearts. 
Irregularly appearing ventricular traces are indicative of AF. Quantification of (F) AF cycle 
length and (G) inducibility of AF by burst pacing in control and tertiapin-treated neonatal rat 
hearts. *P<0.05 vs control. 





Supplemental Figure VIII. Typical optical signal traces in the atria (red trace) and ventricles 
(black trace) of (A) control and (B) atropine-treated neonatal rat hearts. (C) Quantification of 
APD80 in the atria of control and atropine-treated neonatal rat hearts. NS: non-significant vs 




The key findings of this study are the following. First, the acetylcholine-inducible 
potassium current (IK,ACh), mediated by Kir3.x, is highly atrium specific and 
constitutively active in neonatal rat atrial cell monolayers and intact atria. Second, in 
the presence of this current, sustained reentry can be easily induced electrically 
(≈90% incidence), whereas the incidence decreases strongly after IK,ACh blockade. 
Third, after induction, tachyarrhythmias in atrial cultures are maintained by stable P-1 
and shifting period >1 or aperiodical rotors and result from restitution-driven 
alternans, whereas they are terminated by alternans-mediated PS drift. Fourth, 
mechanistically, it is shown by pharmacological and genetic interventions that Kir3.x 
is a key regulator of rotor induction, dynamics, and termination by controlling APD 
and APD alternans through APD restitution steepening. Finally, Kir3.x represents a 
promising atrium-specific target for antiarrhythmic strategies. 
 
Kir3.x in Models of AF  
Previous studies showed that IK,ACh may play an important role in the onset of AF 
because acetylcholine activates IK,ACh during parasympathetic stimulation and 
thereby shortens APD.15 However, after atrial remodeling, which occurs, for instance, 
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during permanent AF, APD is shortened independently of parasympathetic 
activation, partly because IK,ACh has become constitutively active.
16 Although 
alteration of atrial electrophysiology after atrial remodeling has been established, 
most of the insights into the electrophysiological mechanisms and complex dynamics 
of wave propagation in AF have come from detailed investigations in computer and 
animal models of AF, which did not take into account the molecular consequences of 
atrial remodeling.22 Hence, these results may be applicable to paroxysmal AF, but 
translation to persistent AF and AF after atrial remodeling remains difficult. In the 
present study, models have been used that include 1 of these molecular 
consequences, which is constitutive activation ofIK,ACh. Therefore, the present 
models might provide a novel means to link the molecular biology of (persistent) AF 
to its basic electrophysiological mechanisms.22 
We found that the detrimental effects of IK,ACh-c are strongly dependent on Kir3.x 
expression, as is the case when IK,ACh is activated by increased parasympathetic 
tone.14,15 Because Kir3.1 homomers do not to form a functional channel,23,24 the 
preventive effect of Kcnj3 knockdown is likely attributable to diminished density of 
Kir3.1/Kir3.4 heteromers at the sarcolemma, whereas Kir3.4 downregulation affects 
both Kir3.4 homomers and Kir3.1/Kir3.4 heteromers. This might explain why a 3-fold 
reduction in Kir3.4 level produced results similar to the results of a 5-fold decrease in 
Kir3.1 abundance. Although earlier studies show that there is very little contribution 
of Kir3.4 homomers to IK,ACh,
25 our results suggest that after Kcnj3 knockdown there 
is still residual IK,ACh-c, most likely provided by Kir3.4 homomers, the formation of 
which is inhibited after Kcnj5 knockdown. This could imply that the contribution of 
Kir3.x subunits to IK,ACh and to its constitutively active counterpart differs. 
Nevertheless, the effects of tertiapin on APD, rotor frequency, arrhythmia 
complexity, and inducibility were found to be larger than those of Kir3.1 and Kir3.4 
downregulation. Because the atrial nrCMCs have a higher tolerability for short-
term IK,ACh-c blockade by tertiapin as opposed to long-term IK,ACh-c blockade by LV-
mediated RNAi, tertiapin treatment could provide a somewhat more efficient 
blockade of IK,ACh-c at the moment of electrophysiological analysis. Furthermore, 
long-term downregulation of Kir3.1 or Kir3.4 seemed to induce a depolarization of 
the cardiomyocyte’s membrane potential, decreasing CV even at long PCLs. The 
conduction-slowing effect of Kcnj3/5 knockdown by shRNAs strongly diminishes its 
wavelength-prolonging effect. Therefore, we used tertiapin as an alternative means 




to study the role of IK,ACh-c in AF in whole hearts. The fact that Kir3.1 and Kir3.4 
downregulation still strongly decreased the inducibility of reentry in atrial cell cultures 
shows that the effects of IK,ACh-c inhibition on the slopes in the restitution curves 
prevails over its effects on wavelength. 
 
Mechanisms of AF Maintenance 
For years, there has been ongoing discussion of whether AF is the consequence 
of single or multiple ectopic focal discharges or the result of reentrant waves or 
randomly appearing and disappearing wavelets.22 Isolating the pulmonary veins can 
be successful in preventing paroxysmal AF, which could be interpreted as evidence 
for the focal discharge theory.26 Nevertheless, reentrant sources generating 
fibrillatory conduction as a consequence of a dominant frequency gradient have 
been demonstrated in chronic AF.27 Importantly, in patients with a long history of AF, 
pulmonary vein isolation has a low success rate.5,6 Therefore, at least in permanent 
AF, reentry seems to play an important role. The presence of a dominant frequency 
gradient also makes the multiple wavelet hypothesis less plausible because a 
hierarchy in frequencies defies randomness as postulated in this theory.28 
As demonstrated in our models, constitutive activation of IK,ACh may be one of the 
determinants of the seemingly increasing role of reentry in the maintenance of AF 
over time. We show that the constitutively active IK,ACh causes APD alternans, 
making the atrial tissue prone to wave break and reentry initiation. In most cases, 
after reentry is initiated, multiple stable rotors maintain fibrillation. Without ongoing 
electric remodeling, the emergence of such rotors in the left atrium would lead to 
fibrillatory conduction to the right atrium. However, in several cultures, AF was 
maintained by shifting aperiodical rotors. Because the APD and CV restitution can 
become critically steep if the IK,ACh is constitutively active, causing both spatial and 
temporal heterogeneity in repolarization, rotors can meander and break up. 
Therefore, in the remodeled atrium (ie, with constitutively active IK,ACh), random 
wavelets (ie, random rotors of which the propagated wave front appears as wavelets 
at the atrial surface) could maintain AF. This could also explain the possibility of AF 
originating from a rotor in the right atrium with fibrillatory conduction to the left atrium 
(eg, after left atrium ablation and permanent AF),28 even though the refractory period 
is shorter in the left atrium. The fibrillatory aspect of conduction here could be 
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provided by the seemingly random breakup, appearance, and disappearance of 
rotors in the right atrium as opposed to an APD gradient. 
 
APD Alternans and AF 
Disturbed repolarization is thought to play an important role in producing spatial 
heterogeneity and causing fibrillation in the ventricles. In theory, if fast ectopic firing 
occurs, for instance, from the pulmonary veins, spatial heterogeneity in repolarization 
would also favor reentry initiation in the atria. Hence, it has recently been proposed 
that repolarization alternans could also play an important role in AF. Indeed, it has 
been shown that atrial repolarization alternans occurs frequently before the initiation 
of AF.29-31 In the diseased atrium, changes in calcium handling have been shown to 
cause the APD to alternate as a consequence of calcium instabilities.32 During 
calcium- dependent APD alternans, APD restitution is not necessarily altered. We 
show here for the first time that APD alternans underlying reentry can be caused by 
constitutive activation of IK,ACh, which steepens APD restitution. Hence, we confirm 
that disturbed atrial repolarization is associated with the onset of AF. In addition to 
this association, we show experimentally that wave break and resultant reentry are 
the direct consequence of APD alternans. Earlier in silico work predicted that 
discordant APD alternans leads to wave break if the short AP in a long-short 
sequence reaches the refractory tail of a long AP in a short-long sequence. In 
accordance with these predictions, we found that propagation of a short AP of an 
alternating long-short sequence halts when it meets the refractory tail of a long AP. 
However, in our model, the long AP was usually not the consequence of discordant 
APD alternans, for example, a short-long sequence. Instead, it was the result of a 
large APD dispersion causing areas with APD alternans to border areas with solely 
long APDs. Thus, in our model, we provide an extension to the aforementioned 
theory by showing that spatial APD dispersion in combination with APD alternans 
(while not being classically discordant) can cause AF in cells with constitutively 
active IK,ACh.  
 
Atrial Fibrosis in AF 
Atrial fibrosis is thought to be an important component of AF substrates.33 In this 
study, atrial cell cultures consisted of ≈17% cardiac fibroblasts, as deduced by 
collagen type I immunostaining. Previous studies showed that atrial conduction 




abnormalities as a consequence of fibrosis depend strongly on the pattern of 
fibrosis.34 It was found that long fibrotic strands of tissue could cause significant 
conduction abnormalities and thereby contribute to AF, whereas diffuse fibrosis only 
marginally affected conduction. In our in vitro model, fibroblasts are diffusely spread. 
In addition, the percentage of fibroblasts in this model is lower than in intact neonatal 
rat atria (see also Figures IF, VIIB, and VIIC in the online-only Data Supplement). 
Despite this difference in fibroblast content, the atrial cell culture and whole-heart 
models yielded very similar results in terms of the inducibility of AF and the ability to 
suppress AF by IK,ACh-c blockade. Furthermore, in both our in vitro and whole-heart 
models, pathological conditions that promote fibrosis are absent. It thus appears that 
in our models a possible contribution of fibroblast to AF induction is overshadowed 
by the strong proarrhythmic effects of IK,ACh-c.  
 
Study Limitations 
The present study made use of nrCMCs and neonatal rat hearts, which differ 
electrophysiologically from the more clinically relevant adult human cardiomyocytes 
and hearts. Use of cardiomyocytes from human adults is hampered by the difficulties 
in obtaining human cardiac tissue of sufficient quality for the isolation of 
cardiomyocytes and maintaining human cardiomyocytes in a differentiated state 
during culture. In addition, healthy atrial nrCMCs were used to facilitate the study of 
Kir3.x and IK,ACh-c. It should be noted, however, that constitutive activation of IK,ACh in 
human atrial myocytes is usually preceded by significant atrial remodeling and hence 
may have a different origin than in our model. Therefore, our study focused on a 
proof of principle, investigating the role of IK,ACh on APD alternans, AF prevention, 
and AF termination regardless of its onset. Thus, the results may not be directly 
extrapolatable to the clinical setting. 
  
Conclusions 
In neonatal rat atrial cell monolayers and intact atria, the acetylcholine-inducible 
potassium current is constitutively active and plays a crucial role in the initiation of 
sustained tachyarrhythmias. Mechanistically, it is shown in atrial cell monolayers 
that IK,ACh-c is mediated by Kir3.x and regulates not only the initiation but also the 
maintenance and termination of these arrhythmias by controlling APD and APD 
alternans through APD restitution steepening. Accordingly, this study provides 
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insights into the molecular basis of atrium-specific IK,ACh-c and reveals the crucial role 
it could play in proarrhythmic and antiarrhythmic mechanisms in atrial tissue. These 
novel insights could contribute to the development of mechanistically driven and 
atrium-specific, antiarrhythmic strategies. 
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All animal experiments were approved by the Animal Experiments Committee of the 
Leiden University Medical Center and conformed to the Guide for the Care and Use 
of Laboratory Animals as stated by the US National Institutes of Health.  
 
Cell isolation and culture  
Ventricular and atrial cardiomyocytes (CMCs) were isolated from 2-3 old neonatal 
Wistar rats by collagenase digestion as described previously.1 Isoflurane inhalation 
(4-5%) was used to anaesthetize animals. After adequate anesthesia had been 
confirmed by the absence of pain reflexes, hearts were excised. Subsequently, large 
vessels were removed and atria were separated from ventricles. Atrial and 
ventricular tissue was gently minced and digested using collagenase type 1 (450 
U/ml; Worthington, Lakewood, NJ) and DNase I (18,75 Kunitz/ml; Sigma-Aldrich, St. 
Louis, MO) during 2 subsequent 30-min digestion steps with agitation in a water bath 
at 37ºC. Cell suspensions were pre-plated on Primaria-coated culture dishes (Becton 
Dickinson, Breda, the Netherlands) for 120 min to allow for preferential attachment of 
non-myocytes. Next, the unattached cells (mainly CMCs) were passed through a 
nylon cell strainer with a mesh pore size of 70 μm (Becton Dickinson) to remove cell 
aggregates and, after counting, the cells were plated isotropically on fibronectin 
(Sigma-Aldrich)-coated, round glass coverslips (15-mm diameter) in 24-well plates 
(Corning Life Sciences, Amsterdam, the Netherlands). Cell densities of 2-8×105 
cells/well were used depending on the experiment. To restrict unwanted expansion 
of the remaining non-myocytes, cell proliferation was inhibited by incubation with 
Mitomycin-C (10 μg/ml; Sigma-Aldrich) for 2 h at day 1 of culture as described 
previously.1,2 All cultures were refreshed daily with Dulbecco’s modified Eagle’s 
medium (DMEM)/HAM’s F10 (1:1, v/v; both from Life Technologies, Bleiswijk, the 
Netherlands) supplemented with 5% horse serum (Life Technologies) and cultured in 





Cells were stained for the markers of interest after several rinses with ice-cold Error! 
Not a valid link.to wash out the culture medium, fixation with 1% formaldehyde in 
PBS and permeabilization with 0.1% Triton X-100 in PBS. Primary antibodies (1:200 
dilution in PBS+5% fetal bovine serum [FBS; Life Technologies]) and corresponding 
Alexa Fluor 488/568-conjugated secondary antibodies (1:400 dilution in PBS+5% 
FBS; Life Technologies) were left on the cells for 16 and 2 h, respectively, at 4ºC. 
Cultures were stained using antibodies directed against α-actinin (Sigma-Aldrich) as 
CMC marker, myosin light chain 2a (MLC2a; a gift from Dr. S.W. Kubalak, 
Charleston, SC) and natriuretic peptide precursor A (NPPA, Merck Millipore, 
Billerica, MA) as markers for atrial CMCs and myosin light chain 2v (MLC2v; 
Synaptic Systems, Goettingen, Germany) to identify ventricular CMCs. Non-
myocytes were characterized immunostaining using antibodies specific for collagen 
type I (fibroblasts; Abcam, Cambridge, MA), platelet endothelial cell adhesion 
molecule-1 (PECAM-1; endothelial cells; Abcam) and smooth muscle myosin heavy 
chain (smMHC; smooth muscle cells; Abcam). Primary antibodies specific for 
connexin40 (Cx40; Santa Cruz Biotechnology, Dallas, TX) and connexin43 (Cx43; 
Sigma-Aldrich) were used to determine expression of gap junction proteins. 
Counterstaining of the nuclei was performed by a 5-min incubation at room 
temperature with 10 μg/ml Hoechst 33342 (Life Technologies) in PBS+5% FBS. 
Cells were rinsed twice with PBS+5% FBS after incubation with primary antibodies, 
secondary antibodies and Hoechst 33342. Coverslips were mounted in Vectashield 
mounting medium (Vector Laboratories, Burlingame, CA) to minimize 
photobleaching. Images were taken at equal exposure times between compared 
groups using a fluorescence microscope equipped with a digital color camera (Nikon 
Eclipse 80i; Nikon Instruments Europe, Amstelveen, the Netherlands). Dedicated 
software (NIS Elements [Nikon Instruments Europe] and ImageJ [version 1.43; 
National Institutes of Health, Bethesda, MD]) were used to store and quantify 
immunofluorescence signals, respectively. All proteins of interest were studied in at 
least 3 different cultures per experimental group, from which at least 15 
representative images were taken.  
 
Immunohistology  
Neonatal rat hearts were rinsed with PBS, fixed overnight using 4% formaldehyde in 
PBS and dehydrated by immersion in 70% ethanol (3 h), 96% ethanol (3 h), 100% 




ethanol (3 h) and 1-butanol (overnight), respectively. Hearts were embedded in 
paraffin, cut in 5-μm-thick sections and mounted on StarFrost adhesive microscope 
slides (Knittel Glass, Braunschweig, Germany). Next, sections were deparaffinized in 
xylene and rehydrated by the subsequent immersion in 100% ethanol, 96% ethanol, 
70% ethanol and PBS for 5 min each. Antigen retrieval was performed by incubating 
the slides with 0.05% trypsin and 0.1% CaCl2 in dimineralized water at pH 7.8 for 15 
min at 37°C and 15 min at 20°C, respectively. Sections were immunostained 
overnight with the aforementioned primary antibodies directed against MLC2a, α-
actinin and collagen type I diluted 1:100 in PBS with 1% bovine serum albumin 
(BSA; Sigma-Aldrich) and 1% Tween-20 (PBSBT). Corresponding secondary 
antibodies (Alexa Fluor 488/568-conjugated antibodies, Life Technologies) diluted in 
PBSBT were incubated for 2 hours, after which the nuclei were counterstained with 
10 μg/ml Hoechst 33342 in PBSBT. Image acquisition, processing and analysis were 
done using the fluorescence microscope and software described above.  
 
Western blotting  
CMC cultures were rinsed twice with ice-cold PBS to wash out the culture medium. 
Next, the cells were lysed in RIPA buffer (50 mM Tris–HCl [pH 8.0], 150 mM NaCl, 
1% Triton X-100, 0.5% sodium deoxycholate, 0.1% sodium dodecyl sulfate 
supplemented with protease inhibitors [cOmplete, Mini Protease Inhibitor Cocktail 
Tablet; Roche Applied Science, Penzberg, Germany]). Lysates were subsequently 
flash frozen in liquid nitrogen, thawed and centrifuged at 4ºC and 21,130×g for 15 
min to get rid of undissolved material. The protein concentration in the supernatant 
was determined using BCA Protein Assay Reagent (Thermo Fisher Scientific, Etten-
Leur, the Netherlands). Proteins (10 μg per sample; ≥3 samples per group) were 
then size-fractionated in NuPage Novex 12% Bis-Tris gels (Life Technologies) and 
transferred to Hybond polyvinylidene difluoride membranes (GE Healthcare, Diegem, 
Belgium) by wet electroblotting. Membranes were blocked in Tris-based saline, 0.1% 
Tween-20 (TBST) supplemented with 5% BSA for 1 h at room temperature. Next, the 
blots were incubated with primary antibodies directed against Cx40 (1:1,000), Cx43 
(1:100,000), Kir3.1 (1;1,000; Alomone Labs, Jerusalem, Israel), Kir3.4 (1; 1,000; 
Santa Cruz Biotechnology), MLC2a (1:200,000), MLC2v (1:5,000), NPPA (1:5,000) 
and glyceraldehyde 3-phosphate dehydrogenase (1:120,000; loading control; Merck 
Millipore) for 1 h at room temperature in TBST+5% BSA. Following 3 rinses with 
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TBST, the blots were incubated with appropriate horseradish peroxidase-conjugated 
secondary antibodies (Santa Cruz Biotechnology) diluted 1:1,000 in TBST+5% BSA 
for 1 h at room temperature. After another 3 rinses with TBST, membranes were 
immersed in ECL Prime Western blot detection reagent (GE Healthcare) and 
chemiluminescence was captured using the ChemiDoc XRS imaging system (Bio-
Rad Laboratories, Veenendaal, the Netherlands).  
For Western blotting of whole hearts, hearts were excised, atria and ventricles 
were carefully separated and rinsed in ice-cold PBS before lysis in RIPA buffer using 
a TissueLyser LT (QIAGEN, Benelux, Venlo, the Netherlands). The whole heart 
lysates were subsequently processed in the same manner as the lysates of cultured 
cells.  
 
Construction of self-inactivating lentivirus (SIN-LV) shuttle plasmids  
To repress rat Kcnj3 expression, a SIN-LV shuttle construct encoding a short hairpin 
(sh) RNA targeting mouse Kcnj3, and matching perfectly with the coding sequence 
of the rat Kcnj3 gene, was obtained from the MISSION shRNA library (Sigma-
Aldrich; clone TRCN0000069736). To knock down rat Kcnj5 expression, the 
hybridization product of oligodeoxyribonucleotides  
5’ 
CCGGGACCACAAGAAGATCCCCAAACTCGAGTTTGGGGATCTTCTTGTGGTCTT
TTTG 3’ and  
5’ 
AATTCAAAAAGACCACAAGAAGATCCCCAAACTCGAGTTTGGGGATCTTCTTGT
GGTC 3’ was inserted in between the unique SgrAI and EcoRI recognition sites of 
SHC007 (MISSION shRNA library; Sigma-Aldrich) to replace its Photinus pyralis 
luciferase (PpLuc)-specific shRNA-coding sequence. Next, the marker gene cassette 
in these constructs and in SHC007, which consisted of the human phosphoglycerate 
kinase 1 gene promoter and the puromycin-N-acetyltransferase-coding sequence 
was replaced by the human eukaryotic translation elongation factor 1 alpha 1 gene 
promoter and the Aequorea victoria enhanced green fluorescent protein (eGFP)-
coding sequence. This yielded the SIN-LV shuttle plasmids pLKO.1-mKcnj3-
shRNA.hEEF1a1.eGFP, pLKO.1-rKcnj5-shRNA.hEEF1a1.eGFP and pLKO.1-PpLuc-
shRNA.hEEF1a1.eGFP, which were used to generate LV-Kir3.1↓, LV-Kir3.4↓ and 
LV-PpLuc↓ particles, respectively.  





SIN-LV production  
Vesicular stomatitis virus G protein-pseudotyped SIN-LV particles were generated by 
transfecting subconfluent monolayers of 293T cells with the packaging plasmids 
psPAX2 (Addgene, Cambridge, MA; plasmid number: 12260) and pLP/VSVG (Life 
Technologies) and one of the 3 aforementioned SIN-LV shuttle constructs at a molar 
ratio of 2:1:1. The 293T cells were cultured in high-glucose DMEMcontaining 10% 
FBS. The transfection mixture, which consisted of 40 μg of plasmid DNA and 120 μg 
of polyethyleneimine (Polysciences Europe, Eppelheim, Germany) in 2 ml of 150 mM 
NaCl per 175-cm2 cell culture flask (Greiner Bio-One, Alphen aan den Rijn, the 
Netherlands) was directly added to the culture medium. Sixteen hours later, the 
transfection medium in each flask was replaced by 15 ml of DMEM supplemented 
with 5% FBS and 25 mM HEPES-NaOH (pH 7.4). At 40-48 h after the start of the 
transfection procedure, the culture medium was harvested and cleared from cellular 
debris by centrifugation for 10 min at 3,000×g and filtration through a 33-mm 
diameter, 0.45-μm pore size polyethersulfone syringe filter (Millex Express; Merck 
Millipore). To concentrate and purify the SIN-LV particles, 30 ml of vector suspension 
were layered onto a 5-ml cushion of 20% (wt/vol) sucrose in PBS and centrifuged at 
15,000 rotations per min for 2 h at 4ºC in an SW32 rotor (Beckman Coulter, 
Fullerton, CA). Next, the supernatant was discarded and the pellet containing the 
SIN-LV particles was suspended in 500 μl of PBS-1% BSA by gentle rocking 
overnight at 4ºC. The concentrated vector suspension was divided in 50-100 μl 
aliquots and stored at -80ºC until use. The 3 SIN-LVs were applied to the atrial CMC 
cultures at doses that resulted in transduction of essentially all cells in the cultures. 
The transduction level was assessed using a Zeiss Axiovert 200M inverse 
fluorescence microscopy to visualize eGFP fluorescence.  
 
In vitro optical mapping  
At day 9 of culture, action potential (AP) propagation was investigated on a whole-
culture scale by optical mapping using the voltage-sensitive dye di-4-ANEPPS (Life 
Technologies) as described previously.1,2 During optical mapping cells were 
stimulated electrically using a custom-made, epoxy-coated unipolar platinum 
electrode with square suprathreshold electrical stimuli at 1 and 2-20 Hz (2-Hz 
increments). Fibrillation was induced by burst pacing with a cycle length of 20-100 
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ms. A specialized electrical stimulus module with corresponding software 
(Multichannel Systems, Reutlingen, Germany) was used to perform electrical 
stimulation. Data analysis and construction of activation maps were performed with 
specialized software (BrainVision Analyzer 1101; Brainvision, Tokyo, Japan) after 
pixel signals were averaged with 8 of its nearest neighbors, to minimize noise 
artifacts. Conduction velocity (CV) in cultures with uniform or reentrant activation 
patterns was calculated perpendicular to the activation wavefront, between two 3 by 
3 pixel grids typically spaced 2-8 mm apart. CV, activation frequency, APD during 
maximal paced activation frequency (i.e. minimal APD) and APD during 1 Hz pacing 
were determined at 6 different locations equally distributed throughout the culture 
and averaged before further analysis. APD was determined at 80% of repolarization 
(APD80) because of the rat AP shape. Wavelength was calculated by multiplying 
average CV with APD80 (for uniform propagation) or reentrant cycle length.1 
Complexity was defined as the number of phase singularities (PSs) per culture, 
determined by using the phase space method as described previously.1  
The effect of several drugs (100 nmol/L tertiapin [Alomone Labs], 200 nmol/L 
atropine (Sigma-Aldrich) and 2 μmol/L carbachol (Sigma-Aldrich)3 was studied by 
pipetting them directly into the medium, dispersing them by gentle agitation, 
immediately followed by optical mapping.  
 
Whole heart mapping  
Neonatal (2-3 days old) Wistar rats were anesthetized by isoflurane inhalation (4-
5%) and adequate anesthesia was confirmed by the absence of pain reflexes. 
Subsequently, the thoracic wall was cut and lifted to expose the heart. Oxygenated 
Tyrode’s solution (comprising [in mM] NaCl 130, CaCl2 1.8, KCl 4.0, MgCl2 1.0, 
NaH2PO4 1.2, NaHCO3 24 and glucose 5.5 at pH 7.4) supplemented with 20 mM 
2,3-butanedione monoxime (Sigma-Aldrich, BDM) with or without 200 nM tertiapin to 
minimize motion artifacts and to block Kir3.x channels, respectively, was carefully 
injected in a 200 uL bolus into the left ventricle using a 30-G needle. The heart was 
excised just prior to absence of visible contractions, and submersed in Tyrode’s 
solution with BDM and tertiapin to remove remaining blood. Next, hearts were 
incubated in Tyrode’s solution with BDM and tertiapin containing 2 μM di-4-ANEPPS 
for 2 min at 37°C, after which the heart was rinsed and submersed in Tyrode’s 
solution with BDM and tertiapin and placed on top of a 37°C heating plate under the 




optical mapping camera. AF was induced by burst pacing at a cycle length of 20-100 
ms using a custom-made bipolar platinum electrode. Control hearts were treated in 
an identical manner except that tertiapin was left out during the entire procedure. 
Typical optical mapping experiments were performed within 6 min after excision of 




Cell culture characterization  
Immunocytological analysis at day 9 of culture showed that 100% of the CMCs (i.e. 
α-actinin-positive cells) in the atrial cell cultures were MLC2a-positive (i.e. of atrial 
origin) while in the ventricular cell cultures no MLC2a-positive CMCs were detected 
(Supplemental Figure IA,C). In addition, NPPA levels were much higher in the atrial 
than in the ventricular CMC cultures (Supplemental Figure IB). Western blot 
analyses confirmed these results and showed that MLC2v was exclusively present in 
the ventricular cell cultures (Supplemental Figure ID). Atrial CMC cultures contained 
more Cx40 than the ventricular CMC cultures, while Cx43 levels were higher in 
ventricular CMCs as judged by both Western blotting (Supplemental Figure ID) and 
immunocytology (Supplemental Figure IE). Atrial cell cultures were also analyzed by 
collagen type I, PECAM-1 and smMHC staining. While none of the cells contained 
detectable amounts of PECAM-1 or smMHC, 17.0±2.5% of the cells stained positive 
for collagen-I (Supplemental Figure IF) suggesting that the non-myocytes in atrial 
cell cultures consisted mainly, if not exclusively, of fibroblasts.  
 
Constitutive activation of IKACh in neonatal rat atrial CMC cultures  
During constitutive activation IKACh becomes activated independently of acetylcholine 
or the acetylcholine receptor. Therefore, to confirm constitutive IKACh (IKACh-c) activity 
in our neonatal rat atrial CMC cultures, atropine (a non-selective muscarinergic 
receptor antagonist) was used to block the acetylcholine receptor during optical 
mapping to study the dependence of APD on acetylcholine receptor activation. 
Atropine had no significant effect on the APD80 (38.5±3.9 vs 38.6±3.9 ms in control 
cultures, p=ns), whereas subsequent treatment with tertiapin significantly increased 
APD80 (to 110.9±13.1 ms, p<0.0001) (Supplemental Figure IIIA,C). This illustrates 
that after blockade of the acetylcholine receptor there is still current flowing through 
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Kir3.x channels shortening APD. Thus, our cultures of neonatal rat atrial CMCs 
indeed possess IKACh-c activity. Nonetheless, treatment of neonatal rat atrial CMCs 
with carbachol (a non-selective muscarinergic receptor agonist) induced a significant 
shortening of APD80 (from 39.6±4.2 to 29.3±3.9 ms, p<0.0001). After subsequent 
atropine treatment APD80 rose to 45.6±6.9 ms, (p<0.0001 vs carbachol-treated 
cells) abolishing the carbachol-induced APD shortening, while addition of tertiapin to 
the carbachol- and atropine-treated CMCs again greatly increased APD80 (to 
119.8±18.5, p<0.0001 vs [carbachol- and] atropine-treated cells) (Supplemental 
Figure IIIB,D). Together, these results show that the short AP in neonatal rat atrial 
CMC cultures is caused by a tertiapin-sensitive current which is independent of 
ligand-induced muscarinergic receptor activation and therefore constitutively active. 
The cells, however, also still possess muscarinergic receptor stimulation-dependent 
Kir3.x activity given the APD shortening-effect of carbachol treatment and its 
inhibition by atropine.  
 
APD alternans in neonatal rat atrial CMCs is independent of intracellular [Ca2+]  
To confirm the restitution-based nature of APD alternans, neonatal rat atrial CMC 
cultures were treated with the cell-permeable Ca2+ chelator BAPTA-AM (10-100 
μmol/L; Life Technologies) to rule out the contribution of intracellular Ca2+ to APD 
alternans and reentry induction. Successful buffering of intracellular Ca2+ was 
confirmed by phase contrast microscopy, showing absence of visible contractions 
after incubation with 10 μmol/L BAPTA-AM during 1-Hz pacing (data not shown). 
Treatment with BAPTA-AM did not prevent APD alternans (Supplemental Figure 
VA), while the frequency of reentry induction after burst pacing remained equal for all 
tested concentrations of BAPTA-AM (84.6% in controls vs 91.7%, 83.3% and 83.3% 
after treatment of the cells with 10, 50 or 100 μmol/L BAPTA-AM, respectively) 
(Supplemental Figure VB). This suggests that APD alternans and consequential 
reentry induction in our model are driven by the IKACh-c-induced steepness in the 
APD/CV restitution curve. 
 




Movie 1:  
Typical example from an optical mapping experiment in a neonatal rat atrial CMC 
culture after burst pacing showing period-1 reentry dynamics. The first part shows 
the high-pass-filtered optical signal exemplifying the repeating activation pattern 
during period-1 reentry. The second part displays the phase map progression of the 
same optical mapping experiment, showing the wave propagation around multiple 
PSs with fixed positioning throughout the experiment.  
Movie 2:  
Typical example from an optical mapping experiment in a neonatal rat atrial CMC 
culture after burst pacing showing aperiodical reentry dynamics. The first part shows 
the high-pass-filtered optical signal exemplifying the transient activation pattern 
during aperiodical reentry. The second part displays the phase map progression of 
the same optical mapping experiment, showing multiple instances of PS formation 
and disappearance leading to aperiodical dynamics.  
Movie 3:  
Typical example from an optical mapping experiment in neonatal rat atrial cultures 
investigating the effect of treatment with LV-Kir3.1↓, LV-Kir3.4↓ or the control vector 
LV-PpLuc↓ after reentry induction by burst pacing. The high-pass-filtered optical 
signal shows less complex conduction patternsand a lower activation frequency in 
cell cultures that had been transduced with the Kcnj3- or Kcnj5-specific shRNA-
coding SIN-LV than in those exposed to the control vector.  
Movie 4:  
Typical movie from optical mapping experiment investigating the effect of tertiapin on 
reentry dynamics and termination. Part 1 shows the high-pass-filtered optical signal 
in an atrial culture after burst pacing during the first 500 ms after tertiapin incubation, 
which is characterized by persisting rotors and period-1 dynamics. The second part 
shows the high-pass-filtered optical signal in an atrial culture after a few seconds of 
tertiapin incubation, characterized by drifting rotors and aperiodical dynamics, which 
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Summary, conclusions and future perspectives  






The general introduction of this thesis, chapter I, starts with a brief comparison of 
the pathological features of skeletal muscle disorders and cardiac diseases. 
Furthermore, the lack of (effective) therapies for many cardiac and skeletal muscle 
diseases is discussed. This paucity in adequate treatment options for 
(cardio)myopathies is partially explained by the limited knowledge about the precise 
mechanisms underlying skeletal and cardiac muscle diseases and, related to this, by 
the non-specific action of many therapeutic interventions. Therefore, the aim of this 
thesis was to establish cellular models and employ viral vector technology to identify 
potential targets for future therapeutic interventions in skeletal and cardiac muscle 
diseases. 
Chapter II describes the development of a bipartite lentivirus vector (LV)-based 
assay to quantify cell fusion in which the cellular fusion partners are transduced with 
a Gaussia princeps luciferase (GpLuc) expression unit (acceptor cells) or with a 
recombinant gene encoding FLPe, a nuclear-targeted and molecularly evolved 
version of flippase (donor cells). GpLuc is a secretory protein allowing repeated 
analysis of the same study object, a great advantage over cell fusion assays using 
Photinus pyralis luciferase (PpLuc), which is not a secretory protein precluding 
consecutive analysis of the same study object. To investigate whether the spread of 
FLPeNLS+ in myotubes is limited due to its nuclear localization signal (NLS), 
myoblasts were transduced with LVs encoding either FLPeNLS+ or an NLS-less 
version of FLPe (FLPeNLS-) and subsequently co-cultured in different ratios with 
myoblasts containing the FLPe-activatable GpLuc expression cassette. At different 
times after induction of cell-to-cell fusion the GpLuc activity in the culture medium 
was determined. In general, GpLuc expression increased with increasing fractions of 
GpLuc-transduced myoblasts and both FLPeNLS+ and FLPeNLS- activated the latent 
GpLuc gene but when the percentage of FLPe-expressing myoblasts was limiting, 
FLPeNLS+ generally yielded slightly higher signals than FLPeNLS- while at low 
acceptor-to-donor cell ratios FLPeNLS- was usually superior. Thus, it was shown that 
NLS does not limit the ability of FLPeNLS+ to spread through myofibers and to induce 
reporter gene expression. However, at high fraction of FLPe-expressing myoblasts 
the presence of the NLS negatively affected reporter gene expression. These results 




show that a rapid and simple chemiluminescence assay for quantifying cell-to-cell 
fusion progression based on GpLuc has been developed.  
In chapter III different properties of Gelatin/Siloxane/Hydroxyapatite (GS-Hyd) 
scaffolds are investigated such as in vivo biodegradability, cytotoxic effects and 
ability to support cell adhesion. Mesenchymal stem cells (MSCs) were treated with 
different volumes of the scaffold suspension for evaluation of its cytotoxic effects. 
MSCs were also cultured on the scaffold for 2 weeks to evaluate the ability of the 
scaffold to promote cell adhesion and growth. The GS-Hyd scaffold did not exert 
noticeable cytotoxic effects on the MSCs and these cells could adhere to the 
scaffold, expand their elongations and form colonies. To study its biodegradability 
the GS-Hyd scaffolds were implanted in thigh muscle, testicle and liver of Wistar 
rats. At different times after implantation, scaffolds were excised and their dry weight 
was measured. The largest reduction in scaffold weight occurred during the first days 
after implantation and varied from 53% in liver to 71% in thigh muscle at 3 days post 
implantation. Subsequently, scaffold degradation slowed down with 30%, 25% and 
18% of the initial scaffold remaining at 3 weeks after implantation in liver, testis and 
thigh muscle, respectively. Scanning electron microscopy (SEM) indicated obvious 
morphological changes on the surface of the scaffold and in the diameter of the 
pores after 21 days of implantation. In conclusion, the GS-Hyd scaffold seems to be 
a promising tool for cell-based therapeutic interventions, but additional research is 
needed to assess its clinical utility. 
Chapter IV is dedicated to the development of an in vitro model for studying the 
contribution of pathological cardiac hypertrophy (PCH) per se to arrhythmia 
independent of fibrosis or other PCH-related processes. Treatment of neonatal rat 
ventricular cardiomyocyte (nr-vCMC) monolayers with phorbol 12-myristate 13-
acetate (PMA) for two times 24 hours, led to increases in cell surface area (CSA) 
and protein content of the cardiomyocytes. Assessment of the electrophysiological 
properties of PMA-treated and control nr-vCMC monolayers by optical mapping at 
day 9 of culture, showed a decrease in conduction velocity (CV) and increases in 
action potential duration (APD) and APD dispersion upon PMA treatment. It also 
caused a 32% reduction in sarcoplasmic/endoplasmic reticulum Ca2+ ATPase 2 level 
and an increase in natriuretic peptide A (42%) and α1-skeletal muscle actin (34%) 
levels indicating that the hypertrophic response induced by PMA was pathological in 
nature. Upon local 1-Hz stimulation, 54% of the PMA-treated cultures showed focal 
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tachyarrhythmias based on triggered activity, while the rate of tachyarrhythmias was 
only 4% in control nr-vCMC cultures. PMA-treated nr-vCMC cultures may thus 
represent a well-controllable in vitro model for testing new therapeutic interventions 
targeting specific aspects of hypertrophy-associated arrhythmias.  
Chapter V describes the development of in vitro models of post-myocardial 
infarction (MI) compact and patchy fibrosis and the assessment of their pro-
arrhythmic features by optical mapping. To this end, either a single large circular 
anatomical obstruction or multiple smaller circular anatomical obstructions were 
made in the center of confluent nr-vCMC monolayers by forcefully pressing tailor-
made plexiglass stamps onto the cells. To gain mechanistic insight into arrhythmias 
associated with post-MI scars several parameters such as rate of inducibility, cycle 
length and maintenance of reentry were compared between these two types of 
anatomical obstructions. In patchy cultures, reentry was slightly less easily inducible 
(41% vs 52%) and, when it occurred, had a shorter cycle length (234±52 vs 288±38 
ms) than in compact cultures. Sustained reentry was less often observed in patchy 
cultures (40% vs 88% in compact cultures) while the percentage of complex 
arrhythmias was higher (31% vs 11%). Meandering of phase singularities and 
gradients of excitability during reentrant arrhythmias were only detectable in patchy 
cultures. Reentry could be terminated more easily in compact cultures (82% vs 20% 
in patchy cultures). Taken together, this in vitro model of patchy and compact 
obstructions reproduced arrhythmic features similar to those observed after early- 
and non-reperfused MIs, respectively, and may hence provide mechanistic insights 
into the efficacy of anti-arrhythmic interventions in infarcted hearts with different 
anatomical substrates.  
In chapter VI the effects of constitutive acetylcholine-regulated K+ current (IK,Ach-c), 
which flows through Kir3.1 and Kir3.4 channels, on atrial fibrillation is investigated. 
Neonatal rat atrial CMC cultures and intact atria were burst paced to induce reentry. 
Treatment of these cultures with tertiapin prolonged APD, indicating the presence of 
IK,ACh-c. Furthermore, tertiapin decreased rotor frequency and complexity. Reduction 
of Kir3.1 or 3.4 expression through transduction of cells with LVs encoding Kcnj3- or 
Kcnj5-specific shRNAs gave similar results. Tertiapin prevented/terminated reentry 
by prolonging APD and changing APD and CV restitution slopes, thereby lowering 
the probability of APD alternans and inducing rotor destabilization. Whole-heart 
mapping experiments confirmed key findings (e.g. >50% reduction in atrial fibrillation 




inducibility after IK,ACh-c blockade). This study provided new molecular and 
mechanistic insights into atrial tachyarrhythmias and identified Kir3.1 and Kir3.4 as 
promising atrium-specific targets for anti-arrhythmic strategies. 
In conclusion, the experiments described in this thesis emphasize the importance 
of cellular models for (i) elucidating the mechanisms underlying skeletal and cardiac 
muscle diseases and (ii) identification of novel therapeutic targets. This thesis also 
underlines the usefulness of viral vector-mediated gene transfer technology for the 
development of biological assays and the evaluation of therapeutic targets.  
 
Future perspectives 
Without a thorough understanding of the mechanisms underlying cardiac and 
skeletal muscle diseases, their treatment by pharmacological or genetic interventions 
involve a lot of trial and error. Cellular models are important tools to gain mechanistic 
insights into skeletal muscle degeneration and cardiac arrhythmias mechanisms 
allowing the rational design of new treatments. This relates at least in part to their 
relative simplicity, providing the possibility to investigate a specific pathological 
feature independent of other complications. Despite of having this and some other 
advantages, in vitro cellular models often do not mimic well enough the in vivo 
situation, which may lead to poor in vitro-in vivo correlations. Accordingly, future 
research should focus on the further improvement of these cellular models in such a 
way that they better resemble/represent in vivo pathological states reducing the need 
for preclinical and clinical studies. For example, in the case of in vitro models of 
cardiac hypertrophy it is essential to determine which stage in the transition from 
PCH to heart failure the hypertrophy model represents as this will affect the 
therapeutic approach. Besides by checking the extent of electrophysiological 
changes and incidence and nature of arrhythmias, measuring of the contractile force-
generating capacity and comparative transcriptome analyses will provide useful 
information on this issue. 
An important hurdle in the development of in vitro cellular models arises from the 
low expansion capability of differentiated cells. For example, postnatal CMCs display 
very limited proliferation capacity which demands for repetitive isolation and culture 
of these cells for in vitro studies. Therefore, immortalization of atrial or ventricular 
CMCs from animal or human would circumvent this obstacle. This could be achieved 
through viral vector-mediated transfer, into these cells, of genes such as those 
190 
 
encoding simian virus 40 large T antigen, B cell-specific Moloney murine leukemia 
virus integration site 1 (BMI1) or telomerase (TERT) reverse transcriptase. 
Genetic manipulations through viral vectors (e.g. overexpression of certain genes 
or RNA interference) may also help to gain better mechanistic insights into skeletal 
and cardiac muscle disorders and to further optimize current therapies for these 
diseases.  
Regarding to skeletal muscle wasting, optimization of cell-based therapies may be 
achieved through enhancement of the fusion of donor cells which each other and 
with recipient myocytes and by promoting their myogenic differentiation. For 
instance, forced and controlled expression of fusion-enhancing proteins through 
transduction of (non-muscle) stem cells with viral vectors encoding these proteins 
may be beneficial as could be the regulated expression in these cells of myogenic 
transcription factor genes.  
Genetic intervention may also be employed for therapeutic purposes in cardiac 
arrhythmias. For example, the forced expression of connexins like connexin43 in 
(myo)fibroblasts present in infarct scars may improve conduction and reduce 
arrhythmia incidence. This approach could, however, also be deleterious as coupling 
of CMCs with (myo)fibroblasts would depolarize CMCs and make the tissue 
susceptible to reentrant tachycardias. The latter problem may be overcome by 
simultaneously endowing (myo)fibroblasts with a gene like KCNJ2 whose product is 
involved in setting the resting membrane potential. 
Genetic interventions (overexpression or knockdown) affecting the expression of 
the genes encoding for ion channels involved in the repolarization phase of the 
action potential (AP) may also have anti-arrhythmic effects. For example, 
manipulation of the expression of genes encoding for those ion channels that exert 
their effect on repolarization in the AP phases at which early afterdepolarizations 
occur (e.g. adenosine triphosphate (ATP)-sensitive K+ channels [KATP channels]) 
could provide novel insights into pro- and anti-arrhythmic mechanisms but could also 
have therapeutic potential. 
Effective therapeutic application of viral vectors in vivo often requires uniform and 
near-quantitative transduction of the target tissue and transgene expression at a 
specific level. This is of particular importance when developing gene therapy for 
arrhythmias as heterogeneous transduction and inappropriate transgene expression 
levels may be pro-arrhythmic. 




Hence, efficient delivery and high target cell specificity of viral vectors and precise 
control of transgene expression are of vital importance and deserve further study. 
Other important topics of future gene therapy research are the further improvement 





De algemene introductie van dit proefschrift, hoofdstuk I, begint met een korte 
vergelijking van de pathologische kenmerken van skeletspier- en hartspierziekten. 
Voorts wordt het gebrek aan (effectieve) therapieën voor veel hartspier- en 
skeletspierziekten bediscussieerd. Deze schaarste aan adequate 
behandelingsmogelijkheden voor (cardio)myopathieën kan deels worden verklaard 
door de geringe kennis van de precieze mechanismen die aan skeletspier- en 
hartspierziekten ten grondslag liggen en, hieraan gerelateerd, door de niet-specifieke 
werking van veel therapeutische interventies. Het hoofddoel van dit proefschrift was 
daarom het opzetten van cellulaire modellen en toepassing van virale 
vectortechnologie ter identificatie van potentiële aangrijpingspunten voor 
toekomstige behandelmethoden voor skeletspier- en hartspierziekten.  
In hoofdstuk II wordt de ontwikkeling van een tweedelige lentivirus vector (LV)-
gebaseerde analysemethode beschreven voor het kwantificeren van cel fusie waarin 
de cel fusie-componenten zijn getransduceerd met een Gaussia princeps luciferase 
(GpLuc) expressie eenheid (ontvangende cellen) of met een recombinant gen dat 
codeert voor FLPe, een kerngerichte en moleculair geëvolueerde versie van flippase 
(donorcellen). GpLuc is een secretoir eiwit, waardoor het mogelijk is om herhaalde 
analyses te verrichten van hetzelfde studieobject, een groot voordeel ten opzichte 
van cel fusie analyses die gebruik maken van Photinus pyralis luciferase (PpLuc), 
wat niet een secretoir eiwit is en daardoor achtereenvolgende analyses van 
hetzelfde studieobject uitsluit. Om te onderzoeken of de spreiding van FLPeNLS+ in 
gedifferentieërde skeletspiercellen wordt beperkt door het kernlokalisatiesignaal 
(NLS), werden gedifferentieërde skeletspiercellen getransduceerd met LVs die 
coderen voor FLPeNLS+ of een FLPe versie zonder NLS (FLPeNLS-) en vervolgens in 
verschillende ratio’s in co-cultuur gebracht met myoblasten met een door FLPe 
activeerbare GpLuc expressie cassette. Op verschillende tijdstippen na inductie van 
fusie tussen cellen werd de GpLuc activiteit in het kweekmedium bepaald. In het 
algemeen nam de GpLuc expressie toe met toenemende fracties of GpLuc-
getransduceerde myoblasten, en zowel FLPeNLS+ als FLPeNLS- was in staat om het 
latente GpLuc gen te activeren. Echter, wanneer het percentage myoblasten dat 
FLPe tot expressie bracht beperkend was, gaf FLPeNLS+ over het algemeen iets 
hogere signalen dan FLPeNLS-; maar bij lage ontvanger:donor celratio’s was FLPeNLS- 




meestal superieur. Er werd daarmee aangetoond dat het NLS niet beperkend was 
ten aanzien van het vermogen van FLPeNLS+ om zich door gedifferentieërde 
skeletspiercellen te verspreiden of voor het induceren van reportergenexpressie. Bij 
een hoge fractie FLPe-expresserende myoblasten heeft de aanwezigheid van het 
NLS echter een negatief effect reportergenexpressie. Deze resultaten tonen aan dat 
het is gelukt om een snelle en simpele analysemethode op basis van GpLuc te 
ontwikkelen voor de kwantificatie van de progressie van fusie tussen cellen door 
middel van chemiluminescentie. 
 In hoofdstuk III worden verschillende eigenschappen van 
Gelatine/Siloxane/Hydroxyapatiet (GS-Hyd) matrices onderzocht zoals in vivo 
biologische afbreekbaarheid, cytotoxische effecten en het vermogen celadhesie te 
ondersteunen. Mesenchymale stamcellen (MSCs) werden behandeld met 
verschillende volumes matrixsuspensie voor de evaluatie van de cytotoxische 
effecten. MSCs werden tevens gedurende 2 weken op de matrix gekweekt ter 
evaluatie van het vermogen van de matrix om celadhesie en celgroei te 
bevorderden. De GS-Hyd matrix had geen merkbaar cytotoxisch effect op de MSCs 
en deze cellen waren in staat om zich te hechten aan de matrix, hun uitlopers uit te 
breiden en kolonies te vormen. Om de biologische afbreekbaarheid te bestuderen, 
werden GS-Hyd matrices geïmplanteerd in dijbeenspier, testikel en lever van Wistar 
ratten. Op verschillende tijdstippen na implantatie werd matrices uitgenomen en 
werd hun drooggewicht bepaald. De grootste reductie in matrix gewicht vond plaats 
gedurende de eerste dagen na implantatie en varieerde van 53% in de lever tot 71% 
in dijbeenspier op dag 3 na implantatie. Vervolgens vertraagde de matrixdegradatie 
waardoor er 3 weken na implantatie nog 30%, 25% en 18% van de uitgangsmatrix in 
respectievelijk lever, testis en dijbeenspier resteerde. Scanning elektronmicroscopie 
liet duidelijke morfologische veranderingen aan het oppervlak van de matrix en in de 
poriediameter zien 21 dagen na implantatie. Concluderend lijkt de GS-Hyd matrix 
een veelbelovend hulpmiddel voor celtherapie, maar additioneel onderzoek is nodig 
om de klinische toepasbaarheid vast te stellen.  
Hoofdstuk IV is gewijd aan de ontwikkeling van een in vitro model voor het 
onderzoeken van de specifieke bijdrage van pathologische cardiale hypertrofie 
(PCH) aan ritmestoornissen, onafhankelijk van fibrose of andere PCH-gerelateerde 
processen. Behandeling van monolagen van ventriculaire cardiomyocyten 
geïsoleerd uit neonatale ratten (nr-vCMC) met phorbol 12-myristate 13-acetate 
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(PMA) gedurende 2 ker 24 uur, leidde tot toenames in celoppervlakte en eiwitinhoud 
van de cardiomyocyten. Bepaling van de electrofysiologische eigenschappen van 
PMA-behandelde en controle nr-vCMC monolagen middels optisch mappen op 
kweekdag 9, lieten een afname van de geleidingssnelheid (CV) en toenames van de 
actiepotentiaalduur (APD) en APD dispersie zien na PMA behandeling. Verder 
veroorzaakte de PMA behandeling een 32% afname van het 
sarcoplasmatisch/endoplasmatisch reticulum Ca2+ ATPase 2 gehalte en een 
toename van de natriuretisch peptide A (42%) en α1-skeletspier actine (34%) 
gehaltes, wat aantoonde dat de door PMA-geïnduceerde hypertrofe respons een 
pathologisch karakter had. Na lokale 1-Hz stimulatie, vertoonden 54% van de PMA-
behandelde cultures focale tachyaritmieën op basis van getriggerde activiteit, terwijl 
de controle nr-vCMCs slechts in 4% van de gevallen tachyaritmieën lieten zien. 
PMA-behandelde nr-vCMC kweken kunnen derhalve een goed controleerbaar in 
vitro model zijn voor het testen van nieuwe therapeutische interventies voor het 
bestuderen van specifieke aspecten van hypertrofie-geassocieerde aritmieën.  
In hoofdstuk V wordt de ontwikkeling van in vitro modellen van compacte en 
fragmentarische fibrose als gevolg van een myocardiaal infarct (MI) beschreven, 
alsmede de bepaling van hun pro-aritmische eigenschappen door middel van optisch 
mappen. Hiertoe werd een enkel groot circulair anatomisch obstakel, dan wel 
multipele kleinere circulaire anatomische obstakels gecreëerd in het midden van 
confluente nr-vCMC monolagen door middel van krachtige druk op de cellen met op 
maat gemaakte plexiglas stempels. Voor het verkrijgen van mechanistisch inzicht in 
aritmieën die geassocieerd zijn met post-MI littekens werden verschillende 
parameters vergeleken bij de twee types van anatomische obstakels, zoals de mate 
van induceerbaarheid, cycluslengte en handhaving van “reentry”. In kweken met 
fragmentarische fibrose was “reentry” iets minder gemakkelijk induceerbaar (41% vs. 
52%) en, als het optrad had het een kortere cycluslengte (234±52 vs. 288±38 ms) 
dan in cultures met compacte fibrose. 
Aanhoudende “reentry” werd minder vaak geobserveerd in fragmentarische 
culturen (40% vs. 88% in compacte culturen), terwijl het percentage complexe 
aritmieën hoger was (31% vs. 11%). Meanderende fasesingulariteiten en 
exciteerbaarheidsgradiënten tijdens aritmieën op basis van “reentry” waren alleen 
detecteerbaar in fragmentarische culturen. “Reentry” kon gemakkelijker 
getermineerd worden in compacte cultures (82% vs. 20% in fragmentarische 




culturen). Samenvattend konden met de in vitro modellen van fragmentarische en 
compacte obstakels soortgelijke aritmische eigenschappen worden nagebootst als 
worden gevonden na respectievelijk vroege- en niet-gereperfundeerde MIs. Deze 
modellen kunnen daarom leiden tot mechanistisch inzicht in de werkzaamheid van 
anti-aritmische interventies in geïnfarceerde harten met verschillen anatomische 
substraten. 
In hoofdstuk VI worden de effecten op atriumfibrilleren onderzocht van 
constitutief-actieve acetylcholine-gereguleerde K+ stroom (IK,Ach-c), die via Kir3.1 en 
Kir3.4 kanalen loopt. Culturen van atriale CMCs geïsoleerd uit neonatale ratten en 
intacte atria werden met hoge frequentie gestimuleerd voor inductie van “reentry”. 
Behandeling met tertiapin verlengde de APD in atriale culturen tijdens “reentry”, wat 
duidde op de aanwezigheid van IK,Ach-c. Voorts verlaagde tertiapin de frequentie en 
complexiteit van rotors. Een afname van Kir3.1 of 3.4 expressie door middel van 
transductie van de cellen met LVs die codeerden voor Kcnj3- of Kcnj5-specifieke 
shRNAs gaf vergelijkbare resultaten. Tertiapin voorkwam of termineerde “reentry” 
door verlenging van de APD en door veranderingen van de APD en CV restitutie 
curves, waardoor de kans op APD alternans verminderde en de kans op 
rotordestabilisatie toenam. Mapping experimenten van hele harten bevestigden deze 
bevindingen (b.v. >50% reductie in induceerbaarheid van atriumfibrillatie na IK,Ach-c 
blokkade). Deze studie heeft nieuwe moleculaire en mechanistische inzichten in 
atriale tachyaritmieën opgeleverd en heeft geleid tot de identificatie van Kir3.1 en 
Kir3.4 als veelbelovende atrium-specifieke doelwitten voor anti-aritmische 
strategieën. 
Concluderend benadrukken de experimenten zoals beschreven in dit proefschrift 
het belang van cellulaire modellen voor (i) het ophelderen van de mechanismen die 
ten grondslag liggen aan skelet- en hartspierziekten en (ii) het identificeren van 
nieuwe therapeutische doelwitten. Dit proefschrift onderstreept ook de bruikbaarheid 
van op virale vectoren gebaseerde genoverdrachttechnologieën voor de ontwikkeling 
van biologische analysemethodes en de evaluatie van therapeutische doelwitten.  
 
Toekomstperspectieven 
Zonder een grondig begrip van de onderliggende mechanismen van hart- en 
skeletspierziekten, gaan hun behandeling met farmacologische of genetische 
interventies gepaard met veel praktijkfouten. Cellulaire modellen zijn belangrijke 
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hulpmiddelen voor het verkrijgen van mechanistische inzichten in 
skeletspierdegeneratie en cardiale ritmestoornismechanismen als voorwaarde voor 
het rationele ontwerp van nieuwe behandelingmethoden. Dit is tenminste deels 
gerelateerd aan hun relatieve eenvoud, wat de mogelijkheid biedt om een specifieke 
pathologische eigenschap te onderzoeken, onafhankelijk van andere complicaties. 
Ondanks deze en andere voordelen van in vitro cellulaire modellen bootsen zij de in 
vivo situatie vaak onvoldoende na, wat kan leiden tot slechte in vitro-in vivo 
correlaties. Hierdoor dient toekomstig onderzoek zich te richten op de verdere 
verbetering van deze cellulaire modellen zodat zij een betere weergave vormen van 
de pathologische status in vivo, waardoor de noodzaak voor preklinische en 
klinische studies kan worden verminderd. Bijvoorbeeld, in het geval van in vitro 
modellen van cardiale hypertrofie is het essentieel om te bepalen welk stadium 
tijdens de transitie van PCH tot hartfalen door het hypertrofie model wordt 
weergegeven, aangezien dit de therapeutische aanpak kan beïnvloeden. Naast het 
bepalen van de mate van electrofysiologische veranderingen en de incidentie en het 
karakter van aritmieën, kunnen de bepaling van het contractievermogen en 
transcriptoomanalyses een waardevolle bijdrage leveren.  
Een belangrijke hindernis die genomen moet worden voor de verdere ontwikkeling 
van in vitro cellulaire modellen is het overkomen van de lage expansiecapaciteit van 
gedifferentieerde cellen. Postnatale CMCs vertonen bijvoorbeeld een zeer beperkte 
proliferatiecapaciteit, wat herhaaldelijke isolatie en kweek van deze cellen 
noodzakelijk maakt voor in vitro studies. Immortalisatie van atriale of ventriculaire 
CMCs van dierlijk of menselijk weefsel zou dit probleem kunnen omzeilen. Dit kan 
worden bewerkstelligd door middel van virale overdracht van genen coderend voor 
eiwitten zoals simian virus 40 large T antigen, B cell-specific Moloney murine 
leukemia virus integration site 1 (BMI1) of telomerase (TERT) reverse transcriptase.  
Genetische manipulaties middels virale vectoren (b.v. overexpressie van bepaalde 
genen of RNA interferentie) kunnen voorts leiden tot betere mechanistische inzichten 
in skelet- en hartspierziekten en tot verdere optimalisatie van huidige therapieën 
voor deze aandoeningen.  
Met betrekking tot skeletspieratrofie kan optimalisatie van cellulaire therapieën 
bereikt worden door verbeterde fusie van donorcellen onderling en met spiercellen 
van de ontvanger en door verbetering van hun myogene differentiatie. Bijvoorbeeld, 
geforceerde expressie van fusie-bevorderende eiwitten door transductie van (niet-




myogene) stamcellen met virale vectoren coderend voor deze eiwitten kan 
bevorderlijk zijn, evenals de gereguleerde expressie van myogene 
transcriptiefactoren in deze cellen.  
Genetische interventie kan ook worden ingezet voor de behandeling van 
hartritmestoornissen. Bijvoorbeeld, gedwongen expressie van connexines zoals 
connexine43 in (myo)fibroblasten in infarctlittekenweefsel kan geleiding bevorderen 
en de incidentie van aritmieën doen afnemen. Deze aanpak zou echter ook negatief 
kunnen uitpakken aangezien koppeling van CMCs met (myo)fibroblasten kan leiden 
tot depolarisatie van CMCs, waardoor het weefsel vatbaar wordt voor tachycardieën 
op basis van “reentry”. Dit probleem kan worden aangepakt door gelijktijdige 
uitrusting van (myo)fibroblasten met een gen zoals KCNJ2, waarvan het product is 
betrokken bij het instellen van het rustmembraanpotentiaal.  
Genetische interventies (overexpressie of knockdown) die invloed uitoefenen op 
de expressie van genen die coderen voor ionkanalen die betrokken zijn bij de 
repolarisatiefase van het actiepotentiaal (AP), kunnen ook anti-aritmische effecten 
hebben. Bijvoorbeeld, manipulatie van de expressie van genen die coderen voor de 
ionkanalen die betrokken zijn bij de repolarisatie van de AP fases gedurende welke 
vroege na-depolarisaties optreden (b.v. adenosine trifosfaat (ATP)-gevoelige K+ 
kanalen [KATP kanalen]) zou tot nieuwe inzichten kunnen leiden in pro- en anti-
aritmische mechanismen, maar zou ook therapeutische waarde kunnen hebben. 
Effectieve therapeutische toepassing van virale vectoren in vivo vereist uniforme en 
bijna-kwantitatieve transductie van het doelweefsel en het juiste 
transgenexpressieniveau. Dit zijn belangrijk punten in de context van 
aritmiebehandeling, aangezien heterogene transductie of een inadequaat 
transgenexpressieniveau pro-aritmisch kan zijn.  
Daarom zijn efficiënte toediening en een hoge doelcelspecificiteit van virale 
vectoren, alsmede de precieze beheersing van transgenexpressie van vitaal belang 
en verdienen verder onderzoek. Andere belangrijke onderwerpen van toekomstig 
gentherapeutisch onderzoek zijn de verdere verbetering van de veiligheid en de 
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